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A B S T R A C T
Background
Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery
and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with
spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may
lead to the formation of cystic spaces in the retina termed ’cystoid macular oedema’ (CMO). Non-steroidal anti-inflammatory drugs
(NSAIDs) are commonly used in cataract surgery and may reduce the chances of developing MO.
Objectives
The aim of this review is to answer the question: is there evidence to support the prophylactic use of topical NSAIDs either in addition
to, or instead of, topical steroids postoperatively to reduce the incidence of macular oedema (MO) and associated visual morbidity.
Search methods
We searched a number of electronic databases including CENTRAL, MEDLINE and Embase. Date last searched 2 September 2016.
Selection criteria
We included randomised controlled trials (RCTs) in which adult participants had undergone surgery for age-related cataract. We
included participants irrespective of their baseline risk of MO, in particular we included people with diabetes and uveitis. We included
trials of preoperative and/or postoperative topical NSAIDs in conjunction with postoperative topical steroids. The comparator was
postoperative topical steroids alone. A secondary comparison was preoperative and/or postoperative topical NSAIDs alone versus
postoperative topical steroids alone.
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Data collection and analysis
Two review authors independently selected studies for inclusion, assessed risk of bias and extracted data using standardmethods expected
by Cochrane. We pooled data using a random-effects model. We graded the certainty of the evidence using GRADE and considered
the following: risk of bias of included studies, precision of the effect estimate, consistency of effects between studies, directness of the
outcome measure and publication bias.
Main results
We identified 34 studies that were conducted in the Americas, Europe, the Eastern Mediterranean region and South-East Asia. Over
5000 people were randomised in these trials. The majority of studies enrolled one eye per participant; a small subset (4 trials) enrolled
a proportion of people with bilateral surgery. Twenty-eight studies compared NSAIDs plus steroids with steroids alone. Six studies
comparedNSAIDs with steroids. A variety of NSAIDswere used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac,
flurbiprofen and pranopfen. Follow-up ranged from one to 12 months. In general, the studies were poorly reported. We did not judge
any of the studies at low risk of bias in all domains. Six studies were funded by industry, seven studies were funded from non-industry
sources, and the rest of the studies did not report the source of funding.
There was low-certainty evidence that people receiving topical NSAIDs in combination with steroids may have a lower risk of poor
vision due to MO at three months after cataract surgery compared with people receiving steroids alone (risk ratio (RR) 0.41, 95%
confidence interval (CI) 0.23 to 0.76; eyes = 1360; studies = 5; I2 = 5%). We judged this to be low-certainty evidence because of risk of
bias in the included studies and indirectness, as the extent of visual loss was not always clear. Only one study reported poor vision due to
MO at 12 months and we judged this to be very low-certainty evidence as there were only two events. Quality of life was only reported
in one of the 34 studies comparing NSAIDs plus steroids versus steroids alone, and it was not fully reported, other than to comment
on lack of differences between groups. There was evidence of a reduced risk of MO with NSAIDs at three months after surgery, but
we judged this to be low-certainty due to risk of bias and publication bias (RR 0.40, 95% CI 0.32 to 0.49; eyes = 3638; studies = 21).
There was inconsistent evidence on central retinal thickness at three months (I2 = 87%). Results ranged from -30.9 µm in favour of
NSAIDs plus steroids to 7.44 µm in favour of steroids alone. Similarly, data on best corrected visual acuity (BCVA) were inconsistent,
but nine out of 10 trials reporting this outcome found between-group differences in visual acuity of less than 0.1 logMAR.
None of the six studies comparing NSAIDs alone with steroids reported on poor vision due to MO at three or 12 months. There was
low-certainty evidence that central retinal thickness was lower in the NSAIDs group at three months (mean difference (MD) -22.64
µm, 95% CI -38.86 to -6.43; eyes = 121; studies = 2). Five studies reported on MO and showed a reduced risk with NSAIDs, but we
judged this evidence to be of low-certainty (RR 0.27, 95% CI 0.18 to 0.41; eyes = 520). Three studies reported BCVA at three months
and the results of these trials were inconsistent, but all three studies found differences of less than 0.1 logMAR between groups.
We did not note any major adverse events - the main consistent observation was burning or stinging sensation with the use of NSAIDs.
Authors’ conclusions
Using topical NSAIDs may reduce the risk of developing macular oedema after cataract surgery, although it is possible that current
estimates as to the size of this reduction are exaggerated. It is unclear the extent to which this reduction has an impact on the visual
function and quality of life of patients. There is little evidence to suggest any important effect on vision after surgery. The value of adding
topical NSAIDs to steroids, or using them as an alternative to topical steroids, with a view to reducing the risk of poor visual outcome
after cataract surgery is therefore uncertain. Future trials should address the remaining clinical uncertainty of whether prophylactic
topical NSAIDs are of benefit, particularly with respect to longer-term follow-up (at least to 12 months), and should be large enough
to detect reduction in the risk of the outcome of most interest to patients, which is chronic macular oedema leading to visual loss.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) for the prevention of macular oedema after cataract surgery
What is the aim of this review?
The aim of this Cochrane Review was to find out if NSAID eye drops can prevent a sight-threatening complication of cataract surgery
(swelling at the back of the eye, known as macular oedema). Cochrane researchers collected and analysed all relevant studies to answer
this question and found 34 studies.
Key messages
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There is only low-certainty evidence to support the use of NSAID eye drops to prevent macular oedema affecting vision after cataract
surgery.
What was studied in the review?
There is a clear lens in the eye that focuses the light on the back of the eye. As people get older this lens can become cloudy. A cloudy
lens is known as a cataract. Doctors can remove the cataract and replace it with an artificial lens. This is usually a very successful
operation. Occasionally, people having cataract surgery can get swelling at the back of the eye after the operation. This swelling is
known as macular oedema. It usually gets better on its own accord, but if it persists it can result in poor vision.
NSAIDs are a medication that can treat inflammation. Theymay be able to reduce the chances of this swelling happening. The NSAIDs
studied in this review were eye drops.
What are the main results of the review?
The review authors found 34 relevant studies. These studies were conducted in all parts of the world including the Americas, Europe,
the Eastern Mediterranean region and South-East Asia. Most (28) of these studies compared NSAIDs combined with steroids against
steroids alone. Some of the studies (6) compared NSAIDs with steroids alone. A variety of NSAIDs were used, including ketorolac,
diclofenac, nepafenac, indomethacin, bromfenac, pranopfen and flurbiprofen. People taking part in these trials were followed up from
between one and 12 months. Most studies only followed up to two months or less. Six studies were funded by industry; seven studies
were funded from non-industry sources and the rest of the studies did not report the source of funding.
There was low-certainty evidence that NSAIDs reduce the chance of poor vision due to macular oedema three months after cataract
surgery. Only one study reported on poor vision due to macular oedema at 12 months and we judged this to have very low-certainty
of evidence.
Using NSAIDs was associated with a reduced risk of macular oedema but the review authors judged this to be low-certainty.
Inconsistent results were seen for some measurements of macular oedema, such as the thickness of the tissue at the back of the eye
(central retinal thickness) at three months after surgery. This measurement was not reported by any studies at 12 months after surgery.
Similarly, inconsistent results were seen for vision measurement (visual acuity) but most studies found small differences between people
given NSAIDs and people not given NSAIDs.
Only one study reported quality of life, and this suggested little impact of NSAIDs on quality of life.
Adverse events mainly consisted of a burning or stinging sensation.
How up-to-date is this review?
The review authors searched for studies that had been published up to 2 September 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NSAIDs plus steroids compared with steroids for the prevention of macular oedema after cataract surgery
Patient or population: people having cataract surgery
Setting: eye hospital
Intervention: NSAIDs plus steroids
Comparison: steroids
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with steroids Risk with NSAIDs plus
steroids
Poor vision due to
MO at 3 months af ter
surgery
74 per 1000 30 per 1000
(17 to 56)
RR 0.41
(0.23 to 0.76)
1360
(5 RCTs)
⊕⊕©©
LOW 12
-
Poor vision due to MO
at 12 months af ter
surgery
20 per 1000 26 per 1000
(2 to 407)
RR 1.32
(0.09 to 20.37)
88
(1 RCT)
⊕©©©
VERY LOW 13
-
Quality of lif e at 3
months af ter surgery
See comment - - 74
(1 RCT)
- Reported in 1 study only
using COMTOL ques-
t ionnaire. Data not fully
reported but no sig-
nif icant dif f erences in
terms of quality of lif e,
compliance and sat is-
fact ion scores
Central ret inal thick-
ness at 3 months af ter
surgery;
assessed with OCT
See comment - - 1021
(8 RCTs)
- Trial results were incon-
sistent (I2 = 87%). Re-
sults ranged f rom -30.
9 microns in favour of
NSAIDs plus steroids to
+7.44 microns in favour
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of steroids alone
Adverse ef fects See comment - - (18 RCTs) - In general, no major
adverse ef fects were
noted. The main con-
sistent observat ion was
burning or st inging sen-
sat ion with use of
NSAID drops
MO at 3 months af ter
cataract surgery, clini-
cally symptomatic,
assessed with OCT
130 per 1000 52 per 1000 (42 to 64) RR 0.40 (CI 0.32 to 0.
49)
3638
(21 RCTs)
⊕⊕©©
LOW 145
BCVA at 3 months af ter
surgery;
assessed with logMAR
scale f rom: -1.3 to 1.3
See comment - - 1158
(10 RCTs)
- Trial results were incon-
sistent (I2 = 70%), but all
except one study found
dif ferences less than 0.
1 logMAR, i.e. clinically
indist inguishable f rom
no dif ference
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BCVA: best corrected visual acuity; CI: conf idence interval; M O: macular oedema; NSAID: non-steroidal ant i-inf lammatory drug; OCT : opt ical coherence tomography; RCT :
randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.
2 Downgraded 1 level for indirectness: extent of visual loss not always clearly def ined.
3 Downgraded 2 levels for imprecision: Only 2 events.
4 Downgraded 1 level for publicat ion bias: asymmetric funnel plot suggest ive of publicat ion bias.
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5 We considered downgrading an addit ional 1 level for indirectness as the MO was not always OCT-verif ied and it was not
always clear if the MO was clinically symptomatic. However, we did not do so part ly because the size of the ef fect was quite
strong.
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B A C K G R O U N D
Description of the condition
Cataract refers to the clouding of the natural crystalline lens of
the eye. It is the leading cause of avoidable visual impairment and
blindness in the world. The World Health Organization (WHO)
estimates that unoperated cataract alone accounts for 33%of visual
impairment, an estimated 94 million cases worldwide (Pascolini
2012). In many parts of the world, particularly higher-income
countries, availability of cataract surgery at a relatively early stage
of visual impairment in the disease process has led to this procedure
being one of the most commonly performed surgical procedures
worldwide.
Macular oedema (MO) is the accumulation of extracellular fluid
in the central retina (the macula) which may present following
cataract surgery with lens implantation (pseudophakic macular
oedema) or without (aphakic macular oedema) and may give rise
to poor visual outcome with reduced visual acuity and distortion
of the central vision. The diagnosis of this condition is made both
clinically using slit lamp biomicroscopic examination of the mac-
ula and with the aid of fundus fluorescein angiography or optical
coherence tomography (OCT) (Choi 2005).
The incidence of MO varies with type of surgery, intraoperative
complications and pre-existing risk factors. Reported risk of MO
varies between 0.9% and 5% for modern uncomplicated pha-
coemulsification cataract surgery (Spaide 1993), but can be as high
as 10% in the presence of surgical complications such as vitreous
loss (Blomquist 2002). Vision is not always affected, and the in-
cidence of MO with decrease in visual acuity is reported at 1%
(Ahmed 2013), and is associated with increasing retinal thickness
(Hee 1995). A multicentre audit of 55,567 cataract operations in
the UK’s National Health Service (NHS) showed a risk of 1.62%,
at a median postoperative review time of 31 days (Jaycock 2009).
This was based on surgeons’ reports rather than systematic exam-
ination of the macula and was defined as poor visual outcome at-
tributed to MO.
Other risk factors for MO include ocular inflammatory diseases
such as uveitis, retinal ischaemic conditions such as central and
branch retinal vein conditions, retinal vascular diseases and dystro-
phies, for example retinitis pigmentosa and retinal telangiectasia,
as well as degenerative causes such as age relatedmacular degenera-
tion anddiabetic retinopathywhile the use of topical prostaglandin
analogue therapy in glaucoma remains a theoretical risk (Nelson
2003). The use of topical adrenaline 2% (epinephrine) in apha-
kic patients has also been described to be associated with macular
oedema. Other factors may include cerebrovascular and cardiovas-
cular disease (Jain 2001) but the pathogenesis is unclear.
MO is often self-limiting with spontaneous resolution (Ahmed
2013). The small proportion of patients with chronic persistent
MO may be difficult to treat (Yannuzzi 1995), and they may
experience permanent reduction in vision from atrophy of the
photoreceptor layer of the retina (Ahmed 2013). Chronic oedema
may lead to the formation of cystic spaces in the retina, termed
’cystoid macular oedema’ (CMO).
Description of the intervention
The intervention is the topical use of non-steroidal anti-inflam-
matory drugs (NSAIDs), in this case, eyedrops, in addition to top-
ical steroid eyedrops after cataract surgery. They may also be used
preoperatively, primarily to reduce the risk of pupil constriction
during surgery, but this may potentially also reduce the risk of
MO. Non-steroidal anti-inflammatory agents are a group of drugs
which are in common use orally as over-the-counter treatments
for the reduction of pain, redness and swelling associated with sys-
temic inflammation. Some of these are also available in eyedrop
form as prescription medicines for the reduction of ocular inflam-
mation.
The comparative intervention is the use of topical steroids on
the eye after cataract surgery, which is current standard therapy,
and may in itself reduce the risk of MO. Steroids are a group of
prescription-only drugs which are used systemically to suppress
the symptoms, signs and sequelae of inflammation. They are also
used in their topical eyedrop form for the reduction of ocular
inflammation.
In the last decade or so, several clinical trials have examined the
use of topical NSAIDs in the treatment and prevention of post-
operative inflammation and pseudophakic macular oedema, with-
out the adverse effects of topical corticosteroids (Ballonzoli 2010;
Carnahan 2000; Heier 1999; Polanski 1992; Solomon 2001).
NSAIDs such as ketorolac and indomethacin are cyclo-oxygenase
inhibitors which suppress breakdown of the blood-aqueous bar-
rier that may occur in the early postoperative period (Flach 1987;
Flach 1988; Miyake 1984; Sanders 1984).
Jain 2001 recommended the use of prophylactic NSAIDs in pa-
tients with predisposing factors to developing postsurgical MO,
irrespective of cause. Other clinical studies suggest that topical
NSAIDs may be more effective than topical steroids in re-estab-
lishing the blood-aqueous barrier postoperatively, suggesting an
important role in MO prevention (Flach 1989; Kraff 1990; Ursell
1999).
The meta-analysis conducted in Rossetti 1998 of the use of
NSAIDs suggested possible beneficial effects of NSAIDs for both
the prophylaxis and treatment of MO, but concluded that the
overall quality of the evidence was insufficient to justify recom-
mendation of its widespread use in prophylaxis. A Cochrane Re-
view on treatment of MO following cataract surgery, found that
two out of seven included randomised controlled trials (RCTs)
showed a beneficial effect of NSAIDs on chronic MO (Sivaprasad
2004), although problemswith trial quality and heterogeneity pre-
vented valid meta-analysis.
A recent randomised, placebo-controlled trial looking at the ad-
junctive effect of topical NSAIDs in addition to intravitreal
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steroids (triamcinolone) and intravitreal anti-vascular endothelial
growth factor (bevacizumab) in chronic MO, found a statistically
significant improvement with the use of topical nepafenac in re-
duction of retinal thickness and improvement in visual acuity at
16 weeks (Warren 2010). NSAIDs have also been used with good
tolerance and efficacy, as an alternate treatment for patients with
MO of mixed origin who are steroid responders, and therefore
cannot be treated with steroids (Warren 2008).
How the intervention might work
NSAIDs are cyclo-oxygenase inhibitors and may work by reduc-
ing the production of pro-inflammatory prostaglandins. Inflam-
mation within tissue is caused by the production of pro-inflam-
matory products by several pathways. NSAIDs act to suppress the
cyclo-oxygenase pathway of inflammation, inhibiting production
of prostaglandins (Eisenach 2010).
Why it is important to do this review
As cataract surgery is the second most commonly performed op-
eration worldwide, and MO occurs in between 1% and 10% of
all cataract surgeries (depending on risk and complications) and
leads to poor visual outcome, there is a significant volume of visual
morbidity which can be potentially prevented if it is found that
NSAIDs are effective in its prophylaxis. NSAIDs are relatively in-
expensive, easily obtainable and carry the potential to significantly
improve the outcome of cataract surgery worldwide.
Despite some evidence in favour of the beneficial effects of
NSAIDs in MO, uncertainty remains about whether it has signif-
icant benefit in the prevention of MO when used perioperatively
in addition to steroids. A recent editorial posed the question as
to how prescribing NSAIDs for routine cataract surgery became
so popular in the USA without compelling evidence of a visual
benefit to patients (Kim 2016a). This uncertainty is reflected in
widespread variation in clinical practice. For example, NSAIDs
are much less frequently used in the UK for this indication. This
review attempts either to resolve the persisting clinical uncertainty
or to identify the need for further research to achieve such resolu-
tion.
This review is confined to addressing the use of NSAIDs in the
prophylaxis of MO. A separate Cochrane Review on treatment
of established cystoid macular oedema (CMO) has already been
published (Sivaprasad 2004), but the effectiveness of NSAIDs in
treatment remains uncertain. MO can lead to permanent struc-
tural damage in the central retina, therefore a prevention strategy
may be more effective than treatment after the damage has been
done.
O B J E C T I V E S
The aim of this review is to answer the question: is there evidence
to support the prophylactic use of topical NSAIDs either in addi-
tion to, or instead of, topical steroids postoperatively to reduce the
incidence of macular oedema (MO) and associated visual morbid-
ity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) in this re-
view. We excluded within-person studies i.e. studies where eyes
are randomly allocated to the intervention and comparator due to
the possibility that the effect of non-steroidal anti-inflammatory
drugs (NSAIDs) in one eye may affect the outcome in the other.
Types of participants
We included trials inwhich adult participants had undergone stan-
dard surgery for age-related cataract. We included participants ir-
respective of their baseline risk of MO, in particular, we included
people with diabetes and uveitis.
Types of interventions
The primary comparison of this review was topical NSAIDs
in addition to topical steroids versus topical steroids alone in
cataract surgery. Surgery can include extracapsular cataract extrac-
tion (ECCE; large incision with sutures), manual small incision
cataract surgery (MSICS; small incision without sutures), pha-
coemulsification cataract surgery (mechanised small incision extra-
capsular extraction) and intracapsular cataract extraction (ICCE;
planned and unplanned intracapsular procedures).
We included trials of preoperative and/or postoperative topical
NSAIDs in conjunction with postoperative topical steroids. The
comparator was postoperative topical steroids alone.
A secondary comparison was preoperative and/or postoperative
topical NSAIDs alone versus topical postoperative steroids alone.
We included studies irrespective of whether incident MO was
subsequently treated.
Types of outcome measures
Primary outcomes
• The proportion of people with a poor vision outcome due
to MO in the study eye at three months after surgery.
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We defined poor vision outcome as best corrected visual acuity
(BCVA) not improving to 6/9 or better (or equivalent with other
notations of vision) attributed to a diagnosis of MO (detected
clinically, angiographically or on optical coherence tomography
(OCT)). This included participants who developed MO and re-
quired and received treatment.
Our primary outcome was measured at three months after surgery,
which we took as any observation between one month and six
months after surgery. We also examined poor visual outcome due
to MO at 12 months after surgery, which we took as any observa-
tion between six and 18 months after surgery.
Secondary outcomes
• Any quality of life or patient satisfaction measure relating to
the patient’s experience of surgery on the study eye., at three
months and 12 months after surgery
• Change in central retinal thickness from preoperative
assessment in the study eye, at three months and 12 months after
surgery, as measured by OCT scan. If change in central retinal
thickness was not available we used the final value.
Adverse effects
We looked at known harms of NSAIDs including respiratory ef-
fects and gastrointestinal disturbance, in addition to intolerance
of medication and allergic reactions. We recorded any other harms
such as liver toxicity, as has been reported with some NSAIDs.
Resource use and costs
In our protocol (Abeysiri 2011) we planned to look at economic
evaluations of the cost-effectiveness and cost per quality-adjusted
life year (QALY)/disability-adjusted life year (DALY) modelling.
We amended this to look at resource use and costs more generally.
Additional outcomes (National Institute for Health and
Care Excellence (NICE))
We collected data on the following additional outcomes as part of
our collaboration with NICE.
• Macular oedema (MO) (clinically symptomatic, OCT-
verified).
• Inflammation.
• BCVA.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (2016, Issue 8), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Cita-
tions, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to September 2016), Embase (January 1980 to Septem-
ber 2016), Latin American and Caribbean Health Sciences Lit-
erature Database (LILACS) (1982 to September 2016), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 2 September 2016.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), Embase (Appendix 3),
LILACS (Appendix 4), ISRCTN (Appendix 5), ClinicalTrials.gov
(Appendix 6), and the ICTRP.
Searching other resources
We searched the reference lists of the studies included in the re-
view. We used the Science Citation Index to find studies that have
cited the individual trials. We did not handsearch conference pro-
ceedings or journals specifically for the review.
Data collection and analysis
Selection of studies
Three review authors (CL, BL,DL) screened the titles and abstracts
resulting from the searches independently.We obtained full copies
of the potentially relevant trials. Three review authors (CL, BL,
DL) independently assessed full copies for inclusion according to
the ’Criteria for considering studies for this review.’ We resolved
disagreements by discussion.
We listed all excluded studies and provided a brief justification for
exclusion (See Characteristics of excluded studies).
Data extraction and management
Four review authors (JE, CL, DL, BL) independently extracted
data using a pre-piloted data extraction template in Covidence
(Covidence 2016). A fifth review author (CB) generated a random
sample of 20% of studies and checked data input for these. We
resolved discrepancies by discussion.
We collected the following information on study characteristics
(Appendix 8).
• Study design: parallel group RCT, one or both eyes
included and/or reported.
• Participants: country, total number of participants, age, sex,
inclusion and exclusion criteria.
• Intervention and comparator details: including number
randomised to each.
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• Primary and secondary outcomes as measured and reported
in the trials, adverse events, methods of measurement (e.g. which
chart is used for visual acuity assessment, which OCT scanner
was used).
• Length of follow-up.
• Date study conducted.
• Funding and conflicts of interest reported.
• Trial registration number.
We collected data on our predefined outcomes separately for inter-
vention and comparator groups. Formulti-arm studies we planned
to use data relevant to our intervention and comparator groups. If
two groups contain relevant data (for example, if pre/postoperative
application of NSAIDs) we combined groups using the RevMan
calculator (RevMan 2014).
As far as possible, we extracted data for an intention-to-treat (ITT)
analysis. We contacted trial investigators as needed. Data were
imported directly from Covidence into Review Manager 5 by JE
(RevMan 2014), and checked by the other review authors (CL,
DL, BL). CB then conducted a final random assessment.
Assessment of risk of bias in included studies
We used Cochrane’s ’Risk of bias’ tool for assessing risk of bias
in each included study. Four review authors (JE, CL, DL, BL)
independently assessed risk of bias according to methods set out
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We followed the specific rules as set
out in Table 1 and resolved disagreements by discussion.
We contacted trial investigators for Miyake 2011 for clarification
of random allocation.
Measures of treatment effect
We calculated the risk ratio for outcome measures reported as
dichotomous data (for example, poor visual acuity attributed to
MO within three months). We calculated the mean difference
for measures of retinal thickness. We planned to analyse ordinal
outcome data as dichotomous data if an established defensible cut-
off point is available, such as quality of life measures. We did not
plan to meta-analyse adverse effects.
Unit of analysis issues
Trials includedmay randomise one or both eyes to the intervention
or comparator. If both eyes were allocated to the same treatment,
we planned to analyse as ’clustered data’ if data were available.
In the event four trials included data on both eyes, but this was
generally a small proportion of the total participants. We have
analysed as reported.We excluded studieswhich allocated different
eyes to different treatments as there may be a confounding cross-
over effect due to systemic absorption.
Dealing with missing data
We assessed all included trials for number of participants excluded
or lost to follow-up. We documented reasons for loss to follow-up
by treatment group, if reported. We aimed to do an ITT analysis
for included trials using imputed data; if computed by the trialists
we did not plan to impute missing data on their behalf.
Assessment of heterogeneity
Where heterogeneity was observed between individual study re-
sults we did not combine studies but present a tabulated summary
of results. We did not rely on statistical significance of a Chi2 test
to indicate heterogeneity but examined the forest plot of the study
results and the overall characteristics of the studies. We looked
at the consistency between studies by examining the I2 statistic
value. We considered I2 values over 50% to indicate substantial
inconsistency, but we also considered the direction of effects.
Assessment of reporting biases
We considered selective outcome reporting under the risk of bias
assessment (Table 1). We planned to look at funnel plots and
consider tests for asymmetry for bias assessment in the event of 10
or more trials contributing data to a meta-analysis.
Data synthesis
We aimed to use a random-effects model provided we did not de-
tect substantial inconsistency between individual study results. If
there were fewer than three trials in a comparison we planned to
use the fixed-effect model. Where heterogeneity was observed be-
tween studies (see Assessment of heterogeneity) we did not com-
bine studies but presented a narrative summary of results.
’Summary of findings’ table
We prepared a ’Summary of findings’ table presenting relative and
absolute risks. We graded the overall certainty of the evidence for
each outcome using the GRADE classification (Atkins 2004). We
considered the following: risk of bias of included studies, precision
of the effect estimate, consistency of effects between studies, di-
rectness of the outcome measure and publication bias. JE did the
assessment and this was checked by other authors. We included
the following outcomes in the ’Summary of findings’ tables.
1. Poor vision outcome due to MO at three months after
surgery.
2. Poor vision outcome due to MO at 12 months after surgery.
3. Quality of life at three months after surgery.
4. Central retinal thickness at three months after surgery.
5. Adverse effects.
6. MO (clinically symptomatic, OCT-verified) at three
months after surgery
7. BCVA at three months after surgery.
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Subgroup analysis and investigation of heterogeneity
We planned to conduct a subgroup analysis on the primary out-
come comparing the effect of treatment on people with higher
baseline risk of MO (diabetes/uveitis) with people with lower risk
of MO (no diabetes/uveitis), but we did not do them as planned
as there were not enough data on the primary outcome.
Sensitivity analysis
We planned to perform three sensitivity analyses on the primary
outcome, but we did not do them as planned as there were not
enough data on the primary outcome.
• Excluding studies at high risk of bias in one or more
domains.
• Excluding industry-funded studies.
• Comparing fixed-effect and random-effects models (if three
or more trials).
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 928 references (Figure
1). The Cochrane Information Specialist removed 337 duplicate
records and we screened the remaining 591 reports. We rejected
526 records after reading the abstracts and obtained the full-
text reports of 65 references for further assessment. We identi-
fied 43 reports of 34 studies which met the inclusion criteria (see
Characteristics of included studies for details), and excluded 18
reports of 18 studies (see Characteristics of excluded studies for
details). One unpublished trial is currently awaiting assessment
(CTRI/2009/091/001078). We identified three ongoing studies
(NCT01694212; NCT01774474; NCT02646072).
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Figure 1. Study flow diagram.
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Included studies
We have summarised the characteristics of the 34 included stud-
ies below. Details for individual studies can be found in the
Characteristics of included studies. The information is also sum-
marised in Table 2; Table 3; Table 4; Table 5; Table 6
Setting and conduct of Study
See Table 2.
The studies were conducted in Brazil (Ticly 2014; Tzelikis 2015),
Canada (Almeida 2008; Almeida 2012; Solomon 1995), China
(Li 2011; Wang 2013; Zhang 2008), Egypt (Elsawy 2013), Ger-
many (Quentin 1989; Solomon 1995), Greece (Chatziralli 2011;
Moschos 2012) , Italy (Italian Diclofenac Study Group 1997;
Rossetti 1996), Japan (Asano 2008; Endo 2010; Miyake 2007;
Miyake 2011; Miyanaga 2009), Mexico (Cervantes-Coste 2009),
South Korea (Jung 2015), Sweden (Zaczek 2014), Switzerland
(Umer-Bloch 1983), Turkey (Tunc 1999; Yavas 2007) and the
USA (Brown 1996; Donnenfeld 2006; Kraff 1982; Mathys 2010;
Singh 2012; Tauber 2006; Wittpenn 2008; Yannuzzi 1981; Yung
2007).
They were all parallel group RCTs, i.e. participants were randomly
allocated to intervention or comparator. Three of the studies were
described as “open-label” (Almeida 2008;; Endo 2010; Wang
2013).
Four studies were funded by industry alone (Brown 1996; ;
Solomon 1995; Tauber 2006; Wittpenn 2008; ); seven studies re-
ported only non-industry funding (Almeida 2008; Almeida 2012;
Jung 2015; Kraff 1982; Mathys 2010; Wang 2013; Yannuzzi
1981); two studies had funding from both industry and non-in-
dustry sources (Donnenfeld 2006; Zaczek 2014) and the rest of
the studies did not report the source of funding.
Declarations of interest were not reported in 12 studies; 17 stud-
ies reported that they had no conflicts of interest and six stud-
ies reported conflicts of interest for one or more investigators
(Donnenfeld 2006; ItalianDiclofenac Study Group 1997;Miyake
2011; Singh 2012; Tauber 2006; Wittpenn 2008).
Six trials were registered on a publicly available database. For three
of these trials the registration was probably prospective as the
month of registration was the same, or before, the month the
study started (Almeida 2008; Mathys 2010; Singh 2012).Three
trials were registered retrospectively (Almeida 2012; Tzelikis 2015;
Wittpenn 2008).
Two trials were reported in abstract form only (Tauber 2006; Yung
2007). However, we contacted the first authors of Tauber 2006
and Yung 2007 and we received additional information in the
form of a poster from Yung 2007.
Participants
See Table 3 and Table 4.
There were variations in the reporting of recruited and randomised
participants. As such it is difficult to establish definitively the total
number of people thatwere randomised in these trials.We estimate
that therewere 5532people (5608 eyes) enrolled in these 34 studies
and 4476 followed up. (Table 3).
Five studies did not report the number of people randomised
(Brown 1996; Tauber 2006; Umer-Bloch 1983; Yannuzzi 1981;
Zhang 2008). For four of these five studies we estimated the num-
ber of people in the trial from the number analysed. One study
provided no information on the number of participants (Brown
1996).
For those studies that did not report follow-up clearly we have
assumed the number randomised and number followed up was
the same.
The majority of the studies (n = 24) enrolled one eye person in
the trial, although this was not always clearly described. In six
studies the number of eyes/people was not reported in enough
detail to be confident howmany eyes per person had been enrolled
(Donnenfeld 2006; Kraff 1982; Tauber 2006; Umer-Bloch 1983;
Wang 2013; Yung 2007), although it is likely that they too largely
performed unilateral surgery.
Four studies performed bilateral surgery on a subset of patients,
and so had more eyes than people in the trial (Almeida 2008;
Elsawy 2013; Yannuzzi 1981; Zhang 2008). The proportion
of people with bilateral surgery was 1% (Yannuzzi 1981), 8%
(Almeida 2008), 11% (Zhang 2008) and 23% (Elsawy 2013).
None of the studies adjusted for within-person correlation. We
have analysed the data as reported.
For the studies that reported average age, the median average age
of participants was 70 years (Table 4). Ages ranged from 37 to 100
years. For the studies that reported gender, the median percentage
of women was 54%.
Fifteen studies reported that they excluded patients with diabetes
or diabetic retinopathy, or were a “low risk population”. Nine
studies did not report the diabetes status of their participants. Nine
studies included people with diabetes and reported the percentage
of the participants with diabetes. The percentage with diabetes was
10%/9% (Chatziralli 2011; Miyake 2011), 21%/20% (Almeida
2008; Cervantes-Coste 2009) and 26% (Jung 2015). Five studies
only included people with diabetes (Elsawy 2013; Endo 2010; Li
2011; Singh 2012; Yung 2007).
The majority of studies either excluded people with uveitis (n =
19) or had a “low risk population” (Almeida 2012), or very low
proportion with uveitis (1/56 people) (Almeida 2008). Thirteen
studies did not report uveitis and it was not included in the exclu-
sion criteria.
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Interventions
See Table 5
Type of surgery
Twenty-four of the 34 studies reported that only phacoemulsifica-
tion was performed for cataract extraction (Table 5). In one study
both extracapsular cataract extraction (ECCE) and phacoemulsi-
fication were performed (Kraff 1982). Four studies reported that
they performed ECCE (Italian Diclofenac Study Group 1997;
Rossetti 1996; Solomon 1995; Tunc 1999), two studies per-
formed ICCE (Quentin 1989; Yannuzzi 1981) and one study
performed a mixture of ECCE/intracapsular cataract extraction
(ICCE) (Umer-Bloch 1983). In two studies that were reported in
abstract form only there was no information on type of surgery but
we have assumed that they used phacoemulsification because of
the date published and location of the study (Tauber 2006; Yung
2007).
Comparison
Twenty-eight of the 34 studies compared non-steroidal anti-in-
flammatory drugs (NSAIDs) with steroids versus steroids. In 14
of these 28 studies, a placebo (for the NSAIDs) was used in the
comparator group. This placebo was not specified in two trials
(Quentin 1989; Rossetti 1996;); was artificial tears in five trials
(Ticly 2014; Tzelikis 2015; Wittpenn 2008; Yung 2007; Zaczek
2014); a vehicle in six studies (Donnenfeld 2006; Kraff 1982;
Singh 2012; Solomon 1995; Umer-Bloch 1983; Yannuzzi 1981);
and sterile saline drops in Almeida 2012. .
Six of the 34 studies compared NSAIDs (on their own) with
steroids (Asano 2008; Brown 1996; Endo 2010; ItalianDiclofenac
Study Group 1997; Miyake 2007; Miyake 2011). Only one of
these studies used a placebo in the steroid group; the contents of
this placebo were not specified. (Italian Diclofenac Study Group
1997).
NSAIDs
The most frequently used NSAID was ketorolac (11 studies)
followed by diclofenac (9 studies), nepafenac (7 studies), in-
domethacin (5 studies), bromfenac (4 studies), pranoprofen (1
study) and flurbiprofen (1 study). Four studies had two different
NSAID groups - ketorolac and nepafenac (Almeida 2012; Tzelikis
2015), ketorolac and bromfenac (Jung 2015) and flurbiprofen and
indomethacin (Solomon 1995). We combined these groups for
the analysis.
The ketorolac concentration was either 0.4% or 0.5%. Diclofenac
was largely used at a concentration of 0.1% (7 studies) but also
used at 1% in Li 2011 and concentration was not specified in
one study (; Rossetti 1996). Nepafenac was used at 0.1% in six
studies and 1% in one study (Singh 2012). Indomethacin 1% was
used in three studies (Solomon 1995;Umer-Bloch 1983; Yannuzzi
1981), 0.1% in Yavas 2007 while the concentration used was not
specified in Kraff 1982. Bromfenac 0.1% was used in Miyanaga
2009, Jung 2015 and Wang 2013; it was not specified in Endo
2010. Flubiprofen was used at 0.03% (Solomon 1995). Pranopfen
concentration was not specified (Zhang 2008).
Steroids
Prednisolone was used in 13 studies, usually at 1%.
Dexamethasone was used in 15 studies, at a concentration of 0.1%
in eight studies and 1% in one study (Tunc 1999). The concentra-
tion used was not specified in 6 studies. It was combined with to-
bramycin in four studies (Cervantes-Coste 2009; Li 2011; Rossetti
1996; Zhang 2008) and other antibiotics (Kraff 1982; Moschos
2012; Umer-Bloch 1983).
Betamethasone was used at 0.1% in two studies (Asano 2008;
Miyanaga 2009) and not specified in one study (Endo 2010).
Fluorometholone 0.1% was used as the sole topical corticosteroid
therapy in three studies (Miyake 2007;Miyake 2011;Wang 2013)
and used as part of a tapering regimen in one study (Kraff 1982).
The type of steroids used in Yannuzzi 1981 were not specified.
Other medications
Most studies reported the use of additional antibiotics. See
Characteristics of included studies.
Outcomes
Maximum follow-up ranged from one month (8 studies) to 12
months postoperatively (Kraff 1982; Yannuzzi 1981) (Table 6).
The majority of trials followed up to two months or less (23 stud-
ies). Five studies followed up to three months (Elsawy 2013; Singh
2012; Umer-Bloch 1983; Yavas 2007; Yung 2007) and six stud-
ies followed up longer: 140 days (Italian Diclofenac Study Group
1997), six months (Quentin 1989; Rossetti 1996; Solomon 1995)
and 12 months (Kraff 1982; Yannuzzi 1981). Kraff 1982 had a
low follow-up of 10 % at 12 months
Table 6 shows the outcomes reported in the studies.
Excluded studies
See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The majority of trialists did not report sufficient information to
judge selection bias. These trials were marked as unclear for se-
quence generation and allocation concealment. Only two trials
were judged at low risk of bias on both sequence generation and
allocation concealment (Tzelikis 2015; Wittpenn 2008).
Eight trials reported a method of sequence generation judged to
be likely to generate an unpredictable sequence. Some trials used
random number tables (Kraff 1982; Rossetti 1996; Wang 2013),
other reports suggested computer-generated random numbers or
allocation schedules (Mathys 2010; Tzelikis 2015), others referred
to random numbers or randomly generated lists but did not spec-
ify how these were created (Donnenfeld 2006; Moschos 2012;
Wittpenn 2008).
Four trials reported a convincing method of allocation conceal-
ment (Asano 2008; Tzelikis 2015; Wittpenn 2008; Zaczek 2014).
In Asano 2008 the assignment code was kept secret by a named
individual until the end of the study; in Tzelikis 2015 all inves-
tigators were masked to treatment group; Wittpenn 2008 used a
central co-ordination centre for allocation and in Zaczek 2014 the
allocation was prepared in such a way that neither investigators
nor participants could identify the group.
In three studies, we judged that the allocation was probably
not concealed adequately (Almeida 2008, Wang 2013; Yannuzzi
1981).
Blinding
Ten studies were not masked and we judged them to be at high risk
of both performance and detection bias (Almeida 2008; Elsawy
2013; Endo 2010; Jung 2015; Li 2011; Miyanaga 2009; Moschos
2012; Tauber 2006; Wang 2013; Zhang 2008).
Eight studies were masked and we judged them to be at low risk of
both performance and detection bias (Almeida 2012; Asano 2008;
Kraff 1982; Singh 2012; Ticly 2014; Tzelikis 2015; Umer-Bloch
1983; Zaczek 2014).
Two studies that did not mask participants, stated explicitly that
outcome assessors were masked (Mathys 2010; Wittpenn 2008).
For six studies, there was not enough information to judge the
risk of either performance or detection bias (Donnenfeld 2006;
Miyake 2011;Quentin 1989; Rossetti 1996; Solomon 1995; Yung
2007).
Incomplete outcome data
We judged five studies to be at high risk of attrition bias. In Asano
2008, there was variable follow-up by outcome, and it was not
clearly explained why. Some of the stated exclusion criteria for
the study, such as inflammation after surgery, would have been
related to the outcome. In Endo 2010, follow-up was unequal
between study groups and reason for loss to follow-up was not
clearly reported. In Umer-Bloch 1983, 35 people withdrew before
the end of the study because of intraoperative complications or
they had, as only later recognised, an exclusion criteria as defined
as maculopathy, diabetic retinopathy, prior uveitis or a systemic
steroid therapy. It was not reported to which groups these patients
belonged. In Wittpenn 2008, there was very low follow-up at six
weeks, with 77/546 (14%) people followed-up. In Yannuzzi 1981
there was a high loss to follow-up at 12 months: 38/100 (38%) in
the NSAIDs group and 50/131 (38%) in the control group were
followed-up.
We judged 11 studies to be at low risk of attrition bias. For the
other studies there was not enough information to judge.
Selective reporting
For most studies there was little information to judge selective
outcome reporting because we did not have access to a trial reg-
istry entry or study protocol. We judged three studies to be at
low risk of selective outcome reporting on the basis that the trial
was prospectively registered and all outcomes prespecified on the
clinical trials registry entry were reported (Almeida 2008; Mathys
2010; Singh 2012). For three studies it was clear that some out-
comes were not fully reported and so we judged them to be at high
risk of selective outcome reporting bias (Asano 2008; Solomon
1995; Tauber 2006).
Effects of interventions
See: Summary of findings for the main comparison NSAIDS
plus steroids compared with steroids for the prevention of macular
oedema after cataract surgery; Summary of findings 2 NSAIDS
compared with steroids for the prevention ofmacular oedema after
cataract surgery
Non-steroidal anti-inflammatory drugs plus steroids
versus steroids
Primary outcome
Poor vision due to macular oedema
Five studies reported this outcome at three months (eyes = 1360)
(Analysis 1.1). Follow-up ranged from four weeks to two months.
Two studies reported optical coherence tomography (OCT)-con-
firmedmacular oedema (MO)with visual acuity < 6/9 in one study
(Wittpenn 2008) but the level of visual impairment not defined
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in the other (Wang 2013). Solomon 1995 defined the presence of
clinical MO as visual acuity <=20/40 and angiographic evidence
of CMO. Cervantes-Coste 2009 reported that none of the par-
ticipants developed clinically significant macular oedema nor vi-
sion loss. Chatziralli 2011 reported that none of the participants
developed clinically significant CMO as assessed via fundoscopy
and the Amsler grid test. There was some evidence of selective
reporting in Solomon 1995, which provided most of the informa-
tion for the meta-analysis. Data were only reported for the earlier
follow-up at days 21 to 60. Quote: “By day 121-240 the incidence
of clinical CME [cystoid macular edema] was less than 2% in all
three groups and no significant differences were seen.”
People receivingnon-steroidal anti-inflammatory drugs (NSAIDs)
combined with steroids had a lower risk of poor vision due to
macular oedema (MO) at three months after surgery compared
with people receiving steroids alone. The pooled risk ratio (RR)
was 0.41, 95% confidence interval (CI) 0.23 to 0.76; eyes = 1360;
studies = 5. There was no evidence of any major inconsistency (I
2 = 5%). We judged this to be low-certainty evidence (Summary
of findings for the main comparison). We downgraded for risk of
bias, as the trials were poorly reported and were largely at high
or unclear risk of bias. We downgraded for indirectness, as the
outcomes reported by the trials only approximated the outcome
which we wished to collect, which was poor vision (best corrected
visual acuity (BCVA) < 6/9) due to MO.
One study reported this outcome at 12 months (Yannuzzi 1981).
There was high attrition in this study (only 38% of eyes followed
up) and only two events (RR 1.32, 95% CI 0.09 to 20.37; eyes =
88). We judged this to be very low-certainty evidence, downgrad-
ing for risk of bias and imprecision (2 levels; Summary of findings
for the main comparison).
Secondary outcomes
Quality of life/patient satisfaction
One study reported quality of life at 1 month after surgery us-
ing the Comparison of Ophthalmic Medications for Tolerability
(COMTOL) questionnaire (Almeida 2012), No differences in the
impact upon quality of life measures were identified between the
treatment and control groups. The use of topical NSAIDs was
also reported to have good tolerability and comparable side-effect
profile to placebo. However the data in this study were not fully
reported and a response rate of only 60% was achieved with sig-
nificant attrition with 65 out of 162 patients declining to answer
the interview after surgery for “logistical reasons”.
Quote: “The global [health-related quality of life] HRQOL ques-
tions showed no difference in the extent to which quality of life
was affected by medication side effects between “not at all” and
any reported effect (question 6; P = 0.8476). Regarding the extent
quality of life was affected by activity limitations, there was no
difference between “not at all” and any reported limitations (ques-
tion 9; P = 0.8584). According to the COMTOL questionnaire,
there was no difference in compliance between the 3 study groups
(question 10; P = 0.3801). Most patients in all 3 groups reported
being satisfied with the medication, and there was no difference
between satisfied responses and dissatisfied responses (question 11;
P = 0.4777)”).
Central retinal thickness
Nine studies reported this outcome (eyes = 1112) (Analysis 1.2).
Follow-up ranged from one to two months. Six studies reported
central retinal thickness at the end of the follow-up period, three
studies reported change in thickness from baseline. Trial results
were inconsistent (I2 = 87%). Results ranged from -30.9 µm in
favour of NSAIDs plus steroids to +7.44µm in favour of steroids
alone (Summary of findings for the main comparison).
Six studies reported change in macular volume (eyes = 570) (
Analysis 1.3). The pooled mean difference (MD) was -0.14 mm
3 (95% CI -0.21 to -0.07). There was some inconsistency (I2 =
50%), mainly attributable to Mathys 2010.
Adverse effects
SeeTable 7. In the studies that reported adverse effects, no evidence
of serious adverse events were seen. Themost notable adverse effect
associated with NSAID use was burning or stinging sensation.
Resource use and costs
None of the studies commented on this.
Additional National Institute for Health and Care
Excellence (NICE) outcomes
Macular oedema (MO) (clinically symptomatic, optical
coherence tomography-verified)
Twenty-one studies reported this outcome (eyes = 3638) (Analysis
1.4). Follow-up ranged from twoweeks to just less than sixmonths.
Most studies reported “cystoid” macular oedema but it was not
always clearly defined nor was it clear that it was clinically signifi-
cant. Nine studies used OCT, although it was not always clear if
the OCTwas used to verify theMO; nine studies used fluorescein
angiography, often using the Miyake 1977 classification; clinical
assessment for the presence of MO was made in two studies.
There was an asymmetric funnel plot, suggesting that publication
bias might be an issue (Figure 3).
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Figure 3. Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema.
People receiving NSAIDs combined with steroids had a lower
risk of MO after surgery compared with people receiving steroids
alone. The pooledRRwas 0.40, 95%CI 0.32 to 0.49; I2 = 0%.We
judged this to be low-certainty evidence (Summary of findings for
themain comparison).We downgraded one level for risk of bias, as
the studies were at unclear or high risk of bias and we downgraded
one level for publication bias as an asymmetric funnel plot was
suggestive of publication bias. We considered downgrading one
level for indirectness, as theMOwas not always OCT-verified and
it was not always clear if the MO was clinically significant but in
the event did not as the size of the effect was strong.
Inflammation
Three studies reported inflammation as a dichotomous outcome
(Analysis 1.5). In Cervantes-Coste 2009 there were no cases of
“inflammatory cells greater than 1+ during first week of postoper-
ative visits.” In Chatziralli 2011, at day 28, inflammation, which
was defined as corneal oedema or Tyndall reaction or conjuncti-
val hyperemia was seen in two participants in the NSAIDs plus
steroid group (RR 4.86, 95% CI 0.24 to 99.39); by day 35 this
had disappeared. In Zhang 2008, 20 participants in the steroids
group had inflammation defined as “Tyn granule +” compared to
0 participants in the NSAIDs plus steroids group at one month
(RR 0.02, 95% CI 0.00 to 0.38). In view of such different results,
we did not pool the data from these trials.
Two studies reported flare in photons/millisecond (eyes = 216)
(Analysis 1.6). The MD was -1.41 photons/millisecond in favour
of NSAIDs plus steroids (95% CI -2.30 to -0.52), but there was
some inconsistency between the two studies (I2 = 49%). There was
some evidence of skew for the control group of Miyanaga 2009
(mean/standard deviation (SD) < 2).
Jung 2015 reported “summed ocular inflammation score” which
was the sum of the scores of cells and flare, scored against a maxi-
mum total score of 9. The inflammatory score at one month was
0.21 ± 0.42 in the bromfenac group and 0.32 ± 0.48 in the ketoro-
lac group (P = 0.853). The score in the control group was 0.84 ±
0.76.
Best corrected visual acuity
Ten studies reported BCVA (eyes = 1158) (Analysis 1.7). For
Mathys 2010 change in BCVA was reported in letters. We con-
verted this to logMAR score by multiplying by -0.02 and we esti-
mated the SD from the P value.
There was statistical heterogeneity (I2 = 70%), and not all effect
estimateswere in the same direction, sowe didnot provide a pooled
estimate. However, we note that most studies found differences
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clinically indistinguishable from no difference.
Non-steroidal anti-inflammatory drugs versus
steroids
Primary outcome
Poor vision due to macular oedema
None of the studies reported this outcome.
Secondary outcomes
Quality of life/patient satisfaction
None of the studies reported this outcome.
Central retinal thickness
Two studies reported central retinal thickness (Analysis 2.1). The
pooled MD was -22.64 µm (95% CI -38.86 to -6.43; I2 = 0%) in
favour of NSAIDs. We judged this to be low-certainty evidence
(Summary of findings 2). We downgraded one level for risk of
bias, as the studies were at unclear or high risk of bias, and we
downgraded one level for imprecision as the confidence intervals
include a clinically unimportant effect.
Adverse effects
SeeTable 7. In the studies that reported adverse effects, no evidence
of serious adverse events were seen. Themost notable adverse effect
associated with NSAID use was burning or stinging.
Resource use and costs
None of the studies commented on this.
Additional NICE outcomes
Macular oedema (clinically symptomatic, optical coherence
tomography-verified)
Five studies reported this outcome (eyes = 520) (Analysis 2.2). All
studies assessed MO using fluorescein angiography. The pooled
RRwas 0.27 (95%CI 0.18 to 0.41) in favour of NSAIDs.We note
that for Asano 2008 there may have been selective reporting - data
on MO were reported only at five weeks, but were not reported at
the end of eight weeks follow-up in that study.
We judged this to be low-certainty evidence (Summary of findings
2). We downgraded one level for risk of bias, as the studies were
at unclear or high risk of bias and we downgraded one level for
publication bias because of an asymmetric funnel plot suggestive
of publication bias (Figure 4). We would not usually do a funnel
plot with so few studies, but as the funnel plot for this outcome,
for the comparison NSAIDs plus steroids versus steroids alone was
asymmetric (Figure 3), we felt that publication bias may be an
issue here as well.
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Figure 4. Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema.
Inflammation
Five studies reported aqueous flare (eyes = 346) (Analysis 2.3).
There was substantial inconsistency ( I2 = 68%) and some evidence
of skewed data so we did not report a pooled value.
Best corrected visual acuity
Three studies reported BCVA (eyes = 220) (Analysis 2.4). There
was statistical heterogeneity (I2 = 84%) so we did not report a
pooled value, but we note that all three studies found between
group differences that were clinically indistinguishable from no
difference.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
NSAIDscompared with steroids for the prevention of macular oedema after cataract surgery
Patient or population: people having cataract surgery
Setting: eye hospital
Intervention: NSAIDs
Comparison: steroids
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with steroids Risk with NSAIDs
Poor vision outcome
due to MO at 3 months
af ter surgery
- - - - - No data were available
for this outcome.
Poor vision outcome
due to MO at 12 months
af ter surgery
- - - - - No data were available
for this outcome.
Quality of lif e at 3
months af ter surgery
No data were available
for this outcome.
Central ret inal thick-
ness at 3 months af ter
surgery;
assessed with OCT
The mean central ret i-
nal thickness at 3
months af ter surgery
was 228 microns
MD 22.64 microns
lower
(38.86 lower to 6.43
lower)
- 121
(2 RCTs)
⊕⊕©©
LOW 14
-
Adverse ef fects - - - 488
(4 RCTs)
- 1 study had 2 unspec-
if ied complicat ions in
142 part icipants, 2
studies reported that
no adverse events were
noted in either group, 1
study (55 people) men-
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t ioned 15 mild adverse
ef fects but unclear if re-
lated to treatment
MO at 3 months af ter
cataract surgery; clini-
cally symptomatic
assessed with OCT
130 per 1000 35 per 1000
(23 to 53)
RR 0.27 (0.18 to 0.41) 520
(5 RCTs)
⊕⊕©©
LOW 123
BCVA at 3 months af ter
surgery;
assessed with logMAR
scale f rom: -1.3 to 1.3
See comment - - 220
(3 RCTs)
- Trial results were incon-
sistent (I2 = 84%), but
all studies found dif fer-
ences less than 0.1 log-
MAR,
i.e. clinically indist in-
guishable f rom no dif -
ference.
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BCVA: best corrected visual acuity; CI: conf idence interval; M D: mean dif ference; M O: macular oedema; NSAID: non-steroidal ant i-inf lammatory drug; OCT : opt ical coherence
tomography; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded 1 level for risk of bias: studies at unclear or high risk of bias.
2 Downgraded 1 level for publicat ion bias: asymmetric funnel plot suggest ive of publicat ion bias.
3 We considered downgrading 1 level for indirectness as the MO was not always OCT-verif ied and not always clear if it was
clinically symptomatic however we did not do so, part ly because the ef fect was strong.
4 Downgraded 1 level for imprecision: conf idence intervals include clinically unimportant ef fect.
5 Downgraded 1 level for inconsistency.
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison; Summary of
findings 2.
We identified 34 studies that were conducted in the Americas,
Europe, the Eastern Mediterranean region and South-East Asia.
Over 5000 people were randomised in these trials. The majority
of studies probably enrolled one eye per participant, a small subset
(4 trials) enrolled a proportion of people with bilateral surgery.
Twenty-eight of these 34 studies compared non-steroidal anti-
inflammatory drugs (NSAIDs) plus steroids with steroids alone.
Six studies compared NSAIDs (on their own or with placebo)
with steroids. A variety of NSAIDs were used, including ketorolac,
diclofenac, nepafenac, indomethacin, bromfenac and pranopfen.
Follow-up ranged from one month to 12 months. The majority of
studies (n = 23) followed up to two months or less. In general, the
studies were poorly reported. We did not judge any of the studies
at low risk of bias in all domains.
There was low-certainty evidence that people receiving topical
NSAIDs in combination with steroids may have a lower risk of
poor vision due to macular oedema (MO) at three months after
cataract surgery compared with people receiving steroids alone
(risk ratio (RR) 0.40, 95% confidence interval (CI) 0.27 to 0.61;
eyes = 1360; studies = 5; I2 = 5%). There were very little data for
12 months (only one study reported poor vision due toMO at this
time point) andwe judged this to have very low-certainty evidence.
Similarly, we judged the evidence on ’clinically symptomatic MO’
to be low-certainty. There was evidence on central retinal thickness
at three months, but this was inconsistent (I2 = 87%). Results
ranged from -30.9 microns in favour of NSAIDs plus steroids to
7.44 microns in favour of steroids alone. Similarly, data on best
corrected visual acuity (BCVA) were inconsistent. Nine out of 10
trials reporting this outcome found between-group differences of
less than 0.1 logMAR.
None of the six studies comparing NSAIDs alone with steroids
reported on poor vision due toMO at three months or 12 months.
We judged the evidence onMOtobe low-certainty. Therewas low-
certainty evidence that mean central retinal thickness was lower
in the NSAIDs group at three months (mean difference (MD) -
22.64 microns, 95% CI -38.86 to -6.43; eyes = 121; studies = 2;
I2 = 0%). Two studies reported BCVA at three months, and the
results of these trials were inconsistent, but both found differences
of less than 0.1 logMAR between groups.
Quality of life was only reported in one of the 34 studies, and it was
not fully reported other than to comment on lack of differences
between groups. In general, no major adverse events were noted -
the main consistent observation was burning or stinging.
Overall completeness and applicability of
evidence
There were a relatively large number of trials, and these studies
have a wide global range which means their results will be globally
applicable.
The included studies compared NSAIDs and steroids in cataract
surgery using phacoemulsification, extracapsular cataract extrac-
tion (ECCE) and intracapsular cataract extraction (ICCE) surgical
techniques. However, the more recent trials exclusively used pha-
coemulsification, which may make their findings less applicable
to parts of the world where resources are less available and ECCE
is standard.
The aim of this review was to assess whether the use of NSAIDs
had an impact on visual loss due to MO in the long-term. The
evidence is very sparse with respect to that question, with only one
study with high attrition, reporting on visual loss due to MO at
12 months after surgery. This is clearly an important gap in the
evidence.
There are many trials looking at the short-term effects of NSAIDs,
but there is considerable variation in terms of types, doses and
regimens of NSAIDs and steroids used. One aspect that we have
not highlighted in this review, but has been discussed elsewhere
(Kim 2016a), is the potency of the steroid used in the comparison
group.Use of lowpotency steroids, such as fluorometholone 0.1%,
may lead to an overestimate of the relative effect of NSAIDs.
Certainty of the evidence
We graded the evidence as low- to very low-certainty. In general,
the trials were poorly reported and it was difficult to judge the
extent to which bias had been avoided. We did not judge any of
the studies at low risk of bias for all domains. Many trials were
not properly masked and, in a few studies, there were problems
with attrition bias and selective outcome reporting. For outcomes
that had more data we identified the possibility of publication bias
with an asymmetric funnel plot. There were also problems with
directness. For example, many studies reported “CMO” but were
not clear whether or not this was ’clinically significant’, or indeed
what this meant in terms of whether it caused both symptoms and
signs. And in many of the older studies this could not be verified
by optical coherence tomography (OCT).
Potential biases in the review process
We have made several modifications to the original protocol (see
Differences between protocol and review), but these were made
before the data extraction and analysis phases of the review.
Agreements and disagreements with other
studies or reviews
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A recent systematic review and meta-analysis has been published
(Wielders 2015). This review included 17 trials. The reason why
they had fewer trials than the current review was because they
only included studies of phacoemulsification cataract surgery and
they excluded studies that did not report the incidence of cystoid
macular oedema (CMO).
The review byWielders 2015 reported effect measures in the same
order of magnitude as that suggested by this review, but because
they reported odds ratios (ORs), rather than risk ratios (RRs),
these effect estimates are exaggerated (further away from null).
The authors concluded that the odds of CMO were reduced in
people who were given NSAIDs, but they did not incorporate a
judgement on the overall certainty (or quality) of the evidence in
their conclusions, even though they had assessed the risk of bias in
the included trials using two different methods. It is also notable
that, although the abstract highlights the fact that 17 trials were
included in the review, it is less clearly pointed out that the effect
estimates were based on a relatively small subset of these trials.
This review was subsequently criticised because it did not fully
incorporate an assessment of visual loss due to CMO, because the
conclusions were based on so few trials, and because of the likely
exclusion of studies that did not report any events (Kim 2016).
A report by the American Academy of Ophthalmology, also pub-
lished in 2015, was more conservative in its conclusions (Kim
2015). This was a narrative review of the literature with no meta-
analysis, nor any assessment of the quality of the evidence. They
concluded that NSAIDs reduced the incidence of CMO, and may
increase visual recovery, depending on the treatment of the com-
parator group, however, they concluded that the use of NSAIDs
did not alter long-term (3 months) visual outcomes, a finding
which is supported by the current review.
One slightly older systematic review published in 2014, included
15 trials and did include an overall GRADE assessment of the
certainty of the evidence, which they judged to be low- to mod-
erate-certainty for inflammation, low-certainty for visual acuity
and high-certainty for CMO (Kessel 2014). This review again fo-
cused on phacoemulsification. It was restricted to the comparison
of NSAIDs (on their own or with placebo) versus steroids alone.
They cited the previously published protocol of this review justify-
ing theirs as being different for these two reasons. They evaluated
inflammation within one week of surgery and MO at any time
point. There are some differences between the current review and
Kessel 2014 in terms of the included studies. This is because the
searches for the current review were restricted to evidence relating
to MO. However, the trials contributing data to the analysis of
MO are similar in the two reviews. Kessel 2014 included one study
that we judged was probably not a randomised controlled trial
(RCT) (Miyake 2000), and one study that we have included in the
NSAIDs plus steroids comparison (Wang 2013). The estimates of
effect for MO reported in Kessel 2014 and reported in this review
are of a similar order of magnitude, although Kessel 2014 reports
a stronger effect. This can be attributed to the fact that, when
extracting data from studies using the Miyake 1977 classification,
Kessel 2014 considered Grades 2 to 3 as MO, whereas in the cur-
rent review we considered Grades 1 to 3. The main difference be-
tween the reviews is in the grading of the certainty of the evidence.
Kessel 2014 considered the evidence to be high-certainty. It is not
clearly stated why, but the footnote refers to a RR of 6, which we
understand to mean that it is a strong effect, therefore they have
not downgraded. We have considered the evidence on MO to be
low-certainty, downgrading for risk of bias and publication bias
(Summary of findings 2).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Using topical NSAIDs may reduce the risk of developing macular
oedema after cataract surgery, although it is possible that current
estimates as to the size of this reduction are exaggerated due to
selective non-reporting of negative studies. It is unclear the extent
to which this reduction has an impact on the visual function and
quality of life of patients. There is little evidence to suggest any
important effect on vision after surgery
The value of adding topical NSAIDs to steroids, or using them
as an alternative to topical steroids with a view to reducing the
risk of poor visual outcome after cataract surgery is uncertain.
This is reflected in wide variations in modern practice. The role
of the relative effectiveness and safety of NSAIDs as an alternative
to steroids in the control of post operative inflammation is being
addressed in another Cochrane Review (Gonzales 2013).
Implications for research
Future trials should address the remaining clinical uncertainty of
whether prophylactic topical NSAIDs are of benefit, particularly
with respect to longer-term follow-up (at least to 12 months),
and should be large enough to detect to detect reduction in the
risk of the outcome of most interest to patients, which is chronic
macular oedema leading to visual loss. They should be rigorously
conducted and double-masked.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Almeida 2008
Methods Study design: Parallel group RCT
Open-label
Participants Country: Canada
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR (53)
• Number (%) of people followed up: 38 (72%) eyes
• Average age in years: 71
• Age range in years: 45-92
• Percentage women: 51%
• Ethnic group: NR
• Percentage with diabetes: 19%
• Percentage with uveitis: 2%
Comparator: Steroids alone
• Number of people (eyes) randomised: NR (53)
• Number (%) of people followed up: 42 (79%) eyes
• Average age in years: 72
• Age range in years: 45-92
• Percentage women: 70%
• Ethnic group: NR
• Percentage with diabetes: 23%
• Percentage with uveitis: 0%
Inclusion criteria: Clinic patient having phacoemulsification with IOL implantation in
their first eye; agreed to participate
Exclusion criteria: Hypersensitivity to the NSAID drug class; aspirin/NSAID-induced
asthma; pregnancy in the third trimester
Pretreatment: More women in control group (70%) versus ketorolac group (51%), but
unclear of importance of this difference
Eyes: 106 eyes of 98 patients enrolled but clinical trials registry specifies first eye surgery
only
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.5% (Acular)
◦ Times per day: 4 times
◦ Duration preoperative: 2 days
◦ Duration postoperative: 28 days
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, twice a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 14
Comparator: Steroids alone
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, twice a day for 7 days
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Almeida 2008 (Continued)
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 14
All participants also received gatifloxacin 0.3% (Zymar) 4 times a day for 1 week
Type of surgery: phacoemulsification
Outcomes Follow-up: 1 month
• Adverse effects
• CMO (not defined but OCT used)
• Change in total macular volume
Contact details Authors name: Sherif El-Defrawy
Institution: Queen’s University, Ontario, Canada
Email: eldefras@hdh.kari.net
Address: Department of Ophthalmology, Queen’s University, Hotel Dieu Hospital,
Brock Wing 230A, 166 Brock Street, Kingston, Ontario K7L 5G2, Canada
Notes Funding sources: “Funded by a Queen’s University grant, Kingston, Ontario, Canada”
Declaration of interest: “No author has a financial or proprietary interest in anymaterial
or method mentioned.”
Date study conducted: June 2006 to May 2007 (from clinical trials registry entry)
Trial registration number: NCT00335439
Contacting study investigators: Not contacted
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how
list was generated.
Allocation concealment (selection bias) High risk Quote: “open-label non-masked.”
Judgement comment: High risk of bias,
given open-label nature of trial
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: Open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: Open-label study.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “98 were assessed at 1 week and 80
at 1 month.”
Judgement comment: 38/53 (72%) in ke-
torolac group seen at 1 month versus 42/
53 (79%) of non-treated group. One case
of CMO excluded in non-treated group; 3
ketorolac-related AEs excluded
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Selective reporting (reporting bias) Low risk Judgement comment: Only one outcome
specified on clinical trials registry and this
outcome was the main focus of the pub-
lished report
Almeida 2012
Methods Study design: Parallel group RCT
Participants Country: Canada
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 54 (NR but overall 84% follow-up)
• Average age in years: NR (but overall average age was 72 years)
• Age range in years: NR (but overall range was 50 to 88 years)
• Percentage women: NR (but overall 54% were women)
• Ethnic group: NR
• Percentage with diabetes: NR (but “low risk” population)
• Percentage with uveitis: NR (but “low risk” population)
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 54 (NR but overall 84% follow-up)
• Average age in years: NR (but overall average age was 72 years)
• Age range in years: NR (but overall range was 50 to 88 years)
• Percentage women: NR (but overall 54% were women)
• Ethnic group: NR
• Percentage with diabetes: NR (but “low risk” population)
• Percentage with uveitis: NR (but “low risk” population)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 54 (NR but overall 84% follow-up)
• Average age in years: NR (but overall average age was 72 years)
• Age range in years: NR (but overall range was 50 to 88 years)
• Percentage women: NR (but overall 54% were women)
• Ethnic group: NR
• Percentage with diabetes: NR (but “low risk” population)
• Percentage with uveitis: NR (but “low risk” population)
Inclusion criteria: 18 years of age or older; cataract and were expected to have pha-
coemulsification with implantation of a posterior chamber IOL
Exclusion criteria: Pre-existing retinal disease (e.g. diabetic retinopathy, vein occlusion,
exudative macular degeneration); previous uveitis, previous intraocular surgery; allergy
or hypersensitivity to NSAIDs. “Enrolled patients who had complicated cataract surgery
(e.g. significant corneal edema, posterior capsule rupture, vitreous loss, dropped nuclear
material, retained cortical material, or an IOL not placed in the capsular bag) were
subsequently excluded.”
Pretreatment: “There were no differences in age, sex, or operative eye between the 3
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groups.”
Eyes: Probably one eye only included in the trial but not clearly reported and unclear
how selected
Interventions Intervention 1: NSAIDs plus steroids
• ketorolac 0.5% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Intervention 2: NSAIDs plus steroids
• nepafenac 0.1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids plus placebo
• sterile saline drops
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
All participants received gatifloxacin 0.3% drops 4 times a day starting 3 days before
surgery and continued for 1 week after surgery
Type of surgery: Phacoemulsification
Outcomes Follow-up: 1 month
• Quality of life (COMTOL questionnaire)
• Change in CRT (not used in the analysis because no SD reported)
• Change in BCVA logMAR
• Change in total macular volume
• Change in average macular cube thickness
Contact details Authors name: David RP Almeida
Institution: Queen’s University, Ontario, Canada
Email: dalmeida@evolation-medical.com
Address:Department of Ophthalmology, Queen’s University, Hotel Dieu Hospital, 166
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Brock Street, Eye Centre (Johnson 6), Kingston, Ontario K7L 5G2, Canada
Notes Funding sources: “Funded by an unrestricted Queen’s University educational research
grant.”
Declaration of interest: “No author has a financial or proprietary interest in anymaterial
or method mentioned.”
Date study conducted: March 2010 to May 2011
Trial registration number: NCT01395069
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to re-
ceive a placebo (sterile saline drops), nepafenac 0.
1%, or ketorolac 0.5%.”
Judgement comment: Not reported how list was
generated.
Allocation concealment (selection bias) Unclear risk Quote: “The placebo, nepafenac, and ketorolac
suspensions were supplied in identical generic
drop bottles that were individually made by the
Kingston General Hospital Investigational Phar-
macy division. Bottles concealedmedication infor-
mation and were labelled with study identification
number, patient identification number, expiration
date, and emergency contact information only.”
Judgement comment: Unclear if investigators in-
volved in the treatment allocation were masked
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo, nepafenac, and ketorolac
suspensions were supplied in identical generic
drop bottles that were individually made by the
Kingston General Hospital Investigational Phar-
macy division. Bottles concealedmedication infor-
mation and were labelled with study identification
number, patient identification number, expiration
date, and emergency contact information only.”
Judgement comment: Placebo-controlled study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The placebo, nepafenac, and ketorolac
suspensions were supplied in identical generic
drop bottles that were individually made by the
Kingston General Hospital Investigational Phar-
macy division. Bottles concealedmedication infor-
mation and were labelled with study identification
number, patient identification number, expiration
date, and emergency contact information only.”
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Judgement comment: Placebo-controlled study
which probably means that the outcome assessors
were masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “One hundred sixty-two patients, 54 in
each arm, made up the intent-to-treat data set.”
Quote: “Ninety-seven patients (35 placebo, 32 ke-
torolac, 30 nepafenac) completed the COMTOL
interview questionnaire (60.0% response rate).”
Judgement comment: 84% follow-up. Not clearly
reported but no evidence for any differential drop
out by intervention group. 31 patients out of 193
lost to follow-up (16%).However, only 97patients
(60%) completed the COMTOL interview ques-
tionnaire and no further breakdown of losses to
follow-up in each group provided
Selective reporting (reporting bias) Unclear risk Judgement comment: Outcomes on clinical trial
registry entry (NCT01395069) were reported but
the trial was retrospectively registered
Asano 2008
Methods Study design: Parallel group RCT
Participants Country: Japan
Setting: 5 Eye hospitals
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 75 (75)
• Number (%) of people followed up: 71 (95%)
• Average age in years: 66
• Age range in years: NR
• Percentage women: 56%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 75 (75)
• Number (%) of people followed up: 71 (95%)
• Average age in years: 66
• Age range in years: NR
• Percentage women: 55%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Age 55 to 75 years of age; nuclear hardness of Emery-Little grade IV
or less; surgery in 1 eye only
Exclusion criteria: Acute infection or inflammation within 1 month after initiation of
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the study; allergy to NSAIDs, steroids, or fluorescein; history of eye trauma or intraocu-
lar disease other than cataract; pseudoexfoliation syndrome; uveitis; glaucoma; diabetes
and related complications; kidney disease;asthma or chronic airway disease; uncontrolled
hypertension;severe heart failure; myocardial infarction or cerebrovascular disorders; in-
traoperative complications such as posterior capsule rupture, vitreous loss, retained lens
nucleus, or lens fragments in the vitreous
Pretreatment:None noted. Compared age, gender, duration of surgery, ultrasound time,
irrigating solution and hardness of crystalline lens
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs alone
• diclofenac sodium 0.1% (brand name not reported)
◦ Times per day: 4 times on day of surgery; 3 times a day postoperative
◦ Duration preoperative: days: 3 hours, 2 hours, 1 hour, and 30 minutes before
surgery
◦ Duration postoperative: days: 56
Comparator: Steroids alone
• betamethasone sodium 0.1% (brand name not reported)
◦ Times per day: 4 times on day of surgery; 3 times a day postoperative
◦ Duration preoperative: days: 3 hours, 2 hours, 1 hour, and 30 minutes before
surgery
◦ Duration postoperative: days: 56
Concomitant mydriatic and antibiotic agents were permitted.
Type of surgery: Phacoemulsification
Outcomes Follow-up: 8 weeks
• Adverse effects
• CMO reported at 5 weeks only (fluorescein angiography using Miyake 1977
classification, grades I-III taken as CMO)
• Laser flare-cell photometry (mean value of anterior chamber flare reported)
• BCVA logMAR (final value)
Contact details Authors name: Kensaku Miyake
Institution: Shohzankai Medical Foundation, Miyake Eye Hospital
Email: miyake@spice.or.jp
Address: Shohzankai Medical Foundation, Miyake Eye Hospital, 3-15-68, Ozone, Kita-
ku, Nagoya, 462-0825, Japan
Notes Funding sources: NR
Declaration of interest: “No author has a financial or proprietary interest in anymaterial
or method mentioned.”
Date study conducted: April 2004 to September 2005
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “The test drugs were assigned to patients
at random after the controller validated that the
assigned therapy was indistinguishable from the
alternative therapy.”
Judgement comment: Not reported how list was
generated.
Allocation concealment (selection bias) Low risk Quote: “The controller kept the assignment code
until completion of the study.”
Judgement comment: This probably means that
the allocation was concealed from the investiga-
tors although it was not clearly reported who the
controller was exactly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The test drugs were assigned to patients
at random after the controller validated that the
assigned therapy was indistinguishable from the
alternative therapy. The controller kept the assign-
ment code until completion of the study. The con-
troller created an emergency code, whichwas given
to the principal investigator in an envelope. The
investigator could open the envelope if severe ad-
verse effects developed.The test drugswere admin-
istered to each patient 3 hours, 2 hours, 1 hour,
and 30 minutes before surgery and 3 times a day
for 8 weeks after surgery.”
Judgement comment: Although not clearly stated
that participants and personnel were unaware of
which treatment received, the study was placebo-
controlled and efforts made to keep the allocation
away from investigators sowe assume thatmasking
was done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The test drugs were assigned to patients
at random after the controller validated that the
assigned therapy was indistinguishable from the
alternative therapy. The controller kept the assign-
ment code until completion of the study. The con-
troller created an emergency code, whichwas given
to the principal investigator in an envelope. The
investigator could open the envelope if severe ad-
verse effects developed.The test drugswere admin-
istered to each patient 3 hours, 2 hours, 1 hour,
and 30 minutes before surgery and 3 times a day
for 8 weeks after surgery.”
Judgement comment: Although not clearly stated
that outcome assessors were unaware of which
treatment received, the study was placebo-con-
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trolled and effortsmade to keep the allocation away
from investigators so we assume that masking was
done
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Of the 150 eyes initially included in this
study, 75 were assigned to the diclofenac group
and 75 to the betamethasone group. Four patients
in each group dropped out of the study: 1 in each
group due to complications; 3 in the diclofenac
group and 2 in the betamethasone group due to a
discontinuation proposal (there were patients who
withdrew their consent during the course of this
study); 1 in the betamethasone group for not re-
turning to the hospital 2 weeks after surgery. Sev-
enty-one eyes in each group completed the study.
”
Judgement comment: In the results text quoted
follow-up appeared to be high (95%) and equal
between groups but in table 3 visual acuity results
follow-up was lower 58/75 (77%) versus 52/75
(69%) and unclear why
Judgement comment: Some of the exclusion crite-
riamay have lead to bias if they occurred differently
between two treatment groups: “acute infection or
inflammation within 1 month after initiation of
the study” and “intraoperative complications such
as posterior capsule rupture, vitreous loss, retained
lens nucleus, or lens fragments in the vitreous”,
however these exclusions were not reported
Selective reporting (reporting bias) High risk Judgement comment: No access to protocol or tri-
als registry entry but noted that data onCMOwere
reported only at 5 weeks, but other data available
at 8 weeks follow-up
Brown 1996
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention group: NSAIDs alone
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR (but people with DR excluded)
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• Percentage with uveitis: 0 (people with uveitis excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR (but people with DR excluded)
• Percentage with uveitis: 0 (people with uveitis excluded)
Inclusion criteria: Undergoing phacoemulsification with posterior capsular opacifica-
tion after lens (PCOL) implantation
Exclusion criteria: History of systemic or ocular inflammation (iritis, uveitis); taking
oral or ophthalmic steroids or NSAIDs; other ocular disease such as glaucoma, corneal
disease, or diabetic retinopathy
Pretreatment: Group differences not reported.
Eyes: Unclear if one or both eyes included.
Interventions Intervention group: NSAIDs alone
• diclofenac sodium 0.1% (Voltaren Ophthalmic, Ciba Vision Ophthalmics
Duluth, Ga)
◦ Times per day: 4 times a day for 7 days; twice a day for 21 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• prednisolone acetate 1% (Pred Forte, Allergan)
◦ Times per day: 4 times a day for 7 days; twice a day for 21 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
All patients had gentamicin drops for 7 days postoperative.
Type of surgery: Phacoemulsification
Outcomes Follow-up: 1 month
• Laser flare-cell photometry (mean value of anterior chamber flare reported,
photons) but was not possible to calculate SD so not used in the analysis.
Contact details Authors name: Rose Marie Brown
Institution: New York Hospital - Cornell Medical Center
Email: NR
Address: Cornell University Medical College, 520 E. 70th St, Starr 817, New York, NY
10021
Notes Funding sources: “Supported in part from a grant from Ciba Vision Ophthalmics,
Duluth, Ga.”
Declaration of interest: NR
Date study conducted: 1991
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “We conducted a prospective, randomised
study.” “The patients were randomly assigned to
receive...”
Judgement comment: Not reported how list was
generated. Study was described as “randomised”
but with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment: Not reported how alloca-
tion administered. Study was described as “ran-
domised” but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this, patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: For measurement of inflam-
mation - Quote: “Neither examiner knew which
of the study groups the patient was enrolled in.”
But for other outcomes, masking not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Unclear how many people seen at 1 month
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to protocol or tri-
als registry entry
Cervantes-Coste 2009
Methods Study design: Parallel group RCT
Participants Country:Mexico
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 30 (30)
• Number (%) of people followed up: 30 (100%)
• Average age in years: 73
• Age range in years: 52 to 88
• Percentage women: 67%
• Ethnic group: NR
• Percentage with diabetes: 17%
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 30 (30)
• Number (%) of people followed up: 30 (100%)
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• Average age in years: 71
• Age range in years: 51 to 85
• Percentage women: 60%
• Ethnic group: NR
• Percentage with diabetes: 23%
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Adult patients 40 years of age or older; diagnosed with senile and/
or metabolic cataract (according to the Lens Opacities Classification System LOCS III,
with classification NO and NC 2-3); scheduled for surgery by phacoemulsification and
IOL implantation inside the capsular bag; normal fundoscopy exam (if observance was
possible)
Exclusion criteria: Pregnancy or breastfeeding; history of ocular inflammatory or in-
fectious eye disease; treatment for eye infection within 30 days prior to inclusion in the
study;alterations on the eye surface (including dry eye); history of ocular surgery and/
or trauma; knowledge or suspicion of allergy or hypersensitivity to the preservatives,
steroids, topical NSAIDs, or any other component of the study medication; use of eye
medications, including prostaglandin analogues; use of topical or systemic steroids within
30 days prior to inclusion in the study; use of topical or systemic NSAIDs within 14
days prior to inclusion in the study; non-controlled diabetes mellitus, based on clinical
history and blood glucose level (126 mg); proliferative diabetic retinopathy, and/or mac-
ular oedema; preoperative mydriasis less than 6 mm prior to the study; synechiae; ocular
alteration preventing adequate mydriasis such as iris atrophy; macular alteration docu-
mented by OCT, including macular oedema of any etiology, macular holes, epiretinal
membrane, macular degeneration related to age, and central serous chorioretinopathy;
the use of contact lens in the eye involved during the study
Pretreatment: No differences noted; compared age, gender, operated eye, ocular and
systemic pathology
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• nepafenac 0.1% (brand name not reported)
◦ Times per day: 1 drop every 15 minutes (4 doses) 1 hour prior to surgery; 3
times a day otherwise
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 42
• dexamethasone (combined with tobramycin) (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 10
Comparator: Steroids alone
• dexamethasone (combined with tobramycin) (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 10
Type of surgery: Phacoemulsification
Outcomes Follow-up: 6 weeks
• Poor vision outcome due to MO (“None of the patients developed clinically
significant macular oedema associated with vision loss”)
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• CRT at follow-up (final value)
• Adverse effects
• Inflammation (“inflammatory cells greater than 1+ during first week of
postoperative visits”)
• Total macular volume
Subgroup analysis by diabetes reported.
Contact details Authors name: Guadalupe Cervantes-Coste
Institution: Asociación Para Evitar la Ceguera en México I.A.P. Hospital
Email: gpecervantes@hotmail.com
Address: Av. México 85-5, México City, 06100 México
Notes Funding sources: NR
Declaration of interest: The authors have no conflicts of interest to disclose.
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This was a prospective, randomised,
single-masked, single-center, longitudinal, experi-
mental and comparative study in patients under-
going phacoemulsication cataract surgery.”
Judgement comment: Not reported how list was
generated. Trial described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The identity of patients receiving pre-
operative mydriatic or preoperative mydriatic and
nepafenac was concealed from the surgeons.”
Judgement comment: Only the surgeons appeared
to be masked.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement Comment: The study compared
nepafenac versus no treatment so is essentially
open-label. No information was provided on
masking. We assume that in absence of reporting
on this outcome, assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All patients completed the follow-up visits
over a 6-week period.”
Judgement comment: No patients appeared to
have been excluded or lost to follow-up
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Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Chatziralli 2011
Methods Study design: Parallel group RCT
Participants Country: Greece
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 73 (NR)
• Number (%) of people followed up: 70 (96%)
• Average age in years: 74
• Age range in years: NR
• Percentage women: 39%
• Ethnic group: NR
• Percentage with diabetes: 9%
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 72 (NR)
• Number (%) of people followed up: 68 (94%)
• Average age in years: 74
• Age range in years: NR
• Percentage women: 41%
• Ethnic group: NR
• Percentage with diabetes: 10%
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: NR
Exclusion criteria:History of intraocular surgery on the eye to be operated; any previous
episode of uveitis in the eye to be operated; severe systemic disease (heart failure of the
New York Heart Association stage III of IV, endstage renal failure, pulmonary failure,
receiving chemotherapy); regular, systemic use of steroid or NSAIDs during the last 3
months
Pretreatment: None noted; compared age, gender, baseline visual acuity, education,
marital status, smoking, and various systemic ocular factors
Eyes: Probably one eye only included in the trial but not clearly reported and unclear
how selected
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.5% (Acular, Allergan)
◦ Times per day: 3 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28
• dexamethasone 0.1% (in combination with tobramycin 0.3%) (Tobradex, Alcon)
◦ Times per day: 5 times a day preoperative, 4 times a day postoperative
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28
Comparator: Steroids alone
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• dexamethasone 0.1% (in combination with tobramycin 0.3%) (Tobradex, Alcon)
◦ Times per day: 5 times a day preoperative, 4 times a day postoperative
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28
Type of surgery: phacoemulsification
Outcomes Follow-up: 6 weeks
• Poor vision outcome due to MO
• Adverse effects, pain and ocular discomfort (itching or foreign-body sensation) on
a 0-10 visual analogue scale CMO (fundoscopy plus Amsler grid)
• Inflammation (presence of corneal oedema, Tyndall reaction or conjunctival
hyperemia)
• BCVA logMAR (final value)
Contact details Authors name: Irini Chatziralli
Institution: Department of Ophthalmology, Veroia General Hospital
Email: eirchat@yahoo.gr
Address: Department of Ophthalmology, Veroia General Hospital, 28, Papanastasiou
Street, GR-17342 Athens (Greece)
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: October 2009 to January 2010
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomised to 1 of the
2 postoperative treatment arms.”
Judgement comment: Not reported how list was
generated.
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study was masked to the patients, i.e.
they received unmarked bottles so as to be unaware
of which treatment they received.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment:No information onmasking
of outcome assessors. We assume that in absence
of reporting on this outcome, assessors were not
masked
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Follow-up high and rea-
sonably equal between groups: 70/73 (96%) in
NSAIDs group versus 68/72 (94%) in steroid
group
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Donnenfeld 2006
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 25 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR (age overall was 73 years)
• Age range in years: NR
• Percentage women: NR (overall 55% women)
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 25 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR (age overall was 73 years)
• Age range in years: NR
• Percentage women: NR (overall 55% women)
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 25 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR (age overall was 73 years)
• Age range in years: NR
• Percentage women: NR (overall 55% women)
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 25 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR (age overall was 73 years)
• Age range in years: NR
• Percentage women: NR (overall 55% women)
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• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Scheduled for phacoemulsification.
Exclusion criteria:Known sensitivity to any ingredient in the studymedications;monoc-
ular status; a history of previous intraocular surgery;diabetes mellitus; a history of uveitis,
iritis, or intraocular inflammation; use of a systemic NSAID during the study or the
week before surgery; or pupils that did not dilate to more than 5.0 mm before surgery
or requiring mechanical pupil stretching; pregnant, nursing an infant, or planning a
pregnancy
Pretreatment: “There were no significant between-group differences in any demographic
variable or baseline value.”
Eyes: Unclear if one or both eyes included.
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (brand name not reported)
◦ Times per day: 4 times a day for 3 days preoperative; 3 times every 15
minutes before surgery; 4 times a day for 21 days postoperative
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 21
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 14 days; twice a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (brand name not reported)
◦ Times per day: 4 times a day for 1 day preoperative; every 15 mins in hour
before surgery; 4 times a day for 21 days postoperative
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 21
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 14 days; twice a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (brand name not reported)
◦ Times per day: every 15 mins in hour before surgery; 4 times a day for 21
days postoperative
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 14 days; twice a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
Comparator: Steroids plus placebo
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times a day for 14 days; twice a day for 7 days
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
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Donnenfeld 2006 (Continued)
• placebo (vehicle)
◦ Times per day: every 15 mins in the hour before surgery. 4 times a day
postoperatively
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
All participants received topical gatifloxacin 0.3% 4 times a day for 3 days before cataract
surgery and for 1 week after surgery
Type of surgery: Phacoemulsification
Outcomes Follow-up: 3 months
• Adverse effects (patient discomfort on a 1 to 5 scale and need for analgesia)
• CMO (at 2 weeks only, “clinically significant CME” but otherwise not defined,
no OCT)
• Inflammation (“Mean inflammation score” but was not possible to calculate SD)
• BCVA logMAR (final value)
Contact details Authors name: Eric D. Donnenfeld
Institution: Ophthalmic Consultants of Long Island
Email: eddoph@aol.com
Address: Ophthalmic Consultants of Long Island, Ryan Medical Arts Building, 2000
North Village Avenue, Suite 402, Rockville Centre, New York 11570, USA
Notes Funding sources: “Supported in part by an unrestricted grant fromAllergan Inc., Irvine,
California, and the Lions Eye Bank for Long Island, Long Island, New York, USA”
Declaration of interest: “Drs. Donnenfeld, Perry, and Wittpenn are consultants to
Allergan Pharmaceuticals. No other author has a financial or proprietary interest in any
material or method mentioned.”
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Group assignment was based on a ran-
dom-number-generated protocol that was created
before initiation of the study.”
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled, but not
clear if maskingwas successful - some of the groups
had different schedules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled but not
clear if maskingwas successful - some of the groups
had different schedules. Corneal endothelial cell
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Donnenfeld 2006 (Continued)
counts and OCT scans were evaluated by masked
specialists. It was unclear whether assessors of other
outcomes were aware of the treatment allocation,
or if only the specialists were affected
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Elsawy 2013
Methods Study design: Parallel group RCT
Participants Country: Egypt
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 35 (43)
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: 34%
• Ethnic group: NR
• Percentage with diabetes: 100%
• Percentage with uveitis: NR
Comparator: Steroids alone
• Number of people (eyes) randomised: 35 (43)
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: 40%
• Ethnic group: NR
• Percentage with diabetes: 100%
• Percentage with uveitis: NR
Some inconsistencies in the data. Not clearly stated exactly number of people (eyes)
randomly allocated to each group and followed up
Inclusion criteria:High risk characteristics for the postoperative development of CME,
one of the risk factors for CME (beside diabetic retinopathy). History of retinal vein
occlusion or presence of epiretinal membrane or preoperative use of prostaglandin ana-
logues eye drops
Exclusion criteria: NR
Pretreatment: Compared age, gender, type of diabetes, duration of diabetes, retinal vein
occlusion, epiretinal membrane and prostaglandin drops. Some imbalances, e.g. more
prostaglandin eye drop use in control group
Eyes: 86 eyes of 70 people.
Type of surgery: Phacoemulsification
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Elsawy 2013 (Continued)
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (brand name not reported)
◦ Times per day: twice a day
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 84
• dexamethasone 0.1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 84
Comparator: Steroids alone
• dexamethasone 0.1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 84
Type of surgery: Phacoemulsification
Outcomes Follow-up: 12 weeks
• CMO (clinical examination, unclear if OCT-verified)
Contact details Authors name: Moataz F Elsawy
Institution: Menoufia University Hospital
Email: mfelsawy@yahoo.co.uk
Address: Ophthalmology Department, Menoufia University Hospital, Menoufia,
53211, Egypt
Notes Funding sources: NR
Declaration of interest: “The authors report no conflicts of interest in this work.”
Date study conducted: January 2011 to March 2012
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The randomisation process used four
opaque envelopes in two containers. The first con-
tainer had (1) for dexamethasone drops only, and
(2) for combined drops, and the second container
had the name of patients listed for cataract surgery
on that day. Patients were randomised to one of
the regimes by asking an independent person to
choose one envelope from each container.”
Judgement comment: Unusual random allocation
process.
Allocation concealment (selection bias) Unclear risk Quote: “The randomisation process used four
opaque envelopes in two containers. The first con-
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Elsawy 2013 (Continued)
tainer had (1) for dexamethasone drops only, and
(2) for combined drops, and the second container
had the name of patients listed for cataract surgery
on that day. Patients were randomised to one of
the regimes by asking an independent person to
choose one envelope from each container. All pa-
tients underwent phacoemulsification (divide and
conquer).”
Judgement comment: Unusual allocation process.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this, patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this, outcome assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Endo 2010
Methods Study design: Parallel group RCT
Open-label
Participants Country: Japan
Setting: Eye hospital
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 40 (40)
• Number (%) of people followed up: 31 (78%)
• Average age in years: 68
• Age range in years: NR (overall age range 37-84 years)
• Percentage women: 48%
• Ethnic group: NR
• Percentage with diabetes: 100%
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 35 (35)
• Number (%) of people followed up: 31 (89%)
• Average age in years: 69
• Age range in years: NR
• Percentage women: 42%
• Ethnic group: NR
• Percentage with diabetes: 100%
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• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Patients with diabetes undergoing small incision phacoemulsification
with IOL implantation
Exclusion criteria: foveal thickness of 250 microns or more; severe diabetic retinopathy
for which ocular surgery (including photocoagulation) indicated;use of topical medica-
tions for glaucoma, uveitis and other diseases that cause CMO; ocular allergies to brom-
fenac or steroids (steroid group); use of systemic steroids or NSAIDs; serious cardiac,
cerebral or renal disease
Pretreatment: No major imbalances; compared age, gender, hypertension, blood urea
nitrogen. HbA1c slightly higher in NSAIDs group
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs alone
• bromfenac sodium (Bronuck, Senju,Pharmaceutical Company Ltd, Osaka,Japan)
◦ Times per day: twice a day
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 42
Comparator: Steroids alone
• betamethasone sodium phosphate (with fradiomycin sulfate) followed by
fluorometholone 0.1%(Rinderon-A, Shionogi, Osaka, Japan and Flumetholon 0.1%,
Santen)
◦ Times per day: 4 times a day for 7 days (betamethasone); 4 times a day for 35
days (fluorometholone)
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 42
Preoperatively, all participants received gatifloxacin (four times daily for 1 day preop-
eratively; on the day of surgery, they received 0.5% tropicamide, 0.5% phenylephrine
hydrochloride every 30 mins 2 hours preoperatively. Postoperatively, gatifloxacin four
times daily until week 6, and 0.5% tropicamide and 0.5% phenylephrine hydrochloride
once daily for 1 week
Type of surgery: Phacoemulsification
Outcomes Follow-up: 6 weeks
• CRT at follow-up (final value)
• Adverse effects
• Inflammation (anterior chamber flare values, photon count per millisecond)
• BCVA logMAR (final value)
Contact details Authors name: Naoko Endo
Institution: Tokyo Women’s Medical University Diabetes Centre
Email: 51026745@mail.goo.ne.jp
Address: Tokyo Women’s Medical University Diabetes Centre, 8-1 Kawada-cho, Shin-
juku-ku, Tokyo 162-0054, Japan
Notes Funding sources: NR
Declaration of interest: “The authors have no financial interest in any aspect of this
article.”
Date study conducted: March 2005 to May 2007
Trial registration number: NR
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Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A prospective open-label trial was
conducted using the envelope method.”
Judgement comment: Not reported how
list was generated.
Allocation concealment (selection bias) Unclear risk Judgement comment: Although men-
tioned “envelope method”, not enough in-
formation on how the allocation was ad-
ministered
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: Open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: Open-label study.
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: 17% (13/75) of pa-
tients were excluded. Vague reasons were
provided. Three were excluded because of
difficulty with theOCTmeasurement. Ten
people (10 eyes) dropped out of the study
for the following reasons: poor health (8)
, posterior capsular rupture (1) and epi-
demic keratoconjunctivitis (1). No details
were provided about the ’difficulties with
OCTmeasurements’ and ’poor health’. 31/
40 (78%) in NSAIDs group and 31/35
(89%) in steroids group were followed-up
but reasons for dropout by group were not
clearly reported
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to proto-
col or trial registry entry
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Italian Diclofenac Study Group 1997
Methods Study design: Parallel group RCT
Participants Country: Italy
Setting: Eye hospital
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 141 (141)
• Number (%) of people followed up: 118 (84%)
• Average age in years: 68
• Age range in years: NR
• Percentage women: 51%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 140 (140)
• Number (%) of people followed up: 111 (79%)
• Average age in years: 68
• Age range in years: NR
• Percentage women: 53%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: 45 to 75 years of age; age-related cataract.
Exclusion criteria: Ocular malformations; dry-eye syndrome (Schirmer I < 5 mm);
glaucoma or ocular hypertension (lOP > 22 mmHg); vitreoretinal pathology; surgical
complications (posterior capsule rupture, Descemet’s membrane detachment, vitreous
loss, significant intraocular haemorrhage, IOL dislocation); severe systemic affections;
ocular surgery in the previous 2 months or had had bilateral surgery; hypersensitive to
one or more of the study compounds; pregnant or nursing woman
Pretreatment: No major imbalances in age, sex, IOP and operated eye.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs alone
• diclofenac 0.1% (Voltaren Ophthalmic)
◦ Times per day: 5 drops in 3 hours before surgery; 5 times a day on days 1 to
5; 3 times a day on days 6 to 140
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 140
Comparator: Steroids plus placebo
• dexamethasone 0.1% (brand name not reported)
◦ Times per day: 5 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 5
• placebo (not specified)
◦ Times per day: 5 drops in 3 hours before surgery; 3 times a day days 6 to 140
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 140
Type of surgery: ECCE
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Italian Diclofenac Study Group 1997 (Continued)
Outcomes Follow-up: 140 days
• Adverse effects
• CMO (“angiographic CME” using Miyake 1977)
Contact details Authors name: Lucio Lobefalo
Institution: NR
Email: NR
Address: via Gran Sasso 100, 1-66100 Chieti, Italy
Notes Funding sources: NR
Declaration of interest: “S. Bianco, MD, is a Ciba Vision Ophthalmics officer. None
of the other authors has a proprietary or financial interest in diclofenac.”
Date study conducted: October 1992 to February 1994
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled but
masking of participants not described specifically
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “In each center, all patients were observed
by the same examiner; surgeons and examiners
were masked at all postoperative visits.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Follow-up: 118/140 (84%)
in diclofenac group and 111/141 (79%) in dex-
amethasone group followed up. Follow-up reason-
ably high and not very different between the two
groups
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to protocol or tri-
als registry entry
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Jung 2015
Methods Study design: Parallel group RCT
Participants Country: South Korea
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 28 (28)
• Number (%) of people followed up: NR
• Average age in years: 67
• Age range in years: NR
• Percentage women: 54%
• Ethnic group: NR
• Percentage with diabetes: 25%
• Percentage with uveitis: NR
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 32 (32)
• Number (%) of people followed up: NR
• Average age in years: 68
• Age range in years: NR
• Percentage women: 53%
• Ethnic group: NR
• Percentage with diabetes: 28%
• Percentage with uveitis: NR
Comparator: Steroids
• Number of people (eyes) randomised: 31 (31)
• Number (%) of people followed up: NR
• Average age in years: 67
• Age range in years: NR
• Percentage women: 58%
• Ethnic group: NR
• Percentage with diabetes: 26%
• Percentage with uveitis: NR
Inclusion criteria: Males or non-pregnant females aged between 20- to 80-years-old
Exclusion criteria: Poor general condition, including high blood pressure, poor blood
glucose control, or
renal failure; history of ocular trauma or disease; history of intraocular surgery; systemic
or topical NSAIDs or corticosteroids use within 4 weeks of enrolment; known hyper-
sensitivity to salicylates or other NSAIDs; and use of alpha-1 adrenergic antagonist or
other analogous systemic medications that may increase the tendency for miosis during
the operation (intraoperative floppy iris syndrome)
Pretreatment: Nomajor imbalances, age, sex, hypertension, diabetes, macular thickness
and volume and ocular surface status compared
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• bromfenac sodium 0.1% (Bronuck, Senju Pharmaceutical co Ltd, Osaka, Japan)
◦ Times per day: twice a day plus 2 drops at 20-min intervals 2 hrs before
surgery
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28
• prednisolone acetate 1% (brand name not reported)
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◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Intervention: NSAIDs plus steroids
• ketorolac 0.45% (Acuvail, Allergan Inc, CA, USA)
◦ Times per day: twice a day plus 2 drops at 20-min intervals 2 hrs before
surgery
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 14
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
All patients received topical gatifloxacin 0.3% 4 times a day for 28 days
Type of surgery: Phacoemulsification
Outcomes Follow-up: 1 month
• Change in macular thickness
• Change in macular volume
• Adverse effects
• Inflammation (flare)
Contact details Authors name: Dr. Tae-im Kim
Institution: Yonsei University College of Medicine
Email: tikim@yuhs.ac
Address: Department of Ophthalmology, Yonsei University College of Medicine, 50-1
Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Notes Funding sources: “This research was supported by Basic Science Research Program
through the National Research Foundation of Korea (NRF) funded by the Ministry of
Education, Science and Technology 2013R1A1A2058907).”
Declaration of interest: “The authors have no financial conflicts of interest.”
Date study conducted: November 2013 to June 2014
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
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Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: Open-label or no informa-
tion on masking. We assume that in absence of re-
porting on this outcome assessors were notmasked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Kraff 1982
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 330 (NR)
• Number (%) of people followed up: 323 (98%)
• Average age in years: 69
• Age range in years: 37-91
• Percentage women: 60%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 170 (NR)
• Number (%) of people followed up: 169 (99%)
• Average age in years: 68
• Age range in years: 45-97
• Percentage women: 54%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Included criteria: Eligible for extracapsular cataract extraction with implantation of a
Shearing posterior chamber lens
Excluded criteria: NR
Pretreatment: None noted; age, gender, follow-up and endothelial cell density preoper-
ative compared
Eyes: Unclear if one or both eyes included.
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Interventions Intervention: NSAIDs plus steroids
• indomethacin (brand name not reported)
◦ Times per day: 5 times every 10 to 15 mins 18 hrs before surgery; 1 x 12 hrs
before surgery; 1 x at bedtime; 1 x 2 hrs before surgery; 1 x 1.5 hrs before surgery; 1 x
30 mins before surgery; 4 times a day postoperative
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 274
• dexamethasone (in combination with neomycin sulfate, polymyxin B sulfate) for
4 days followed by dexamethasone alone for 4 weeks followed by fluorometholone for
at least 6 months (Maxitrol and Maxidex)
◦ Times per day: 4 times a day (dexamethasone) and 3 times a day
(fluorometholone)
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 274
Comparator: Steroids plus placebo
• dexamethasone (in combination with neomycin sulfate, polymyxin B sulfate) for
4 days followed by dexamethasone alone for 4 weeks followed by fluorometholone for
at least 6 months (Maxitrol and Maxidex)
◦ Times per day: 4 times a day (dexamethasone) and 3 times a day
(fluorometholone)
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 274
• placebo (vehicle)
◦ Times per day: 5 times every 10 to 15 mins 18 hrs before surgery; 1 x 12 hrs
before surgery; 1 x at bedtime; 1 x 2 hrs before surgery; 1 x 1.5 hrs before surgery; 1 x
30 mins before surgery; 4 times a day postoperative
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 274
Type of surgery: ECCE and phacoemulsification (unplanned ICCE n = 19 were ex-
cluded)
Outcomes Follow-up: between 2.5 and 12 months. Quote: “The mean interval between surgery
and angiography was 4.1 months, with a range of 2.5 to 12 months. Ninety percent
of the angiograms were performed between 2.5 and 5 months after surgery, and 10%
between 6 and 12 months after surgery.”
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977)
• Snellen acuity only (not included in the analyses).
Contact details Authors name: Manus C Kraff
Institution: Abraham Lincoln School of Medicine, University of Illinois
Email: NR
Address: 5600 W. Addison Street, Chicago, IL 60634
Notes Funding sources: Core Grant EY 1792 NEI Bethesda Maryland
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Judgement comment: Randomisation was using a
table of random numbers
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment:Quote: “The studywas dou-
ble-masked; neither the physician nor the patient
knew what drops the patient was receiving.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Judgement comment:Quote: “The studywas dou-
ble-masked; neither the physician nor the pa-
tient knew what drops the patient was receiving.
” Quote: “The angiograms were read in a masked
fashion by a retired specialist (LMJ) who had no
knowledge of either the drug regimen or the type
of surgical procedure.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Some patients were ex-
cluded (n = 19) and not reported: two with vitre-
ous loss, two with vitreous pressure and a shallow
anterior chamber and 15 with possible rupture of
the posterior capsule. Unclear which groups these
were in. Follow-up high for visual acuity (> 95%)
but lower for CMO (60% in indomethacin group
versus 64% in placebo)
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Li 2011
Methods Study design: Parallel group RCT
Participants Country: China
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 104 (104)
• Number (%) of people followed up: NR
• Average age in years: 72
• Age range in years: NR
• Percentage women: 66%
• Ethnic group: Chinese
• Percentage with diabetes: 100%
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• Percentage with uveitis: NR
Comparator: Steroids alone
• Number of people (eyes) randomised: 113 (113)
• Number (%) of people followed up: NR
• Average age in years: 72
• Age range in years: NR
• Percentage women: 59%
• Ethnic group: Chinese
• Percentage with diabetes: 100%
• Percentage with uveitis: NR
Included criteria: Diabetes mellitus type 2 patients who received phacoemulsification
together with artificial lens implants intervention
Excluded criteria: Diabetic retinopathy, age-related macular degeneration, epiretinal
membrane and retinal vascular disorders
Pretreatment: Unclear if group differences.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• diclofenac 1% (brand name not reported)
◦ Brand name: NR
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
• dexamethasone (combined with tobramycin) (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• dexamethasone (combined with tobramycin) (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 28
Type of surgery: Phacoemulsification
Outcomes Follow-up: 1 month
• CRT at follow-up (final value)
• CMO (“clinically apparent”, OCT used)
• Snellen acuity only (not included in analyses)
Contact details Authors name: Min-Chao Li
Institution: Department of Ophthalmology, Affiliated Nanhai Hospital of Southern
Medical University, Foshan
Email: liminchao@126.com
Address:Department of Ophthalmology, Affiliated Nanhai Hospital of Southern Med-
ical University, Foshan 528200, Guangdong Province, China
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: January 2009 to December 2010
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Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: As per translation: “Unclear,
not specified if there was any participant with-
drawal or lost during the study period.”
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Mathys 2010
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 42 (42)
• Number (%) of people followed up: 39 (93%)
• Average age in years: 74
• Age range in years: 51-90
• Percentage women: 54%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 42 (42)
• Number (%) of people followed up: 40 (95%)
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• Average age in years: 70
• Age range in years: 44-88
• Percentage women: 53%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Planning to have cataract surgery by KLC at the Ambulatory Care
Center, the University of North Carolina Hospitals
Exclusion criteria: Medically treated diabetes mellitus; history of uveitis;use of topical
prostaglandin analogues for glaucoma; history of earlier intraocular surgery in the same
eye; retinal vascular disease; macular degeneration;abnormal preoperative OCT mea-
surements
Pretreatment: Nepafenac group were slightly older, similar gender, preoperative VA,
follow-up time, slightly longer phaco time
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• nepafenac 0.1% (brand name not reported)
◦ Times per day: 3 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
All participants received nepafenac 0.01% drops in the operated eye thrice, 5 mins
apart, immediately before surgery to maintain pupillary dilation and postoperatively,
moxifloxacin 0.5% four times a day for 10 days
Type of surgery: Phacoemulsification
Outcomes Follow-up: 2 months
• Change in CRT
• Adverse effects
• BCVA logMAR (final value)
Contact details Authors name: KL Cohen
Institution: School of Medicine, University of North Carolina
Email: klc@med.unc.edu
Address:Department of Ophthalmology, School of Medicine, University of North Car-
olina at Chapel Hill, 5100 Bioinformatics Building, 130 Mason Farm Road, CB no.
7040, Chapel Hill, NC 27599-7040, USA
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Notes Funding sources: “This work was supported in part by Research to Prevent Blindness,
Inc., New York, NY.”
Declaration of interest: “Kenneth C Mathys and Kenneth L Cohen have no financial
interest.”
Date study conducted: June 2007 to April 2008
Trial registration number: NCT00494494
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were randomised according to
the even/odd subject identification number, using
computer-generated random numbers, to the con-
trol group (standard of care only) or the treatment
group (standard of care plus nepafenac).”
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “were consecutively enrolled in this ran-
domised, non-masked, parallel-group clinical trial.
”
Judgement comment: Participants were not
masked.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At the 2 months visit, technicians, who
were masked to treatment, measured ETDRS
BCVA, and OCT scans were performed.”
Judgement comment: Experienced ophthalmic
photographers, who were masked to treatment,
obtained Stratus OCT (Carl Zeiss Meditec, Inc.,
San Francisco, CA, USA) scans using the fast mac-
ular thickness protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The mean time to follow-up was 73.31
days ( ± 21.58 SD, range 55-146) in the treatment
group and 68.98 days ( ± 13.98, range 50-120) in
the standard-of- care group.”
Judgement comment: 39/42 (93%) of interven-
tion group and 40/42 (95%) of comparator group
followed-up.Missing data less than 20% (i.e.more
than 80% follow-up) and equal follow-up in both
groups and no obvious reason why loss to follow-
up should be related to outcome
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Selective reporting (reporting bias) Low risk Judgement comment: Outcomes on trial registry
entry were reported
Miyake 2007
Methods Study design: Randomised control trial
Participants Country: Japan
Setting: Eye hospital
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 31 (31)
• Number (%) of people followed up: 25 (81%)
• Average age in years: 65
• Age range in years: NR
• Percentage women: 48%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 31 (31)
• Number (%) of people followed up: 25 (81%)
• Average age in years: 66
• Age range in years: NR
• Percentage women: 60%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Age 50 to 70 years; subjected for unilateral surgery or to have 6
months’ span between surgeries in patients with bilateral cataract
Exclusion criteria: Eyes encountering acute ocular infection or inflammation during
the first month of the study; eyes showing sensitivity to diclofenac or fluorometholone;
eyes showing sensitivity to fluorescein sodium; eyes with insufficient dilation, (pupil
diameter 4 mm) and with hazy media affecting laser Doppler flowmetry (LDF); eyes
with history of other ocular surgeries; eyes with pseudoexfoliation syndrome; history
of trauma; uveitis, glaucoma or other disorders; complication of diabetes and kidney
disorders; heart failure, cardiac infarction, and cerebrovascular disease; uncontrollable
hypertension; rupture of the posterior capsule, vitreous loss, and other complications
during a cataract/IOL implantation procedure
Pretreatment: No major imbalances; compared age and sex.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs alone
• diclofenac 0.1% (Diclod, Wakamoto, Tokyo, Japan)
◦ Times per day: 4 times on day of surgery (3, 2, 1, 0.5 hrs before surgery); 3
times a day postoperative
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 35
Comparator: Steroids alone
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• fluorometholone 0.1% (Flumethrone, Santen, Osaka, Japan)
◦ Times per day: 4 times on day of surgery (3, 2, 1, 0.5 hrs before surgery); 3
times a day postoperative
◦ Duration preoperative: days: on day of surgery
◦ Duration postoperative: days: 35
Quote “Other topical drugs used before and after surgery included mydriatics and an-
tibiotics only.”
Type of surgery: Phacoemulsification
Outcomes Follow-up: 5 weeks
• CMO (fluorescein angiography using Miyake 1977 classification)
• Inflammation (mean aqueous flare, ?units)
• Snellen acuity only, not included in the analysis
Contact details Authors name: Kensaku Miyake
Institution: Shohzankai Medical Foundation, Miyake Eye Hospital
Email: miyake@spice.or.jp
Address:Miyake Eye Hospital, 3-15-68, Ozone, Kita-ku, Nagoya 462-0825, Japan
Notes Funding sources: NR
Declaration of interest: Reported none for all authors.
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Each patient was randomly assigned
to one of the twogroups by one of the authors
(SA), using the envelope method.”
Judgement comment: Not reported how list
was generated.
Allocation concealment (selection bias) Unclear risk Quote: “Each patient was randomly assigned
to one of the twogroups by one of the authors
(SA), using the envelope method.”
Judgement comment: Reported that en-
velopes used but unclear if they were sequen-
tially numbered, sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment: Study described as
being “conducted in a prospective, dou-
ble-masked, randomised manner.” Patients
probably masked not clearly described
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Judgement comment: Fluorescein angiogra-
phy and laser flarimetry assessed by masked
observers and analysis was masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: 25/31 (80%) of eyes
in both groups were followed up and reasons
for loss to follow-up did not appear to be
related to outcome
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to protocol
or trial registry entry
Miyake 2011
Methods Study design: Parallel group RCT
Participants Country: Japan
Setting: Eye hospital
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 30 (30)
• Number (%) of people followed up: 28 (93%)
• Average age in years: 64
• Age range in years: 48-82
• Percentage women: 47%
• Ethnic group: NR
• Percentage with diabetes: 7%
• Percentage with uveitis: 0% (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 30 (30)
• Number (%) of people followed up: 27 (90%)
• Average age in years: 66
• Age range in years: 37-83
• Percentage women: 45%
• Ethnic group: NR
• Percentage with diabetes: 10%
• Percentage with uveitis: 0% (excluded)
Inclusion criteria: Aged over 20 years; phacoemulsification cataract extraction and IOL
implantation betweenOctober 2007 and April 2008 at ShohzankaiMedical Foundation,
Miyake Eye Hospital
Exclusion criteria: Systemic, topical, or ointment steroidal agents within 14 days of
surgery; had had an intraocular or periocular injection of steroidal agents within 90
days of surgery; had taken systemic or topical NSAIDs within 7 days of surgery; had a
history of ophthalmic surgery (including laser surgery) or of ocular trauma that could
affect the study results; had pseudoexfoliation syndrome; had a history of chronic or
recurring ocular inflammation (e.g. uveitis or scleritis); had diabetic retinopathy; had
an ocular anomaly (e.g. aniridia, congenital cataract); had iris atrophy; had disorders
that would preclude improvement in visual function; had macular oedema; had severe
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corneal epithelial disorder (e.g. corneal ulcer); had no visual function in the contralateral
eye; were scheduled to have other ocular surgery from baseline to 5 weeks after cataract
surgery; had secondary IOL implantation, were allergic to or might have been sensitive
to NSAIDs, amfenac, or fluorometholone; had a positive skin reaction to fluorescein;
had a tendency to bleed or were currently on anticoagulants; had had prostaglandin-type
treatment for glaucoma within 4 days of surgery; had been included in a previous study
of prostaglandin type antiglaucoma drugs; had joined another clinical study within 30
days of the study; had ocular infection, had uncontrollable diabetes mellitus; had severe
liver, kidney, or heart disorder; might have been pregnant or were currently breastfeeding;
had other factors determined to be unsuitable for the study
Pretreatment: No major imbalances.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs alone
• nepafenac 0.1% (Nevanec)
◦ Times per day: 3 times a day except for day of surgery 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 35
Comparator: Steroids alone
• fluorometholone 0.1% (Flucon)
◦ Times per day: 3 times a day except for day of surgery 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 35
Levofloxacin ophthalmic solution 0.5% (Cravit) was applied to each eye 5 times before
surgery and 3 times a day after surgery for 2 weeks
Type of surgery: Phacoemulsification
Outcomes Follow-up: 5 weeks
• Change in CRT
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977 classification)
• Inflammation (mean flare, photons/millisecond)
Contact details Authors name: K Miyake
Institution: Shohzankai Medical Foundation, Miyake Eye Hospital (K.Miyake, Ota, G.
Miyake), Nagoya, and TokyoMetropolitan Geriatric Hospital (Numaga), Tokyo, Japan
Email: miyake@spice.or.jp
Address: Shohzankai Medical Foundation, Miyake Eye Hospital, 3-15-68, Ozone, Kita-
ku, Nagoya, 462-0825, Japan
Notes Funding sources: NR
Declaration of interest: “Drs. Miyake and Numaga are consultants to Alcon Japan Ltd.
”
Date study conducted: October 2007 to April 2008
Trial registration number: NR
Contacting study investigators: Primary investigator emailed to confirm how patients
allocated
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Quote: “The 2 drugs had identical outer appear-
ances and could not be differentiated. The same
physician (J.N.) served as themedical monitor and
assigned 1 of the drugs to each patient.”
Judgement comment: Unclear if allocation con-
cealed from person recruiting participants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment:Described as “double-blind”
with no information on who was masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment:Described as “double-blind”
with no information on who was masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Missing data less than 20%
(i.e. more than 80% follow-up) and equal follow-
up in both groups and no obvious reason why loss
to follow-up should be related to outcome: 28/30
(93%) in nepafenac group and 27/30 (90%) in the
fluorometholone group
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Miyanaga 2009
Methods Study design: Parallel group RCT
Participants Country: Japan
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 24 (NR)
• Number (%) of people followed up: NR
• Average age in years: 71
• Age range in years: 46-86
• Percentage women: 71%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Intervention: NSAIDs alone
• Number of people (eyes) randomised: 25 (NR)
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• Number (%) of people followed up: NR
• Average age in years: 74
• Age range in years: 48-86
• Percentage women: 68%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 23 (NR)
• Number (%) of people followed up: NR
• Average age in years: 70
• Age range in years: 41-83
• Percentage women: 74%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Scheduled to undergo routine phacoemulsification combined with
IOL
Exclusion criteria: Corneal disease; glaucoma; uveitis; pseudoexfoliation syndrome;
diabetes; other pathologies that might affect treatment responses or evaluations; systemic
or topical anti-inflammatory therapy within 1 month prior to surgery
Pretreatment: Quote: “There were no significant differences between groups in gender
or age.”
Eyes: Probably one eye only included in the trial but not clearly reported and unclear
how selected
Interventions Intervention: NSAIDs plus steroids
• bromfenac 0.1% (Bronuck; Senju Pharmaceutical Co.,Osaka, Japan)
◦ Times per day: twice a day
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 56
• betamethasone 0.1% for 28 days and fluorometholone for 28 days (Rinderon,
Shionogi Pharmaceutical, Japan, and Flumetholon, Santen Pharmaceutical co)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 56
Intervention: NSAIDs alone
• bromfenac 0.1% (Bronuck; Senju Pharmaceutical Co.,Osaka, Japan)
◦ Times per day: twice a day
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 56
Comparator: Steroids alone
• betamethasone 0.1% for 28 days and fluorometholone for 28 days (Rinderon,
Shionogi Pharmaceutical Co., Osaka, Japan, and Flumetholon, Santen Pharmaceutical
Co)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 56
All participants received 0.5% levofloxacin eyedrops four times daily until 2 months
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after surgery, and 0.5% tropicamide and 0.5% phenylephrinehydrochloride once daily
for 2 weeks
Type of surgery: Phacoemulsification
Outcomes Follow-up: 2 months
• Adverse effects
• CMO (“obvious CMO confirmed by OCT”)
• Inflammation (aqueous flare, photons/millisecond)
Contact details Authors name: Masaru Miyanaga
Institution: Miyata Eye Hospital
Email: miyanaga@miyata-med.ne.jp
Address:Miyata Eye Hospital, 6-3 Kurahara, Miyakonojo, Miyazaki 885-0051, Japan
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: February 2006 to August 2006
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this outcome assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Only 1 patient was with-
drawn from the study from the steroid only group
due to CMO 1 month postop. Otherwise follow-
up not reported
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
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Methods Study design: Parallel group RCT
Participants Country: Greece
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 38 (38)
• Number (%) of people followed up: NR
• Average age in years: 77
• Age range in years: NR
• Percentage women: 68%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 41 (41)
• Number (%) of people followed up: NR
• Average age in years: 77
• Age range in years: NR
• Percentage women: 63%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Patients requiring phacoemulsification cataract surgery.
Exclusion criteria: Presence of corneal abnormalities; history of intraocular surgery;
preoperative ECC< 1500 cells/mm2; history of uveitis, diabetes, and age-relatedmacular
degeneration; regular, systemic use of steroid or NSAIDs during the previous 3 months;
and intraoperative complications, such as posterior capsule rupture, vitreous loss, lost
nucleus, zonule dehiscence, and wound leak
Pretreatment: No major imbalances noted.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• diclofenac sodium 0.1% (Denaclof, Novartis Hellas, Athens, Greece)
◦ Times per day: 3 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28
• dexamethasone sodium phosphate 0.1% (combined with chloramphenicol 0.5%)
(Dispersadron (Novartis Hellas, Athens, Greece)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• dexamethasone sodium phosphate 0.1% (combined with chloramphenicol 0.5%)
(Dispersadron, Novartis Hellas, Athens, Greece)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Type of surgery: Phacoemulsification
72Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Moschos 2012 (Continued)
Outcomes Follow-up: 1 month
• CRT at follow-up (final value)
• BCVA logMAR (final value)
Contact details Authors name: Irini P. Chatziralli
Institution: Department of Ophthalmology University of Athens
Email: eirchat@yahoo.gr
Address:Department of Ophthalmology, University of Athens, 28 Papanastasiou street
17342 Athens, Greece
Notes Funding sources: NR
Declaration of interest: “No competing financial interests exist.”
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised (through ran-
dom number generation) to 1 of the 2 postopera-
tive treatment arms.”
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial described as “randomised” but
with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
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Methods Study design: Parallel group RCT
Participants Country: Germany
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 90 (90)
• Number (%) of people followed up: 57 (63%)
• Average age in years: 73 (,median)
• Age range in years: NR
• Percentage women: 53%
• Ethnic group: NR
• Percentage with diabetes: NR (diabetic retinopathy excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 89 (89)
• Number (%) of people followed up: 55 (62%)
• Average age in years: 73 (median)
• Age range in years: NR
• Percentage women: 57%
• Ethnic group: NR
• Percentage with diabetes: NR (diabetic retinopathy excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: No complication during surgery; fluorescein angiography can be
done; compliance of the patient is very probable
Exclusion criteria: Exudative maculopathy; diabetic retinopathy; prior uveitis; glau-
coma; allergic reaction on fluorescein angiography; systemic steroid treatment; therapy
with non-steroid antiphlogistics; treatment with anticoagulation
Pretreatment: Age and gender comparable.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• diclofenac 0.1% (Voltaren ophtha, Civa-Geigy AG and Naclof Dispersa AG)
◦ Times per day: 5 times 2 drops preoperative and 3 x 1 drop postoperative;
then 5 times a day and after discharge 3 times a day.
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 180
• dexamethasone (brand name not reported)
◦ Brand name: NR
◦ Times per day: 4 times a day; 5 times a day; 3 times a day after discharge
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 42
Comparator: Steroids plus placebo
• dexamethasone (brand name not reported)
◦ Times per day: 4 times a day; 5 times a day; 3 times a day after discharge
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 42
• placebo (not specified)
◦ Times per day: 5 x 2 drops preoperative and 3 x 1 drop postoperative; then 5
times a day and after discharge 3 times a day.
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◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 180
All participants received antibiotic eye drops for the first 4 days after surgery
Type of surgery: ICCE
Outcomes Follow-up: not reported, assume 180 days as this is duration of treatment
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977 classification)
• BCVA Snellen only, not included in the analyses
Contact details Authors name: CD Quentin
Institution: Uni Augenklinik Göttingen
Email: NR
Address: Uni Augenklinik GöttingenRobert-Koch-Straße 40, D-3400 Göttingen, Ger-
many
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Not contacted
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment:Described as “double-blind”
with no information on who was masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment:Described as “double-blind”
with no information on who was masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up missing data >
20% but follow-up equal in both groups: 57/90
(63%) followed up in diclofenac group and 55/89
(62%) in the placebo group
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Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Rossetti 1996
Methods Study design: Parallel group RCT
Participants Country: Italy
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 42
• Number (%) of people followed up: NR
• Average age in years: 74
• Age range in years: NR
• Percentage women: 71
• Ethnic group: NR
• Percentage with diabetes: 0
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 46
• Number (%) of people followed up: NR
• Average age in years: 73
• Age range in years: NR
• Percentage women: 57
• Ethnic group: NR
• Percentage with diabetes: 0
• Percentage with uveitis: NR
Inclusion criteria: Extracapsular cataract extraction (ECCE) with implantation of an
IOL
Exclusion criteria: Diabetes; glaucoma; maculopathy; on systemic steroids, acetazo-
lamide, or NSAIDs
Pretreatment: Age, gender and preoperative visual acuity were compared. Higher pro-
portion of women in the diclofenac group (71%) compared with the placebo group
(57%). Otherwise groups were similar
Eyes: Probably one eye only included in the trial but not clearly reported and unclear
how selected
Interventions Intervention: NSAIDs plus steroids
• diclofenac sodium (Voltaren®)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 90
• dexamethasone (combined with tobramycin) (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
Comparator: Steroids plus placebo
• dexamethasone (combined with tobramycin) (brand name not reported)
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◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
• placebo (unspecified)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 90
Type of surgery: ECCE
Outcomes Follow-up: 6 months
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977 classification)
• Snellen acuity only, not included in analyses
Contact details Authors name: Nicola Orzalesi
Institution: Clinica Oculistica Universitti di Milano, Istituto di Scienze Biomediche,
Ospedale San Paolo
Email: NR
Address: Clinica Oculistica Universitti di Milano, Istituto di Scienze Biomediche, Os-
pedale San Paolo, Via di Rudini 8,20142 Milano, Italy
Notes Funding sources: NR
Declaration of interest:None of the authors has a proprietary interest in the instruments
or materials mentioned
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Judgement comment: Randomisation was ob-
tained using a table of random numbers
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial described as “randomised” but
with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment:Not reported howallocation
administered. Trial described as “double-masked”
but with no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: anterior chamber cell and
flare and fluorescein angiography was performed
by masked evaluations. No indication if the rest of
the exam (visual acuity assessment (Snellen chart),
slit- lamp biomicroscopy, lOPmeasurement by ap-
planation tonometry, and ophthalmoscopic eval-
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uation was performed by masked evaluators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Follow-up not explicitly re-
ported. However, demonstrated in several tables
(such as in Table 5 (% of patients in the calculation
of mean (SD) postoperative VA)). None of these
were < 80%
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Singh 2012
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 133 (133)
• Number (%) of people followed up: 125 (94%)
• Average age in years: 67
• Age range in years: 39-87
• Percentage women: 66%
• Ethnic group: white 78%; black 17%
• Percentage with diabetes: 100%
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 130 (130)
• Number (%) of people followed up: 126 (97%)
• Average age in years: 66
• Age range in years: 32-84
• Percentage women: 60%
• Ethnic group: white 86%; black 10%
• Percentage with diabetes: 100%
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Diabetic (type 1 or type 2); 18 years and older; existing diagnosis
of nonproliferative diabetic retinopathy that required cataract extraction with planned
implantation of a posterior chamber IOL; at least 50% of all enrolled patients were
required to have moderate to severe nonproliferative diabetic retinopathy, as defined by
the International Clinical Diabetic Retinopathy Disease Severity Scale 2
Exclusion criteria: Significant corneal staining scores at baseline; history of dry eye
syndrome; other conditions thatmay have causedmacular oedema, includingpre-existing
histories of retinal vein occlusions, ocular surgeries, inflammatory eye diseases, ocular
infections, congenital ocular anomalies, and ocular traumas; central subfield macular
thickness 250 microns or more; baseline cysts, and the presence of macular traction
and epiretinal membranes; use of concomitant medications such as topical or systemic
NSAIDs and steroids
Pretreatment: No major group differences. Compared age, gender, ethnic group, iris
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colour, NPDR classification. visual acuity
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• nepafenac 1% (Nevanac®; Alcon Research Ltd, Fort Worth, TX)
◦ Times per day: 3 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 90
• prednisolone acetate (Omnipred, Alcon)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 14
Comparator: Steroids plus placebo
• prednisolone acetate (Omnipred, Alcon)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 14
• placebo (vehicle)
◦ Times per day: 3 times; one drop prior to surgery
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 90
Interventions
Approximately one-third of the patients were instructed, based on the opinion of the
investigator, to use steroids for more than 2 weeks postsurgery
Type of surgery:NR but presumably was phacoemulsification as USA study conducted
2008
Outcomes Follow-up: 90 days
• Change in CRT (Quote: “Mean maximum change in central subfield macular
thickness measurement”)
• Adverse effects
• CMO (Quote “>= 30% increase in central subfield macular thickness from
baseline” using OCT)
• Inflammation (flare mentioned but data not reported)
• BCVA (loss of more than 5 letters from day 7 postoperative)
Contact details Authors name: Rishi Singh
Institution: Cole Eye Institute, Cleveland Clinic Foundation,
Email: drrishisingh@gmail.com
Address: Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, i-32
Cleveland, OH 44195, USA
Notes Funding sources: NR
Declaration of interest: “RS, LA, GJJ, RPL, JL, HJR, KS, and TW are paid consultants
for Alcon Research Ltd (Fort Worth, TX). DS is an employee of Alcon Research, Ltd.
Medical writing support, which was funded by Alcon Research Ltd, was provided by
Cullen TVogelson and Usha Sivaprasad, of Illuminated Research LLC (FortWorth, TX)
.”
Date study conducted: November 2008 and July 2010
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Trial registration number: NCT00782717
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This was a multicenter, randomised,
double-masked, vehicle-controlled, parallel-group
study”
Judgement comment: Not reported how list was
generated.
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial described as “randomised” but
with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment: Study was double-masked
with a placebo consisting of vehicle only. It was
not clearly stated whether the masking was likely
to have been effective but we have assumed that it
was
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Judgement comment: Study was double-masked
with a placebo consisting of vehicle only. It was
not clearly stated whether the masking was likely
to have been effective but we have assumed that it
was
Quote: “Total macular volume was determined
from a 6 mm diameter circle centered on the
foveal center. Morphological features, including
intraretinal cysts, were analyzed by the reading cen-
ter in a masked fashion.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: 125/133
(94%) in nepafenac group included in the analysis
compared with 126/130 (97%) in control group.
Missing data less than 20%. 95%-96% of patients
enrolled included in final analysis. However, 8 pa-
tients in theNepafenac group and 4 patients in the
Vehicle group excluded from final analysis. Rea-
sons not clearly explained
Selective reporting (reporting bias) Low risk Judgement comment: Outcomes on trial registry
entry were reported
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Methods Study design: Parallel group RCT
Participants Country: Canada (8 sites) and Germany (2 sites)
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 226 (226)
• Number (%) of people followed up at days 21 to 60: 118 (52%)
• Number (%) of people followed up at days: 126 (56%)
• Average age in years: 67
• Age range in years: 39-99
• Percentage women: 50%
• Ethnic group: 95% white
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 234 (234)
• Number (%) of people followed up at days 21 to 60: 134 (57%)
• Number (%) of people followed up at days 121 to 240: 144 (62%)
• Average age in years: 69
• Age range in years: 40-100
• Percentage women: 53%
• Ethnic group 94% white
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 221 (221)
• Number (%) of people followed up at days 21 to 60: 112 (51%)
• Number (%) of people followed up at days 121 to 240: 114 (52%)
• Number (%) of people followed up : See below
• Average age in years: 68
• Age range in years: 26-99
• Percentage women: 56
• Ethnic group 92% white
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: Unilateral extracapsular cataract extraction (by manual nuclear ex-
pression) with posterior chamber lens implantation
Exclusion criteria: Taking aspirin, topical epinephrine, systemic or topical cyclo-oxy-
genase inhibitors, or oral corticosteroid; allergic to cyclo-oxygenase inhibitors; history
of chronic intraocular inflammation; pre-existing macular pathology; history of herpetic
keratitis; corneal or vitreous opacity; non-compliant patients
Pretreatment: No major imbalances in age, gender, ethnic group.
Eyes: One eye, this was the eye scheduled for unilateral extracapsular cataract extraction
Interventions Intervention: NSAIDs plus steroids
• flurbiprofen 0.03% (Ocufen, Ocufur)
◦ Times per day: 4 times a day and 4 drops before surgery
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 90
• prednisolone acetate 1 % or dexamethasone sodium phosphate 0.1 % (brand
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name not reported)
◦ Times per day: NR
◦ Duration preoperative: days: NR
◦ Duration postoperative: days: NR
Intervention: NSAIDs plus steroids
• indomethacin 1% (Indocid)
◦ Times per day: 4 times a day and 4 drops before surgery
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 90
• prednisolone acetate 1% or dexamethasone sodium phosphate 0.1% (brand name
not reported)
◦ Times per day: NR
◦ Duration preoperative: days: NR
◦ Duration postoperative: days: NR
Comparator: Steroids plus placebo
• prednisolone acetate 1% or dexamethasone sodium phosphate 0.1% (brand name
not reported)
◦ Times per day: NR
◦ Duration preoperative: days: NR
◦ Duration postoperative: days: NR
• placebo (flurbiprofen vehicle)
◦ Times per day: 4 times a day and 4 drops before surgery
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 90
Duration postoperative: days - the investigator had the option of extending the treat-
ment for an additional 3 months. This option was chosen for 10.9% (25/230) of ve-
hicle-treated patients, 8.4% (20/238) of flurbiprofen-treated patients, and 9.7% (22/
227) of indomethacin-treated patients. Concomitant medications included aminogly-
coside antibiotics (100% of patients) and topical corticosteroids (prednisolone acetate
1% or dexamethasone sodium phosphate 0.1%) in 88.7% (204/230) of vehicle treated
patients, 87.8% (209/238) of flurbiprofen treated patients, and 88.1% (200/227) of
indomethacin-treated patients
Type of surgery: ECCE
Outcomes Follow-up: 6 months
• Poor vision outcome due to MO (angiographic CME plus visual acuity <=20/40)
• Adverse effects
• CMO (fluorescein angiography 0 = no visible macular oedema; 1 = oedema
without clear cut cystoid spaces; 2 = oedema with clearly evident cystoid spaces; 3 =
florid oedema with cystoid spaces; CME = grades 1 to 3)
• BCVA (Snellen acuity but not reported by treatment group)
Contact details Authors name: Leon D Solomon
Institution: NR
Email: NR
Address: NR
Notes Funding sources: Supported by Allergan, Inc., Irvine California
Declaration of interest: None of the Flurbiprofen-CME Study Group members has a
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commercial or proprietary interest in 0.03% flurbiprofen or 1% indomethacin
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported how list was generated. Trial was de-
scribed as “randomised” but with no further de-
tails
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised,
double-masked” but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment: Described as “double-
masked”. Medications were masked and fluores-
cein angiograms were read in a masked fashion
by 2 retinal specialists. Uncertain if the operating
surgeons or clinicians involved in follow-up were
masked to the allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: Each fluorescein angiogram
was read in amasked fashion by two retinal special-
ists. Unclear if treating ophthalmologists involved
in other aspects of patient care were also masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up: 177/226 (78%)
in flurbiprofen group, 177/234 (76%) in in-
domethacin group, 160/221 (72%) in placebo
group. Reasons for loss to follow-up not described
Selective reporting (reporting bias) High risk Judgement comment: No access to protocol or tri-
als registry entry. Not all follow-up points were re-
ported fully
Tauber 2006
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 16 (NR)
• Average age in years: NR
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• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids alone
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 16 (NR)
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: NR
Exclusion criteria: NR
Pretreatment: Groups differences not reported.
Eyes: Unclear if one or both eyes included.
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (Acular LS)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 30
• prednisolone acetate 1% (ECONOPRED PLUS®)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 7 plus taper
Comparator: Steroids alone
• prednisolone acetate 1% (ECONOPRED PLUS®
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 7 plus taper
Type of surgery: NR
Outcomes Follow-up: 30 days (3 month follow-up mentioned but not reported)
• Change in CRT (but mean/SD not reported)
• Proportion with > 10% increase in retinal thickness
Contact details Authors name: S Tauber
Institution: Ophthalmology, St. John’s Hospital and Clinics, Springfield, MO
Email: NR
Address: Ophthalmology, St. John’s Hospital and Clinics, Springfield, MO
Notes Funding sources: Alcon Laboratories, Inc.
Declaration of interest: “Commercial Relationships S. Tauber, Alcon, F; Alcon, R; J.
Gessler, None; W. Scott, None; C. Peterson, None; P. Hamlet, None.”
Date study conducted: NR
Trial registration number: NR
84Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tauber 2006 (Continued)
Contacting study investigators: Abstract only, authors contacted by email regarding
publication of full study results but no reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this outcome assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) High risk Judgement comment: Some outcomes not re-
ported including 3-month OCT outcomes
Ticly 2014
Methods Study design: Parallel group RCT
Participants Country: Brazil
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 42 (42)
• Number (%) of people followed up: 37 (88)
• Average age in years: 67
• Age range in years: NR
• Percentage women: 43
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 49 (49)
• Number (%) of people followed up: 44 (90)
• Average age in years: 66
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• Age range in years: NR
• Percentage women: 50
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Included criteria: Nuclear cataract density of 2 and 3 determined by LOCS II; ( > 50
years old); indication for cataract surgery with IOL implantation under local anaesthesia
Excluded criteria: Diabetes; NSAID use; use of topical eye drops (including antiglau-
coma drugs); uveitis; macular disease; pseudoexfoliation syndrome; congenital ocular
abnormalities; cataract density of 1 and 4 determined by LOCS II; previous intraocular
surgery; previous injections; complications during cataract surgery (e.g. posterior capsule
rupture, vitreous loss, retained cortical material, or an IOL not placed in the capsular
bag); not follow instructions or if they did not show up for appointments
Pretreatment: No major imbalances in age, gender and visual acuity.
Eyes: Probably one eye only included in the trial but not clearly reported and unclear
how selected
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (Acular LS, Allergan, Inc)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 35
• prednisolone acetate 1% (Pred Forte; Allergan,Inc)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 35
Comparator: Steroids plus placebo
• prednisolone acetate 1% (Pred Forte; Allergan,Inc)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 35
• placebo (dextran 70/hypromellose, Lacribell, Latinofarma;Industrias
Farmaceuticas Ltda)
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 35
Type of surgery: Phacoemulsification
Outcomes Follow-up: 5 weeks
• CRT at follow-up (final value)
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977 classification)
• BCVA logMAR (final value)
Contact details Authors name: Dr. Flavia G. Ticly
Institution: Department of Ophthalmology, University of Campinas (UNICAMP),
Campinas, Sao Paulo, Brazil
Email: flaviaticly@gmail.com
Address:Department of OphthalmologyUniversity of Campinas (UNICAMP)P.O. Box
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6111Campinas 13083-970, Sao Paulo, Brazil
Notes Funding sources: NR
Declaration of interest: Reported no competing financial interests exist.
Date study conducted: February 2011 to March 2012
Trial registration number: NTC01542190
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Each of the 2 intervention
groups received 50 different numbers from a ran-
dom number table. These numbers were trans-
ferred to small individual envelopes and also af-
fixed to one of the relabeled eye drop bottles. Un-
clear how this would work
Allocation concealment (selection bias) Unclear risk Judgement comment: Numbers were transferred
to small individual envelopes and also affixed to
one of the relabeled eye drop bottles. Unclear how
this concealed the allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment: Placebo-controlled study.
We assume the masking was effective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Judgement comment: Placebo-controlled study.
We assume the masking was effective. It was stated
that the surgeon and the ophthalmologist who col-
lected the data were not aware of the group assign-
ment of the patients
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: 89% follow-up. Five pa-
tients (10%) did not complete the trial in the
placebo group while five patients (11%) did not
complete the study in the ketorolac group
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
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Tunc 1999
Methods Study design: Parallel group RCT
Participants Country: Turkey
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 50 (50)
• Number (%) of people followed up: 50 (100%)
• Average age in years: 61
• Age range in years: NR
• Percentage women: 38%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 25 (25)
• Number (%) of people followed up: 25 (100%)
• Average age in years: 65
• Age range in years: NR
• Percentage women: 40%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Patients with unilateral cataracts.
Exclusion criteria: Diabetes; rheumatoid disease; immunological disease; uveitis; glau-
coma; ARMD; retinitis pigmentosa; retinal detachment; NSAIDs use; corticosteroid
use; diuretic use; antihistaminics; previous eye surgery; surgical complications (e.g.. pos-
terior capsular tear, vitreous loss, iatrogenic iridodialysis); combined surgery; postoper-
ative complications (e.g.. iris capture, retinal detachment, choroidal detachment); non-
compliance with medications; use of systemic steroids or NSAIDs during the follow-up
period; definite posterior capsule opacification
Pretreatment: No differences in age sex, and hypertension.
Eyes: One eye, people with unilateral cataracts recruited.
Interventions Intervention: NSAIDs plus steroids
• diclofenac sodium 0.1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 56
• dexamethasone sodium phosphate 1% (brand name not reported)
◦ Times per day: 4 times a day for 21 days; 3 times a day from day 22 to 56
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 56
Comparator: Steroids alone
• dexamethasone sodium 1% (brand name not reported)
• Times per day: 4 times a day for 21 days, 3 times a day from day 22 to 56
• Duration preoperative: days: 0
• Duration postoperative: days: 56
At the end of surgery all participants had subconjunctival injection of dexamethasone
and gentamicin. All participants used 0.03% tobramycin eye drops postoperatively 4
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times a day for 14 days
Type of surgery: ECCE
Outcomes Follow-up: 2 months
• CMO (fluorescein angiography 0 no leakage (CME absent),1 oedema less than
perifoveal, 2 mild perifoveal oedema, 3 moderate perifoveal oedema (approx 1 disc
diameter), 4 severe perifoveal oedema plus drop of 1 line of Snellen acuity since second
postoperative week defined as ”clinically significant“)
Contact details Authors name: Murat Tunc
Institution: Dokuz Eylul University Medical School
Email: NR
Address: Dokuz Eylul University Cumhuriyet Blv No:144, 35210 Alsancak/ zmir,
Turkey
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information on masking. We assume that in
absence of reporting on this participants and per-
sonnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”The angiograms were read by the retina
unit (Dr Saatchi); the patients’ names and treat-
ment protocols were kept hidden
Judgement quote: No other information on other
outcomes.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement Comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement Comment: No access to protocol or
trial registry entry
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Methods Study design: Parallel group RCT
Participants Country: Brazil
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: not reported by group
• Number (%) of people followed up: 45 (45 eyes)
• Average age in years: 65 (reported for whole cohort only)
• Age range in years: 50 to 90 (reported for whole cohort only)
• Percentage women: 56% (reported for whole cohort only)
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: not reported by group
• Number (%) of people followed up: 41 (41 eyes)
• Average age in years: 65 (reported for whole cohort only)
• Age range in years: 50 to 90 (reported for whole cohort only)
• Percentage women: 56% (reported for whole cohort only)
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: not reported by group
• Number (%) of people followed up: 40 (40 eyes)
• Average age in years: 65 (reported for whole cohort only)
• Age range in years: 50 to 90 (reported for whole cohort only)
• Percentage women: 56% (reported for whole cohort only)
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: Older than 40 years; age-related cataract; normal ophthalmological
exam
Exclusion criteria: Previous ocular surgery; central endothelial cell count < 2000 cells/
mm2; glaucoma or IOP > 21 mmHg; amblyopia; retinal abnormalities; steroid or im-
munosuppressive treatment; connective tissue diseases; allergy or hypersensitivity to
NSAIDs; enrolled patients with complicated cataract surgery (e.g. posterior capsule rup-
ture, vitreous loss or an IOL not placed in the capsular bag)
Pretreatment: Group differences at baseline not reported.
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• ketorolac tromethamine 0.4% (Acular LS, Allergan)
◦ Times per day: 4 times
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 28
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 0
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◦ Duration postoperative: days: 28
Intervention: NSAIDs plus steroids
• nepafenac 0.1% (Nevanec, Alcon)
◦ Times per day: 3 times
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 28
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 28
Comparator: Steroids plus placebo
• prednisolone 1% (brand name not reported)
◦ Times per day: 4 times a day for 7 days, 3 times a day for 7 days, twice a day
for 7 days, once a day for 7 days
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 28
• placebo (artificial tears)
◦ Times per day: 4 times
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 28
All participants received moxifloxacin 0.5% 4 times a day 2 days before surgery and 7
days postoperatively
Type of surgery: Phacoemulsification
Outcomes Follow-up: 12 weeks for some outcomes, 30 days for others
• CRT at follow-up (final value)
• Adverse effects
• BCVA logMAR (final value)
Contact details Authors name: Patrick F Tzelikis
Institution: Brasilia Ophthalmologic Hospital
Email: tzelikis@gmail.com
Address: Brasilia Ophthalmologic Hospital, HOB, SQN 203, bloco K, apart 502,
Brasilia, DF 70833-110, Brazil
Notes Funding sources: NR
Declaration of interest: Reported no competing interests
Date study conducted: June 2013 to October 2013
Trial registration number: NCT02084576.
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned in a 1:1:1 ratio to
one of three treatment groups using a computer-
generated randomisation list.”
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Allocation concealment (selection bias) Low risk Quote: “All investigators were masked with regard
to treatment group.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment: Placebo-controlled.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All investigators were masked with regard
to treatment group.”
Judgement comment: Placebo-controlled.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up by intervention group not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment: Trial study protocol regis-
tered at NCT02084576 but does not clearly de-
fine outcomes
Umer-Bloch 1983
Methods Study design: Parallel group RCT
Participants Country: Switzerland
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 35 (NR)
• Average age in years: 68
• Age range in years: NR
• Percentage women: 51%
• Ethnic group: NR
• Percentage with diabetes: NR (but people with diabetic retinopathy were excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: NR
• Number (%) of people followed up: 38 (NR)
• Average age in years: 70
• Age range in years: NR
• Percentage women: 53%
• Ethnic group: NR
• Percentage with diabetes: NR (but people with diabetic retinopathy were excluded)
• Percentage with uveitis: 0 (excluded)
Included criteria: Intracapsular cataract extraction (124 persons); 40 patients with IOL
implantation after cataract extraction
Excluded criteria: Maculopathy; diabetic retinopathy; prior uveitis; systemic steroid
therapy
Pretreatment: Unclear if groups comparable.
Eyes: Unclear if one or both eyes included.
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Interventions Intervention: NSAIDs plus steroids
• indomethacin 1% (Indoptic, Merck, Sharp and Dohme-Chibret)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 84
Comparator: Steroids plus placebo
• dexamethasone (combined with either chloramphenicol (Spersadex) or neomycin
(Maxitrol))
◦ Times per day: NR
◦ Duration preoperative: days: NR
◦ Duration postoperative: days: NR
• placebo (vehicle)
◦ Times per day: 4 times
◦ Duration preoperative: days: 1
◦ Duration postoperative: days: 84
Additional for all participants: cycloplegics (atropine 1%); if necessary timoptic or di-
amox to lower eye pressure
Type of surgery: ECCE (40) ICCE (124)
Outcomes Follow-up: 12 weeks
• Adverse effects
• CMO (fluorescein angiography using Miyake 1977 classification)
• BCVA (Snellen only, not included in the analyses)
Contact details Authors name: U Umer-Bloch
Institution: University Augenklink Zurich
Email: NR
Address: University Augenklinik, Ramistrasse 100, CH-8091 Zurich
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment: Not reported how alloca-
tion was administered. Trial was described as “ran-
domised” but with no further details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment:Medicationplaced by nurses
in a bottle with suspension: one with in-
domethacin another with vehicle. Neither the ex-
aminer nor the patient knew the contents of the
bottle
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Judgement comment: Placebo-controlled using
vehicle only. Patients, nurses, physician analysing
fluorescein angiography were masked
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: For 35 patients the study
was stopped before the end of the study because of
intra-operative complications or they had, as only
later recognized, an exclusion criteria as defined as
maculopathy, diabetic retinopathy, prior uveitis or
a systemic steroid therapy. Not reported to which
groups these patients belonged
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Wang 2013
Methods Study design: Parallel group RCT
Open label
Participants Country: China
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 120 (NR)
• Number (%) of people followed up: 83 (69%)
• Average age in years: 73 (reported for whole cohort only)
• Age range in years: 46-92 (reported for whole cohort only)
• Percentage women: 54% (reported for whole cohort only)
• Ethnic group: 100% Han Chinese
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 120 (NR)
• Number (%) of people followed up: 84 (70%)
• Average age in years: 73 (reported for whole cohort only)
• Age range in years: 46-92 (reported for whole cohort only)
• Percentage women: 54% (reported for whole cohort only)
• Ethnic group: 100% Han Chinese
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: Age-related cataract patients undergoing phacoemulsification with
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posterior chamber IOL implantation
Exclusion criteria: Any ocular diseases that might affect treatment responses or evalu-
ations, such as corneal disease, glaucoma, uveitis, retinal detachment, optic neuropathy
or amblyopia; any systemic diseases that might affect treatment responses or evaluations,
such as diabetes mellitus; potentially pregnant women; systemic or topical anti-inflam-
matory therapy within 1 month prior to surgery and contraindication of oral steroids,
such as patients with peptic ulcer, cancer and tuberculosis; surgical complications, such
as posterior capsule rupture or hyphema; special diseases which might affect surgery in
the eyes, such as limitation of pupil dilation
Pretreatment: Groups were not compared.
Eyes: Not clearly reported but probably one eye per person, unclear how selected
Interventions Intervention: NSAIDs plus (oral) steroids
• bromfenac sodium 0.1% (brand name not reported, Senju Pharmaceutical Co.,
Ltd)
◦ Times per day: twice a day
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 30 and 60
• prednisolone 15 mg PO (brand name not reported)
◦ Times per day: once
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 7
Comparator: Steroids alone
• fluorometholone 0.1% and dexamethasone 0.1% (brand name not reported,
Santen Pharmaceutical Co. Ltd. and Wujing Pharmaceutical Co. Ltd)
◦ Times per day: 3 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 30
• prednisolone 15mg PO (brand name not reported)
◦ Times per day: once
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 7
All participants received levofloxacin eye drops (Santen PharmaceuticalCo., Ltd) 4 times
a day for 1
day preoperatively and 7 days postoperatively.
Type of surgery: Phacoemulsification
Outcomes Follow-up: 2 months
• Poor vision outcome due to MO (unclear what vision cutpoint used)
• CRT at follow-up (final value)
• Adverse effects
• CMO (Quote “CME was defined as central retinal thickness > 250 µm and the
presence of intraretinal cystoid space
• beneath the foveal, with the diagnosis confirmed by the same retinal specialist.”)
• Inflammation (mean photon count values)
• BCVA logMAR
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Contact details Authors name: Ke Yao
Institution: Medical College of Zhejiang University
Email: xlren@zju.edu.cn
Address: Eye Center, 2nd Affiliated Hospital Medical College of Zhejiang University
Hangzhou 310009 (China)
Notes Funding sources: “This study was supported by grants from Zhejiang Key Innovation
Team Project of China (grant no. 009R50039) and Zhejiang Key Laboratory Fund of
China (No.2011E10006).”
Declaration of interest: NR
Date study conducted: October 2010 to December 2011
Trial registration number: NR
Contacting study investigators: Trial authors not contacted
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomly and
prospectively assigned into four groups
(OBS1,OBS2, OFM andODM) by a ran-
dom-numbers table.”
Allocation concealment (selection bias) High risk Judgement comment: The drugs were ap-
plied topically to the assigned patients
open-label. The same physician served as
the medical monitor and assigned one of
the drugs to each patient
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: The drugs were ap-
plied topically to the assigned patients
open-label. The same physician served as
the medical monitor and assigned one of
the drugs to each patient
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: The drugs were ap-
plied topically to the assigned patients
open-label. The same physician served as
the medical monitor and assigned one of
the drugs to each patient
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up was 83/
120 (69%) in NSAIDs group and 84/120
(70%) in the steroid group. Significant loss
to follow-up but similar in both groups
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to proto-
col or trial registry entry
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Wittpenn 2008
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 268 (268)
• Number (%) of people followed up: 227 (85%) given OCT at 4 weeks; 35 (13%) at
6 weeks
• Average age in years: 70
• Age range in years: NR
• Percentage women: 53% (only reported for whole cohort)
• Ethnic group: 82% white (only reported for whole cohort)
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 278 (278)
• Number (%) of people followed up: 251 (90%) given OCT at 4 weeks; 42 (15%) at
6 weeks
• Average age in years: 70
• Age range in years: NR
• Percentage women: 53% (only reported for whole cohort)
• Ethnic group: 82% white (only reported for whole cohort)
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: Scheduled to undergo cataract surgery; 20/20 BCVA potential with-
out any evidence of macular abnormality, including age-related macular changes, epireti-
nal membranes, or other retinal-vascular anomalies
Exclusion criteria: Systemic diseases with ocular manifestations of the disease (e.g.
diabetic patients with normal retinal exams were not excluded); vitreous loss or capsular
disruption/rupture occurred during surgery; postoperative day 1, the surgeon felt the
amount of inflammation was greater than expected and, in his best clinical judgment,
more aggressive anti-inflammatory treatment was indicated
Pretreatment: Quote: “There were no statistically significant between-group differences
in any demographic variable.” But no data reported
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• ketorolac 0.4% (Acular LS, Allergan Inc, Irvine, California, USA)
◦ Times per day: 4 times a day , 4 doses every 15 minutes one hour preoperative
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 28 to 42
• prednisolone acetate 1% (Pred Forte, Allergan Inc)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: “until one 5 ml bottle was empty”
Comparator: Steroids plus placebo
• prednisolone acetate 1% (Pred Forte, Allergan Inc)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
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◦ Duration postoperative: days: “until they exited the study”
• placebo (artificial tears)
◦ Brand name: NR
◦ Times per day: 4 times
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: “until one 5 ml bottle was empty”
The comparator group: “...also received four drops of ketorolac 0.4% one hour prior to
cataract surgery.”
Type of surgery: Phacoemulsification
Outcomes Follow-up: 4 weeks
• Poor vision outcome due to MO (OCT-confirmed CMO with visual acuity < 6/
9.)
• Adverse effects
• CMO (Quote: “Definite CME: Presence of cystoid changes associated with
substantial (> 40µm) retinal thickening evident on OCT. 2. Probable CME: Presence
of changes in retinal contour and increased macular thickness relative to preoperative
baseline, but without definite cystoid changes. 3. Possible CME: Mild to moderate
changes in retinal thickness or contour without cystoid changes”)
Contact details Authors name: John R. Wittpenn
Institution: State University of New York at Stony Brook
Email: jrwittpenn@aol.com
Address: State University of New York at Stony Brook, 2500 Route 347, Building 24,
Stony Brook, NY 11790
Notes Funding sources: “This study was supported by an unrestricted education grant from
Allergan Inc, Irvine, Calfiornia.”
Declaration of interest: “The authors indicate no financial conflict of interest.”
Date study conducted: June 2005 to August 2006
Trial registration number: NCT00348244
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised in a 1:1 ratio
using a randomly generated list of patient identi-
fication numbers.”
Allocation concealment (selection bias) Low risk Quote: “A central coordination center (IMEDS
Inc, Riverside, California, USA; [M.E.]) generated
the allocation sequence, enrolled participants, and
assigned participants to their treatment groups.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The patients and technical staff were un-
masked because regulations prevented the medi-
cations from being repackaged into similar, un-
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marked bottles. The labels were covered but the
technicians were capable of recognizing the bot-
tle color and shape. Patients, however, would only
have been unmasked if they researched the type
and shape of the different bottles.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All investigators were masked with regard
to treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: Very low follow-up at 6
weeks. “Of the 546 patients who entered the study,
77 patients also returned for the week-6 visit, 35 in
the ketorolac/steroid group and 42 in the steroid
group.”
Selective reporting (reporting bias) Unclear risk Judgement comment: No access to protocol and
trial registry entry did not include outcomes
Yannuzzi 1981
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR (100)
• Number (%) of people followed up: 59 eyes (59%)
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: NR (131)
• Number (%) of people followed up: 77 eyes (59%)
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Included criteria: Patients undergoing intracapsular cataract extraction.
Excluded criteria: Undergone procedures other than conventional ICCE; pre-existing
macular disease predisposing tomacular oedema, such as neovascular age-relatedmacular
degeneration
Pretreatment: Baseline comparisons not reported.
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Eyes: 21 people had bilateral cataract surgery - the second eye was randomised separately
Interventions Intervention: NSAIDs plus steroids
• indomethacin 1% (brand name not reported, Merck Sharp & Dohme)
◦ Times per day: Three drops prior to surgery and 4 times a day after
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28-42
• steroids given as part of standard care, not specified exactly what
Comparator: Steroids plus placebo
• steroids given as part of standard care, not specified exactly what
• placebo (vehicle)
◦ Times per day: Three drops prior to surgery and 4 times a day after
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28-42
Quote: ”Routine postoperative drops such as cycloplegics, antibiotics and steroids were
also given as was the custom of the operating ophthalmologist.“
Type of surgery: ICCE
Outcomes Follow-up: 1 year
• Poor vision outcome due to MO (BCVA 6/60 or worse)
• Adverse effects
• CMO (fluorescein angiography, CMO not defined, reported at 5 and 10 weeks)
Contact details Authors name: Lawrence A Yannuzzi
Institution: Manhattan Eye, Ear and Throat Hospital
Email: NR
Address:Manhattan Eye, Ear and Throat Hospital 210 E 64th St, New York, NY 10021,
United States
Notes Funding sources: LuEster Mertz Retinal Research Fund of the Eye, Ear and Throat
Hospital
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Allocation was described as being done
“in a random fashion” but with no further details
Allocation concealment (selection bias) High risk Judgement comment: Pharmacist involved in giv-
ing treatment did not appear to bemasked to treat-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment: Placebo-controlled study
described as “double-masked”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled study
described as “double-masked”
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: Follow-up 59% in both
groups. High loss to follow-up at 1 year 38/100
(38%) inNSAIDs group and 50/131 (38%) in the
control group
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Yavas 2007
Methods Study design: Parallel group RCT
Participants Country: Turkey
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 126 (126)
• Number (%) of people followed up: 121 (96%)
• Average age in years: 64
• Age range in years: NR
• Percentage women: 43%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Comparator: Steroids alone
• Number of people (eyes) randomised: 63 (63)
• Number (%) of people followed up: 58 (92%)
• Average age in years: 65
• Age range in years: NR
• Percentage women: 36%
• Ethnic group: NR
• Percentage with diabetes: 0 (excluded)
• Percentage with uveitis: 0 (excluded)
Inclusion criteria: NR
Exclusion criteria: History of intraocular surgery; any complication during cataract
surgery; glaucoma; uveitis; vitreoretinal pathology; history of diabetes mellitus, hyper-
tension, or cardiac disease; or topical or systemic drug use
Pretreatment: Some imbalances in age and sex but unclear if important.
Eyes: Right eye only included.
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Interventions Intervention: NSAIDsplus steroids
• indomethacin 0.1% (brand name not reported)
◦ Times per day: 4 times a day preoperative; 3 times a day postoperative. Half
received postoperatively only.
◦ Duration preoperative: days: 3
◦ Duration postoperative: days: 30
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 30
Comparator: Steroids alone
• prednisolone acetate 1% (brand name not reported)
◦ Times per day: 4 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 30
All participants received 1 drop of topical antibiotic (ofloxacin 0.3%) 4 times a day daily
for 1 week
Type of surgery: Phacoemulsification
Outcomes Follow-up: 3 months
• CMO (Quote: “Slight fluorescein leakage into the cystic space without enclosing
the entire central fovea or complete fluorescein accumulation in the cystic space was
diagnosed as angiographic CME.”
• BCVA (final value)
Contact details Authors name: Guliz Yavas
Institution: Afyon Kocatepe University
Email: gkumbar@ttnet.net.tr
Address: P.K. 25, 06502 Bahcelievler, Ankara, Turkey
Notes Funding sources: NR
Declaration of interest: “No author has a financial or proprietary interest in anymaterial
or method mentioned.”
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised into 3 groups.”
Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
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but with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Fluorescein angiography was performed
in all patients, and fluorescein leakage to diagnose
angiographic CME was evaluated by a masked ob-
server.”
Judgement comment: Unclear if other outcomes
were masked.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Yung 2007
Methods Study design: Parallel group RCT
Participants Country: USA
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 19 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: 100%
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 18 (NR)
• Number (%) of people followed up: NR
• Average age in years: NR
• Age range in years: NR
• Percentage women: NR
• Ethnic group: NR
• Percentage with diabetes: 100%
• Percentage with uveitis: NR
Inclusion criteria: Diabetic patients having cataract surgery.
Exclusion criteria: NR
Pretreatment: Group differences not reported.
Eyes: Unclear if one or both eyes included.
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Interventions Intervention: NSAIDs plus steroids
• ketorolac 0.5% (brand name not reported)
◦ Times per day: NR
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
• steroid (not specified)
◦ Times per day: NR
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids plus placebo
• steroid (not specified)
◦ Times per day: NR
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
• placebo (not specified)
◦ Times per day: NR
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Type of surgery: NR
Outcomes Follow-up: 12 weeks
• Change in CRT (reported statistical significance only, no data)
Contact details Authors name: C Yung
Institution: Indiana University
Email: NR
Address: Indiana University107 S Indiana Ave, Bloomington, IN 47405, United States
Notes Funding sources: NR
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Abstract only, tried to contact authors but could not
find email address
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial was described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial was described as “randomised”
but with no further details
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled but no
information on who was masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Judgement comment: Placebo-controlled but no
information on who was masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: Follow-up not reported.
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Zaczek 2014
Methods Study design: Parallel group RCT
Participants Country: Sweden
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: 80 (80)
• Number (%) of people followed up: 75 (94%)
• Average age in years: 70
• Age range in years: NR
• Percentage women: 64%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids plus placebo
• Number of people (eyes) randomised: 80 (80)
• Number (%) of people followed up: 77 (96%)
• Average age in years: 68
• Age range in years: NR
• Percentage women: 65%
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Inclusion criteria: 45 and 85 years of age; cataract surgery under local anaesthesia;
translucent cataract for good-quality OCT scans of the macular at baseline
Exclusion criteria: Small pupils (< 5.0 mm after pharmacologic dilation); dark brown
irides; exfoliation syndrome, history of uveitis; glaucoma; macular degeneration; vision
impairing eye disorder except cataract; diabetic patients; pregnant women; patients using
topical or systemic anti-inflammatory treatment; hypersensitivity to any of the given
study treatments; intraoperative difficulties (e.g. loose zonular fibres, extended operat-
ing time, residual cortical material); intraoperative complications (e.g. posterior capsule
rupture and vitreous loss)
Pretreatment: No major imbalances, age, gener and operated eye compared.
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Zaczek 2014 (Continued)
Eyes: One eye, unclear how selected.
Interventions Intervention: NSAIDs plus steroids
• nepafenac 0.1% (brand name not reported)
◦ Times per day: 3 times
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 21
• dexamethasone 0.1% (Isopto-Maxidex)
◦ Times per day: 3 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
Comparator: Steroids plus placebo
• dexamethasone 0.1% (Isopto-Maxidex)
◦ Times per day: 3 times
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 21
• placebo (Tears Naturale II Polyquad)
◦ Times per day: thrice before surgery 5 minutes apart/3 times a day
◦ Duration preoperative: days: 2
◦ Duration postoperative: days: 21
Type of surgery: Phacoemulsification
Outcomes Follow-up: 6 weeks
• Adverse effects
• CMO (OCT-verified but not defined)
• Inflammation (mean anterior chamber reported in figure but no SD could be
calculated)
• BCVA logMAR (final value)
• Change in total macular volume
Contact details Authors name: Anna Zaczek
Institution: Scanloc Healthcare AB
Email: anna. zaczek@scanloc.se
Address: Scanloc Healthcare AB, Lilla Bommen 6, 411 04 Gothenburg, Sweden
Notes Funding sources: Supported by Alcon Research Ltd, Fort Worth, Texas, USA, and S.
A. Alcon-Couvreur N.V. Puurs, Belgium, which produced and provided the masked
eyedrop bottles. Partially supported by Alcon, Inc. Sweden. Financial support was also
provided through the regional agreement on Medical training and Clinical research
(ALF) between Stockholm County Council and Karolinska Institutet (20120623)
Declaration of interest: “No author has a financial or proprietary interest in anymaterial
or method mentioned.”
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Zaczek 2014 (Continued)
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial described as “randomised” but
with no further details
Allocation concealment (selection bias) Low risk Quote: “All products used in this clinical trial were
produced, labelled, packaged, and released by S.A.
Alcon-Couvreur N.V. Puurs, Belgium. Nepafenac
and placebo suspensions were supplied in identi-
cal bottles labelled with a protocol and a patient
number so neither the investigators nor the pa-
tients were able to identify their contents.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All products used in this clinical trial were
produced, labelled, packaged, and released by S.A.
Alcon-Couvreur N.V. Puurs, Belgium. Nepafenac
and placebo suspensions were supplied in identi-
cal bottles labelled with a protocol and a patient
number so neither the investigators nor the pa-
tients were able to identify their contents.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All products used in this clinical trial were
produced, labelled, packaged, and released by S.A.
Alcon-Couvreur N.V. Puurs, Belgium. Nepafenac
and placebo suspensions were supplied in identi-
cal bottles labelled with a protocol and a patient
number so neither the investigators nor the pa-
tients were able to identify their contents”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Missing data less than 20%
(i.e. more than 80% follow-up) and equal follow-
up in both groups and no obvious reason why loss
to follow-up should be related to outcome
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
Zhang 2008
Methods Study design: Parallel group RCT
Participants Country: China
Setting: Eye hospital
Intervention: NSAIDs plus steroids
• Number of people (eyes) randomised: NR (110)
• Number (%) of people followed up: 110 eyes (100%)
• Average age in years: NR
• Age range in years: 55-87 (reported for whole cohort only)
• Percentage women: 55% (reported for whole cohort only)
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Zhang 2008 (Continued)
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Comparator: Steroids alone
• Number of people (eyes) randomised: NR (110)
• Number (%) of people followed up: 110 eyes (100%)
• Average age in years: NR
• Age range in years: 55-87 (reported for whole cohort only)
• Percentage women: 55% (reported for whole cohort only)
• Ethnic group: NR
• Percentage with diabetes: NR
• Percentage with uveitis: NR
Included criteria: NR
Excluded criteria: NR
Pretreatment: No information on pretreatment differences.
Eyes: 220 eyes of 198 people.
Interventions Intervention: NSAIDs plus steroids
• pranoprofen (brand name not reported)
◦ Times per day: NR
◦ Duration preoperative: days: NR
◦ Duration postoperative: days: 28
• dexamethasone (combined with tobramycin)
◦ Times per day: 4 times a day for 2 weeks 3 times a day for 2 weeks
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Comparator: Steroids alone
• dexamethasone (combined with tobramycin)
◦ Times per day: 4 times a day for 2 weeks 3 times a day for 2 weeks
◦ Duration preoperative: days: 0
◦ Duration postoperative: days: 28
Type of surgery: Phacoemulsification
Outcomes Follow-up: 1 month
• CMO (OCT-verified but not defined)
• Inflammation (Tyndall reaction, categorical)
Contact details Authors name: Zhang HY
Institution: Beijing Tongren Eye Center
Email: NR
Address: Beijing Tongren Eye Centre, Beijing Tongren Hospital, Capital Medical Uni-
versity; Beijing Ophthalmology and Visual Science Key Laboratory, Beijing 100730,
China
Notes Funding source: NR
Declaration of interest: NR
Date study conducted: NR
Trial registration number: NR
Contacting study investigators: Trial authors not contacted.
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Zhang 2008 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: Not reported how list was
generated. Trial described as “randomised” but
with no further details
Allocation concealment (selection bias) Unclear risk Judgement comment:Not reported howallocation
administered. Trial described as “randomised” but
with no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this patients and personnel were not masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: No information on mask-
ing. We assume that in absence of reporting on
this outcome assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Missing data less than 20%
(i.e. more than 80% follow-up) and equal follow-
up in both groups and no obvious reason why loss
to follow-up should be related to outcome
Selective reporting (reporting bias) Unclear risk Judgement comment:No access to protocol or trial
registry entry
AE: adverse events
BCVA: best corrected visual acuity
CMO: cystoid macular oedema
CRT: corneal retinal thickness
DR: diabetic retinopathy
ECCE: extracapsular cataract extraction
IOL: intraocular lens
IOP: intraocular pressure
NR: not reported
NSAID: non-steroidal anti-inflammatory drug
OCT: optical coherence tomography
RCT: randomised controlled trial
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abelson 1989 Not topical treatment.
Carenini 1993 Not RCT.
Chen 2015 Study only performed follow-up for 2 weeks in total.
Dehgan 1992 Not able to source paper.
Duong 2015 Not RCT.
Hendrikse 1982 Not able to source paper.
Hollwich 1983 Not relevant comparator.
ISRCTN02628492 Study was terminated due to lack of funding.
Miyake 2000 Probably not random allocation, unclear response from study author
Nishino 2009 Not relevant intervention.
Riley 2006 Not relevant intervention.
Sanders 1982 Not able to source paper.
Sellares 1992 Not able to source paper.
Sholiton 1979 Not topical treatment.
Tang 2015 Not relevant intervention.
Wolf 2007 Not RCT.
Yamaaki 1984 Not RCT.
Yilmaz 2012 Not RCT.
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
CTRI/2009/091/001078
Methods Parallel group RCT
Participants Country: India
704 people aged 50 to 70 years within 40 kms of Vellore town
Exclusion criteria:
Inabiltity to visualise the macula preoperatively in the eye to be operated. Ocular disease that can affect macular
function. Uncontrolled diabetics defined by RBS/PP Sugars > 200 mg/dl. Diabetic maculopathy with oedema in eye
to be operated. Past history of intraocular surgery in the eye under consideration. History of use of topical steroid
drops or NSAID drops within the past 30 days prior to enrolment. Current use of Oral steroids. Known NSAIDs
allergy
Interventions Intervention: ketorolac tromethamine
Comparator: polyvinyl Alcohol
Outcomes Primary outcome:
• Acute pseudophakic cystoid macular oedema
Notes September 2016: Study investigator confirms that this study is unpublished. We are awaiting a response to request
for unpublished data
NSAID: non-steroidal anti-inflammatory drug
Characteristics of ongoing studies [ordered by study ID]
NCT01694212
Trial name or title Preoperative topic diclofenac as a preventionof postoperativemacular edema inpatientswith diabetic retinopa-
thy
Methods Parallel group RCT
Participants Country: Croatia
120 people aged 60 to 90 years
Inclusion criteria:
• presence of nonproliferative diabetic retinopathy
• presence of the cataract (LOCS 2-3)
Exclusion criteria:
• other chronic or acute eye diseases
• hypersensitivity to any component of the diclofenac eye-drops patients on oral anticoagulant therapy
• allergy to salycilates
Interventions Intervention: diclofenac
Comparator: placebo
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NCT01694212 (Continued)
Outcomes Primary Outcome:
• change of central macular thickness at -7, 0, 1, 7, 30, 90 days after the cataract surgery measured with
OCT
Secondary Outcome:
• progression of diabetic retinopathy -7 and 90 days after cataract surgery assessed on fundus
photography (ETDRS) according to ETDRS criteria
• IL-12 concentration immediately before cataract surgery measured in the sample of humour aqueous
taken at the beginning of cataract surgery
Starting date October 2012
End date: December 2016
Contact information Ljubo Znaor, MD PhD, Clinical Hospital Center, Split
Notes
NCT01774474
Trial name or title PRevention of Macular EDema After Cataract Surgery (PREMED)
Methods Parallel group RCT
Participants Country: Netherlands
1135 people aged 21 years and older
Inclusion criteria:
• all patients undergoing routine phacoemulsification (one eye per patient)
• willing and/or able to comply with the scheduled visits and other study procedures
• able to communicate properly and understand instructions
• accepting possible off-label use of intravitreal bevacizumab and/or subconjunctival preservative-free TA
Exclusion criteria will be different for non-diabetic and diabetic patients. All ophthalmic exclusion criteria
are applicable to the study eye only, unless stated otherwise
General exclusion criteria for participation in this study are:
1. age below 21 years old;
2. participation in another clinical study;
3. post-traumatic cataract;
4. combined surgery;
5. functional monoculus;
6. previous ocular surgery;
7. progressive glaucoma with severe visual field defects, use of anti-glaucomatous medication or steroid-
induced IOP elevation that required IOP-lowering treatment;
8. IOP ≥ 25 mmHg;
9. history of any intraocular inflammation or uveitis;
10. history of pseudoexfoliation syndrome, which is expected to cause preoperative complications;
11. history of Fuchs’ endothelial dystrophy or cornea guttata 3+;
12. history of retinal vein occlusion;
13. any macular pathology that might influence visual acuity, other than diabetic macular oedema;
14. use of intravitreal bevacizumab or ranibizumab in the previous 6 weeks or intravitreal aflibercept in the
previous 10 weeks;
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NCT01774474 (Continued)
15. use of intra- or periocular corticosteroid injection in the previous 4 months;
16. current use of topical NSAIDs or corticosteroids;
17. use of systemic corticosteroids (≥ 20 mg prednisolone or equivalence);
18. history of relevant adverse events, including serious adverse events, occurring after administration of
NSAIDs, acetylsalicylic acid, sodium sulphite, corticosteroids or bevacizumab;
19. contraindications for use of topical NSAIDs, topical or subconjunctival corticosteroids or intravitreal
bevacizumab or related drugs.
Non-diabetic patients with a history of CME will be excluded from participation in the study. Additionally,
diabetic patients will be excluded from participation in case of:
1. macular oedema with a CSMT ≥ 450 µm;
2. very severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy requiring
panretinal photocoagulation or vitrectomy;
3. vitreous haemorrhage present during preoperative visit(s);
4. cerebrovascular accident, myocardial infarction or other thromboembolic events in the previous 3
months;
5. a history of recurrent thromboembolic events;
6. a history of severe systemic bleeding in the previous 3 months;
7. major surgery in the previous 3 months;
8. history of glaucoma.
Interventions Intervention: bromfenac
Intervention: bromfenac and dexamethasone
Comparator: dexamethasone
Outcomes Primary outcome:
• change in central subfield mean macular thickness at 6 weeks postoperatively
Secondary outcomes:
• Clinically significant macular oedema at 12 weeks postoperatively
Other outcome measures at 6 and 12 weeks see clinicaltrials.gov/ct2/show/NCT01774474
Starting date July 2013
End date: October 2016
Contact information Prof. Rudy MM Nuijts, MD, PhD rudy.nuijts@0mumc.nl
Laura HP Wielders, MD laura.wielders@mumc.nl
Notes
NCT02646072
Trial name or title Effect of preoperative topical ketorolac on aqueous cytokine levels and macular thickness in cataract surgery
patients
Methods Parallel group RCT
Participants Country: Malaysia
80 participants aged 18 to 90 years
Inclusion criteria:
Diabetic patient group
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NCT02646072 (Continued)
1. Type 2 diabetes mellitus with no diabetic retinopathy
2. If with comorbid, controlled hypertension with no hypertensive crisis in recent six months
3. Listed for phacoemulsification cataract surgery
Non-diabetic patient group
1. No history of diabetes
2. If with comorbid, controlled hypertension with no hypertensive crisis in recent six months
3. Listed for phacoemulsification cataract surgery
Exclusion criteria
1. Smoker
2. Presence of immune disease, local or systemic inflammation
3. Presence of retinal diseases, glaucoma
4. Previous surgical procedure on the eye
5. Intraoperative complications
Interventions Intervention: ketorolac tromethamine
Comparator: no intervention
Outcomes Primary outcome:
• Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays, 9
months
Secondary outcome:
• Changes from baseline in central subfield retinal thickness as assessed by OCT, 9 months
Starting date August 2014
End date: June 2015
Contact information Yin Peng Lai, Univerisity of Malaya
Notes
CME: cystoid macular oedema (edema)
DR: diabetic retinopathy
ETDRS: early treatment diabetic retinopathy study
IOP: intraocular pressure
NSAID: non-steroidal anti-inflammatory drug
OCT: optical coherence tomography
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. NSAIDs plus steroids versus steroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Poor vision due to MO 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 3 months 5 1360 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.23, 0.76]
1.2 12 months 1 88 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.09, 20.37]
2 Central retinal thickness 9 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Change from baseline 3 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 FInal value 6 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Total macular volume 6 570 Mean Difference (IV, Random, 95% CI) -0.14 [-0.21, -0.07]
4 Macular oedema 21 3638 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.32, 0.49]
5 Inflammation 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Inflammation (flare) 2 216 Mean Difference (IV, Fixed, 95% CI) -1.41 [-2.30, -0.52]
7 BCVA 10 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Final value 7 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Change from baseline 3 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. NSAIDs versus steroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Central retinal thickness 2 121 Mean Difference (IV, Fixed, 95% CI) -22.64 [-38.86, -6.
43]
2 Macular oedema 5 520 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.18, 0.41]
3 Inflammation (flare) 5 Mean Difference (IV, Random, 95% CI) Totals not selected
4 BCVA 3 Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 1 Poor vision due to MO.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 1 Poor vision due to MO
Study or subgroup NSAIDs/steroids Steroids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 3 months
Cervantes-Coste 2009 (1) 0/30 0/30 Not estimable
Chatziralli 2011 (2) 0/70 0/68 Not estimable
Solomon 1995 (3) 36/354 35/160 91.7 % 0.46 [ 0.30, 0.71 ]
Wang 2013 (4) 0/83 7/84 4.4 % 0.07 [ 0.00, 1.16 ]
Wittpenn 2008 (5) 0/230 2/251 3.9 % 0.22 [ 0.01, 4.52 ]
Subtotal (95% CI) 767 593 100.0 % 0.41 [ 0.23, 0.76 ]
Total events: 36 (NSAIDs/steroids), 44 (Steroids)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 12 months
Yannuzzi 1981 (6) 1/38 1/50 100.0 % 1.32 [ 0.09, 20.37 ]
Subtotal (95% CI) 38 50 100.0 % 1.32 [ 0.09, 20.37 ]
Total events: 1 (NSAIDs/steroids), 1 (Steroids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
Favours NSAIDs/steroids Favours steroids
(1) Follow-up: 6 weeks, ”clinically significant macular oedema associated with vision loss” (cutpoint not defined)
(2) Follow-up: 6 weeks, fundoscopy and Amsler grid test ”no evidence of clinically significant CME”
(3) Follow-up: days 21-60, CMO on fluoresecein angiography with visual acuity <=20/40
(4) Follow-up: 2 months, OCT-confirmed CMO with ”visual impairment” (not specified cutpoint)
(5) Follow-up: 4 weeks, OCT-confirmed CMO with visual acuity <6/9.
(6) Follow-up: 1 year, CMO on fluorescein angiography with visual acuity <6/60
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Analysis 1.2. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 2 Central retinal thickness.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 2 Central retinal thickness
Study or subgroup NSAIDs/steroids Steroids
Mean
Difference
Mean
Difference
N Mean(SD)[microns] N Mean(SD)[microns] IV,Random,95% CI IV,Random,95% CI
1 Change from baseline
Jung 2015 (1) 60 4.604 (5.2396) 31 12.47 (12.24) -7.87 [ -12.37, -3.36 ]
Mathys 2010 (2) 39 5.6 (13.8) 40 2.78 (12.9) 2.82 [ -3.07, 8.71 ]
Singh 2012 (3) 125 18.9 (19.5) 126 40.8 (49) -21.90 [ -31.11, -12.69 ]
2 FInal value
Cervantes-Coste 2009 (4) 30 194.43 (20.26) 30 203.86 (17.98) -9.43 [ -19.12, 0.26 ]
Li 2011 (5) 104 242.79 (20.75) 113 265.43 (29.3) -22.64 [ -29.35, -15.93 ]
Moschos 2012 (6) 38 152.3 (20.8) 41 152 (16.3) 0.30 [ -7.98, 8.58 ]
Ticly 2014 (7) 37 282.08 (36.65) 44 279.05 (29.11) 3.03 [ -11.58, 17.64 ]
Tzelikis 2015 (8) 45 282.26 (45.21) 40 274.82 (30.45) 7.44 [ -8.79, 23.67 ]
Wang 2013 (9) 85 209.51 (29.014) 84 240.41 (49.274) -30.90 [ -43.11, -18.69 ]
-100 -50 0 50 100
Favours NSAIDs/steroids Favours steroids
(1) Follow-up: 1 month
(2) Follow-up: 2 months
(3) Follow-up: 90 days, ”mean maximum change” from baseline
(4) Follow-up: 6 weeks
(5) Follow-up: 1 month
(6) Follow-up: 1 month
(7) Follow-up: 5 weeks
(8) Follow-up: 1 month
(9) Follow-up: 2 months
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Analysis 1.3. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 3 Total macular volume.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 3 Total macular volume
Study or subgroup NSAIDs/steroids Steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mm3] N Mean(SD)[mm3] IV,Random,95% CI IV,Random,95% CI
Almeida 2008 (1) 38 0.2392 (0.338) 42 0.44 (0.338) 14.8 % -0.20 [ -0.35, -0.05 ]
Almeida 2012 (2) 54 0.43 (1.16) 54 0.76 (1.27) 2.4 % -0.33 [ -0.79, 0.13 ]
Cervantes-Coste 2009 (3) 30 0.038 (0.242) 30 0.28 (0.243) 18.3 % -0.24 [ -0.36, -0.12 ]
Jung 2015 60 0.1673 (0.1574) 31 0.26 (0.19) 26.3 % -0.09 [ -0.17, -0.01 ]
Mathys 2010 (4) 39 0.1 (0.21) 40 0.05 (0.51) 12.3 % 0.05 [ -0.12, 0.22 ]
Zaczek 2014 (5) 75 0.179 (0.222) 77 0.33 (0.276) 26.0 % -0.15 [ -0.23, -0.07 ]
Total (95% CI) 296 274 100.0 % -0.14 [ -0.21, -0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.01, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours NSAIDs/steroids Favours steroids
(1) Follow-up: 1 month, change from baseline
(2) Follow-up: 1 month, change from baseline
(3) Follow-up: 6 weeks, change from baseline
(4) Follow-up: 2 months, change from baseline
(5) Follow-up: 6 weeks, change from baseline
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Analysis 1.4. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 4 Macular oedema.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 4 Macular oedema
Study or subgroup NSAIDs/steroids Steroids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Almeida 2008 (1) 0/53 1/53 0.5 % 0.33 [ 0.01, 8.00 ]
Chatziralli 2011 (2) 0/70 0/68 Not estimable
Donnenfeld 2006 (3) 0/25 3/25 0.5 % 0.14 [ 0.01, 2.63 ]
Elsawy 2013 (4) 2/43 8/43 2.1 % 0.25 [ 0.06, 1.11 ]
Kraff 1982 (5) 19/198 20/108 13.6 % 0.52 [ 0.29, 0.93 ]
Li 2011 (6) 6/104 12/113 5.2 % 0.54 [ 0.21, 1.40 ]
Miyanaga 2009 (7) 0/24 1/23 0.5 % 0.32 [ 0.01, 7.48 ]
Moschos 2012 (8) 0/38 0/41 Not estimable
Quentin 1989 (9) 0/57 0/55 Not estimable
Rossetti 1996 (10) 1/42 7/46 1.1 % 0.16 [ 0.02, 1.22 ]
Singh 2012 (11) 4/125 21/126 4.3 % 0.19 [ 0.07, 0.54 ]
Solomon 1995 (12) 54/370 55/171 42.6 % 0.45 [ 0.33, 0.63 ]
Ticly 2014 (13) 2/37 2/44 1.3 % 1.19 [ 0.18, 8.04 ]
Tunc 1999 (14) 2/50 3/25 1.6 % 0.33 [ 0.06, 1.87 ]
Umer-Bloch 1983 (15) 2/29 10/32 2.2 % 0.22 [ 0.05, 0.92 ]
Wang 2013 (16) 0/83 7/84 0.6 % 0.07 [ 0.00, 1.16 ]
Wittpenn 2008 (17) 0/268 5/278 0.6 % 0.09 [ 0.01, 1.70 ]
Yannuzzi 1981 (18) 11/59 28/77 12.4 % 0.51 [ 0.28, 0.94 ]
Yavas 2007 (19) 9/121 19/58 8.7 % 0.23 [ 0.11, 0.47 ]
Zaczek 2014 (20) 0/75 2/77 0.5 % 0.21 [ 0.01, 4.21 ]
Zhang 2008 (21) 2/110 9/110 2.0 % 0.22 [ 0.05, 1.01 ]
Total (95% CI) 1981 1657 100.0 % 0.40 [ 0.32, 0.49 ]
Total events: 114 (NSAIDs/steroids), 213 (Steroids)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.97, df = 17 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 8.44 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NSAIDs/steroids Favours steroids
retinal specialist.”
as angiographic CME.”
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(1) Follow-up: 1 month. OCT used but CMO not defined.
(2) Follow-up: day 42. ”Clinically significant MO” via fundoscopy and Amsler grid test.
(3) Follow-up: 2 weeks. ”Clinically significant CME”
(4) Follow-up: 12 weeks. clinical examination, unclear if OCT-verified
(5) Follow-up: mean 4.1 (range 2.5 to 12 months), fluorescein angiography using Miyake 1977 classification
(6) Follow-up: 1 month. OCT , ”clinically apparent” CME otherwise not defined
(7) Follow-up: 2 months, ”obvious CMO confirmed by OCT”
(8) Follow-up: 1 month, ”clinically significant CME” unclear if OCT-verified
(9) Follow-up: 180 days, fluorescein angiography using Miyake 1977 classification
(10) Follow-up: 6 months, fluorescein angiography using Miyake 1977 classification
(11) Follow-up: 90 days, >=30% increase in central subfield macular thickness from baseline
(12) Follow-up: days 21-60: ”angiographic CME”
(13) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
(14) Follow-up: 2 months. ”clinically significant” FFA plus drop in 1 line Snellen acuity since 2 weeks postop
(15) Follow-up: 12 weeks, fluorescein angiography using Miyake 1977 classification
(16) Follow-up: 2 months, ”CME was defined as central retinal thickness >250 m and the presence of intraretinal cystoid spacebeneath the foveal, with the diagnosis
confirmed by the same
(17) Follow-up: 4 weeks. clinical and OCT-based
(18) Follow-up: 10 weeks, fluorescein angiography, CMO not defined
(19) Follow-up: 3 months, ”Slight fluorescein leakage into the cystic space without enclosing the entire centralfovea or complete fluorescein accumulation in the cysticspace
was diagnosed
(20) Follow-up: 6 weeks, OCT verified but not defined
(21) Follow-up: 1 month, OCT verified but not defined
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Analysis 1.5. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 5 Inflammation.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 5 Inflammation
Study or subgroup NSAIDs/steroids Steroids Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cervantes-Coste 2009 (1) 0/30 0/30 Not estimable
Chatziralli 2011 (2) 2/70 0/68 4.86 [ 0.24, 99.39 ]
Zhang 2008 (3) 0/110 21/110 0.02 [ 0.00, 0.38 ]
0.01 0.1 1 10 100
Favours NSAIDs/steroids Favours steroids
(1) Follow-up: 6 weeks, ”inflammatory cells greater than 1+ during first week of postoperative visits.
(2) Follow-up: day 28, corneal oedema or Tyndall reaction or conjunctival hyperemia, by day 35 had disappeared.
(3) Follow-up: 1 month, Tyn granule +
Analysis 1.6. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 6 Inflammation (flare).
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 6 Inflammation (flare)
Study or subgroup NSAIDs/steroids Steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD)[photons/ms]N Mean(SD)[photons/ms] IV,Fixed,95% CI IV,Fixed,95% CI
Miyanaga 2009 (1) 24 5.2 (2.2) 23 8.5 (6.5) 10.1 % -3.30 [ -6.10, -0.50 ]
Wang 2013 (2) 85 6.6226 (2.5515) 84 7.82 (3.5854) 89.9 % -1.20 [ -2.14, -0.26 ]
Total (95% CI) 109 107 100.0 % -1.41 [ -2.30, -0.52 ]
Heterogeneity: Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 3.10 (P = 0.0019)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours NSAIDs/steroids Favours steroids
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(1) Follow-up: 2 months
(2) Follow-up: 2 months
Analysis 1.7. Comparison 1 NSAIDs plus steroids versus steroids, Outcome 7 BCVA.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 1 NSAIDs plus steroids versus steroids
Outcome: 7 BCVA
Study or subgroup NSAIDs/steroids Steroids
Mean
Difference
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Random,95% CI IV,Random,95% CI
1 Final value
Chatziralli 2011 (1) 70 0.03 (0.05) 68 0.03 (0.06) 0.0 [ -0.02, 0.02 ]
Miyanaga 2009 (2) 24 0.01 (1.3) 23 0.08 (0.08) -0.07 [ -0.59, 0.46 ]
Moschos 2012 (3) 38 0 (0.01) 41 0 (0.01) 0.0 [ 0.00, 0.00 ]
Tzelikis 2015 (4) 86 0.0505 (0.1107) 40 0.01 (0.05) 0.04 [ 0.01, 0.07 ]
Wang 2013 (5) 85 0.045 (0.061) 84 0.09 (0.1059) -0.04 [ -0.07, -0.02 ]
Yavas 2007 (6) 121 0.0547 (0.1209) 58 0.11 (0.12) -0.06 [ -0.09, -0.02 ]
Zaczek 2014 (7) 75 -0.06 (0.091) 77 -0.05 (0.091) -0.01 [ -0.04, 0.02 ]
2 Change from baseline
Almeida 2012 (8) 54 -0.22 (0.23) 54 -0.22 (0.23) 0.0 [ -0.09, 0.09 ]
Mathys 2010 (9) 39 -0.3 (0.13) 40 -0.32 (0.13) 0.02 [ -0.04, 0.08 ]
Ticly 2014 (10) 37 -0.52 (0.32) 44 -0.64 (0.3) 0.12 [ -0.02, 0.26 ]
-1 -0.5 0 0.5 1
Favours NSAIDs/steroids Favours steroids
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(1) Follow-up: 6 weeks, final value
(2) Follow-up: 2 months, final value
(3) Follow-up: 1 month, final value
(4) Follow-up: 30 days, final value
(5) Follow-up: 2 months, final value
(6) Follow-up: 3 months, final value
(7) Follow-up: 6 weeks. final value, SD estimated from p-value
(8) Follow-up: 1 month
(9) Follow-up: 2 months, SD estimated from p-value
(10) Follow-up: 5 weeks
Analysis 2.1. Comparison 2 NSAIDs versus steroids, Outcome 1 Central retinal thickness.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 2 NSAIDs versus steroids
Outcome: 1 Central retinal thickness
Study or subgroup NSAIDs Steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD)[microns] N Mean(SD)[microns] IV,Fixed,95% CI IV,Fixed,95% CI
Endo 2010 (1) 31 216.9 (19.8) 31 236.1 (63.6) 47.8 % -19.20 [ -42.65, 4.25 ]
Miyake 2011 (2) 30 194.3 (20.7) 29 220.1 (58.2) 52.2 % -25.80 [ -48.24, -3.36 ]
Total (95% CI) 61 60 100.0 % -22.64 [ -38.86, -6.43 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours NSAIDs Favours steroids
(1) Follow-up: 6 weeks, final value
(2) Follow-up: 5 weeks
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Analysis 2.2. Comparison 2 NSAIDs versus steroids, Outcome 2 Macular oedema.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 2 NSAIDs versus steroids
Outcome: 2 Macular oedema
Study or subgroup NSAIDs Steroids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Asano 2008 (1) 13/69 40/69 60.7 % 0.33 [ 0.19, 0.55 ]
Italian Diclofenac Study Group 1997 (2) 4/121 10/108 13.3 % 0.36 [ 0.12, 1.11 ]
Miyake 2007 (3) 1/25 12/25 4.4 % 0.08 [ 0.01, 0.59 ]
Miyake 2011 (4) 4/28 22/27 19.9 % 0.18 [ 0.07, 0.44 ]
Miyanaga 2009 0/25 1/23 1.7 % 0.31 [ 0.01, 7.20 ]
Total (95% CI) 268 252 100.0 % 0.27 [ 0.18, 0.41 ]
Total events: 22 (NSAIDs), 85 (Steroids)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.02, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 6.16 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NSAIDs Favours steroids
(1) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
(2) Follow-up: 140 days, fluorescein angiography using Miyake 1977 classification
(3) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
(4) Follow-up: 5 weeks, fluorescein angiography using Miyake 1977 classification
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Analysis 2.3. Comparison 2 NSAIDs versus steroids, Outcome 3 Inflammation (flare).
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 2 NSAIDs versus steroids
Outcome: 3 Inflammation (flare)
Study or subgroup NSAIDs Steroids
Mean
Difference
Mean
Difference
N Mean(SD)[photon/ms] N Mean(SD)[photon/ms] IV,Random,95% CI IV,Random,95% CI
Asano 2008 (1) 65 8.45 (5.99) 62 7.98 (3.78) 0.47 [ -1.26, 2.20 ]
Endo 2010 (2) 31 3.9 (3.75) 31 6.3 (4) -2.40 [ -4.33, -0.47 ]
Miyake 2007 (3) 25 8.1 (3.8) 25 9 (3) -0.90 [ -2.80, 1.00 ]
Miyake 2011 (4) 30 12 (5.5) 29 19.3 (10.7) -7.30 [ -11.66, -2.94 ]
Miyanaga 2009 25 7.6 (2.8) 23 8.5 (6.5) -0.90 [ -3.77, 1.97 ]
-4 -2 0 2 4
Favours NSAIDs Favours steroids
(1) Follow-up: 8 weeks
(2) Follow-up: 5 weeks
(3) Follow-up: 8 weeks
(4) Follow-up: 5 weeks
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Analysis 2.4. Comparison 2 NSAIDs versus steroids, Outcome 4 BCVA.
Review: Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery
Comparison: 2 NSAIDs versus steroids
Outcome: 4 BCVA
Study or subgroup NSAIDs Steroids
Mean
Difference
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Random,95% CI IV,Random,95% CI
Asano 2008 (1) 58 -0.071 (0.08) 52 -0.07 (0.078) 0.00 [ -0.03, 0.02 ]
Endo 2010 (2) 31 -0.09 (0.056) 31 -0.04 (0.085) -0.05 [ -0.09, -0.01 ]
Miyanaga 2009 (3) 25 0.115 (0.03) 23 0.08 (0.08) 0.04 [ 0.01, 0.07 ]
-100 -50 0 50 100
Favours NSAIDs Favours steroids
(1) Follow-up: 8 weeks, final value
(2) Follow-up: 6 weeks
(3) Follow-up: 2 months
A D D I T I O N A L T A B L E S
Table 1. ’Risk of bias’ assessment
Domain Risk of bias
Low Unclear High
Sequence generation Computer-generated list, ran-
dom table, other method of
generating random list
Not reported how list was gen-
erated.Trialmay be described as
“randomised” but with no fur-
ther details
Alternate allocation, date of
birth, records (these RCTs
should be excluded)
Allocation concealment Central centre (web/telephone
access), sealed opaque
envelopes
Not reported how allocation
administered. Trial may be de-
scribed as “randomised” but
with no further details
Investigator involved in treat-
ment allocation or treatment al-
location clearly not masked
Blinding of participants and
personnel
Clearly stated that participants
and personnel not aware of
which treatment received
Described as “double-blind”
with no information on who
was masked
Open-label or no information
on masking. We assume that
in absence of reporting on this
outcome, patients and person-
nel were not masked
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Table 1. ’Risk of bias’ assessment (Continued)
Blinding of outcome assessors Clearly stated that outcome as-
sessors were masked.
Described as “double-blind”
with no information on who
was masked
Open-label or no information
on masking. We assume that
in absence of reporting on this
outcome, assessors were not
masked
Incomplete outcome data Missing data less than 20% (i.e.
more than 80% follow-up) and
equal follow-up in both groups
and no obvious reason why loss
to follow-up should be related
to outcome
Follow-up not reported ormiss-
ing data > 20% (i.e. follow-up
< 80%) but follow-up equal in
both groups
Follow-up different in each
group and/or related to out-
come.
Selective outcome reporting All outcomes in protocol and/or
trial registry entry are reported
No access to protocol or trial
registry entry.
Outcomes in protocol and/or
trial registry entry selectively re-
ported
Other sources of bias
Note: we did not identify any
important sources of other bias
so this domain is omitted from
the risk of bias tables
No other source of bias. Trial stopped early due to poor
recruitment.
Baseline imbalance, but not
clear that it is important.
Trial stopped early because of
outcome.
Important baseline imbalance
that might have an effect on the
results
Table 2. Studies
Study Country Open-label Funding
sources
Declaration of
interest
Trial
registration
Abstract only
1 Almeida 2008 Canada Yes Non-industry Reported; no
CoI
NCT00335439 No
2 Almeida 2012 Canada No Non-industry Reported; no
CoI
NCT01395069 No
3 Asano 2008 Japan No Not reported Reported; no
CoI
Not registered No
4 Brown 1996 USA No Industry Not reported Not registered No
5 Cervantes-
Coste 2009
Mexico No Not reported Reported; no
CoI
Not registered No
6 Chatziralli
2011
Greece No Not reported Not reported Not registered No
7 Donnenfeld
2006
USA No Industry/Non-
Industry
CoI Not registered No
127Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Studies (Continued)
8 Elsawy 2013 Egypt No Not reported Reported; no
CoI
Not registered No
9 Endo 2010 Japan Yes Not reported Reported; no
CoI
Not registered No
10 Italian
Diclofenac
Study Group
1997
Italy No Not reported CoI Not registered No
11 Jung 2015 South Korea No Non-industry Reported; no
CoI
Not registered No
12 Kraff 1982 USA No Non-industry Not reported Not registered No
13 Li 2011 China No Not reported Not reported Not registered No
14 Mathys 2010 USA No Non-industry Reported; no
CoI
NCT00494494 No
15 Miyake 2007 Japan No Not reported Reported; no
CoI
Not registered No
16 Miyake 2011 Japan No Not reported CoI Not registered No
17 Miyanaga 2009 Japan No Not reported Not reported Not registered No
18 Moschos 2012 Greece No Not reported Reported; no
CoI
Not registered No
19 Quentin 1989 Germany No Not reported Not reported Not registered No
20 Rossetti 1996 Italy No Not reported Reported; no
CoI
Not registered No
21 Singh 2012 USA No Not reported CoI NCT00782717 No
22 Solomon 1995 Canada (8 sites)
andGermany (2
sites)
No Industry Reported; no
CoI
Not registered No
23 Tauber 2006 USA No Industry CoI Not registered Yes
24 Ticly 2014 Brazil No Not reported Reported; no
CoI
Not registered No
25 Tunc 1999 Turkey No Not reported Not reported Not registered No
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Table 2. Studies (Continued)
26 Tzelikis 2015 Brazil No Not reported Reported; no
CoI
NCT02084576 No
27 Umer-Bloch
1983
Switzerland No Not reported Not reported Not registered No
28 Wang 2013 China Yes Non-industry Not reported Not registered No
29 Wittpenn 2008 USA No Industry CoI NCT00348244 No
30 Yannuzzi 1981 USA No Non-industry Not reported Not registered No
31 Yavas 2007 Turkey No Not reported Reported; no
CoI
Not registered No
32 Yung 2007 USA No Not reported Not reported Not registered No
33 Zaczek 2014 Sweden No Industry/Non-
industry
Reported; no
CoI
Not registered No
34 Zhang 2008 China No Not reported Not reported Not registered No
CoI: conflict of interest
Table 3. Participant numbers
Study Number of
people ran-
domised
Number of
people ran-
domised
(missing
data
imputed)*
Number of
eyes
Number
of eyes esti-
mated
(missing
data
imputed)*
Number of
people fol-
lowed up
Number of
people fol-
lowed up
(missing
data
imputed)*
Percentage
follow-up
Eyes
per person
enrolled in
the trial
1 Almeida
2008
98 98 106 106 - 74 75% 106 eyes of
98 people
2 Almeida
2012
193 193 - 193 162 162 84% Probably
one
3 Asano 2008 150 150 150 150 142 142 95% One eye
4 Brown
1996
- - - - - - Probably
one
5 Cervantes-
Coste 2009
60 60 60 60 60 60 100% One eye
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Table 3. Participant numbers (Continued)
6 Chatziralli
2011
145 145 145 145 138 138 95% Probably
one
7 Donnen-
feld
2006
100 100 - 100 - 100 - Unclear
8 Elsawy
2013
70 70 86 86 - 86 - 86 eyes of
70 patients
9 Endo 2010 75 75 75 75 62 62 83% One eye
10 Italian
Diclofenac
Study
Group
1997
281 281 281 281 229 229 81% One eye
11 Jung 2015 91 91 91 91 Not
reported
91 Not
reported
One eye
12 Kraff 1982 500 500 - 500 492 492 98% Unclear
13 Li 2011 217 217 217 217 - 217 - One eye
14 Mathys
2010
84 84 84 84 79 79 94% One eye
15 Miyake
2007
62 62 62 62 50 50 81% Probably
one
16 Miyake
2011
60 60 60 60 55 55 92% One eye
17 Miyanaga
2009
72 72 72 72 - 72 - One eye
18 Moschos
2012
79 79 79 79 - 79 - One eye
19 Quentin
1989
179 179 179 179 112 112 63% One eye
20 Rossetti
1996
88 88 88 88 - 88 - Probably
one
21 Singh 2012 263 263 263 263 251 251 95% One eye
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Table 3. Participant numbers (Continued)
22 Solomon
1995
681 681 681 681 364 364 53% Probably
one
23 Tauber
2006
- 32 - 32 32 32 - Unclear
24 Ticly 2014 91 91 91 91 81 81 89% Probably
one
25 Tunc 1999 75 75 75 75 75 75 - One eye
26 Tzelikis
2015
142 142 142 142 126 126 89% One eye
27 Umer-
Bloch 1983
- 73 - 73 73 73 - Unclear
28 Wang 2013 240 240 - 240 167 167 70% Unclear
29 Wittpenn
2008
546 546 546 546 478 478 88% One eye
30 Yannuzzi
1981
- 201 231 231 - 231 59% 231 eyes of
210 people
31 Yavas 2007 189 189 189 189 179 179 95% One eye;
right eye
only
32 Yung 2007 37 37 - 37 - 37 - Unclear
33 Zaczek
2014
160 160 160 160 152 152 95% One eye
34 Zhang
2008
- 198 220 220 - 220 100% 220 eyes of
198 people
*For studies that did not report the number randomised, we have estimated this from the number followed up. For studies that did not
report the number followed up, we have estimated this from the numbers randomised. Number of eyes estimated assuming one eye
per person, if not clearly stated otherwise.
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Table 4. Participant characteristics
Study Average age Age range % female % with diabetes % with uveitis
1 Almeida 2008 72 45 to 92 61% 21% 1%
2 Almeida 2012 72 50 to 88 54% - but low risk population “low risk population”
3 Asano 2008 66 - 56% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
4 Brown 1996 - - - - but people with DR excluded 0% people with uveitis ex-
cluded
5 Cervantes-Coste
2009
72 51 to 88 64% 20% 0% people with uveitis ex-
cluded
6 Chatziralli 2011 74 - 40% 10% 0% people with uveitis ex-
cluded
7 Donnenfeld 2006 73 - 55% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
8 Elsawy 2013 - - 37% 100% -
9 Endo 2010 69 37 to 84 45% 100% 0% people with uveitis ex-
cluded
10 Italian Diclofenac
Study Group 1997
68 - 52% - -
11 Jung 2015 67 - 55% 26% -
12 Kraff 1982 69 37 to 97 57% - -
13 Li 2011 72 - 63% 100% -
14 Mathys 2010 72 44 to 90 54% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
15 Miyake 2007 66 - 54% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
16 Miyake 2011 65 48 to 82 46% 9% 0% people with uveitis ex-
cluded
17 Miyanaga 2009 72 41 to 86 71% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
18 Moschos 2012 77 - 66% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
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Table 4. Participant characteristics (Continued)
19 Quentin 1989 73 - 55% - but people with DR excluded 0% people with uveitis ex-
cluded
20 Rossetti 1996 74 - 64% 0% people with diabetes ex-
cluded
-
21 Singh 2012 67 32 to 87 63% 100% 0% people with uveitis ex-
cluded
22 Solomon 1995 68 39 to 100 53% - 0% people with uveitis ex-
cluded
23 Tauber 2006 - - - - -
24 Ticly 2014 67 - 47% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
25 Tunc 1999 61 - 39% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
26 Tzelikis 2015 - - - - -
27 Umer-Bloch 1983 69 - 52% - but people with DR excluded 0% people with uveitis ex-
cluded
28 Wang 2013 73 46 to 92 54% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
29 Wittpenn 2008 70 - 53% - -
30 Yannuzzi 1981 - - - - -
31 Yavas 2007 65 - 40% 0% people with diabetes ex-
cluded
0% people with uveitis ex-
cluded
32 Yung 2007 - - - 100% -
33 Zaczek 2014 69 - 65% - -
34 Zhang 2008 - - - - -
DR: diabetic retinopathy
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Table 5. Interventions
Study Type of
cataract
surgery
Comparison NSAIDs Steroid Placebo
in comparator
group
Type of
placebo
1 Almeida 2008 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.5% Prednisolone
1%
No -
2 Almeida 2012 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.
5%, Nepafenac
0.1%
Prednisolone
1%
Yes Sterile saline
drops
3 Asano 2008 Phacoemulsifi-
cation
NSAIDs versus
steroids
Diclofenac 0.
1%
Betamethasone
0.1%
No -
4 Brown 1996 Phacoemulsifi-
cation
NSAIDs versus
steroids
Diclofenac 0.
1%
Prednisolone
1%
No -
5 Cervantes-
Coste 2009
Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Nepafenac 0.
1%
Dexamethasone
(combined with
tobramycin)
No -
6 Chatziralli
2011
Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.5% Dexam-
ethasone 0.1%
(combined with
tobramycin 0.
3%)
No -
7 Donnenfeld
2006
Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.4% Prednisolone
1%
Yes Vehicle
8 Elsawy 2013 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.4% Dexamethasone
0.1%,
No -
9 Endo 2010 Phacoemulsifi-
cation
NSAIDs versus
steroids
Bromfenac Betametha-
sone (with fra-
diomycin
sulfate)
followed by flu-
orometholone
No -
10 Italian
Diclofenac
Study Group
1997
ECCE NSAIDs versus
steroids
Diclofenac 0.
1%
Dexamethasone
0.1%
Yes Not specified
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Table 5. Interventions (Continued)
11 Jung 2015 Phacoemulsifi-
cation
NSAIDs versus
steroids
Bromfenac 0.
1%,
Ketorolac 0.4%
Prednisolone
acetate 1%
No -
12 Kraff 1982 ECCE and pha-
coemulsifica-
tion
NSAIDs plus
steroids versus
steroids
Indomethacin Dexametha-
sone (in combi-
nation with
neomycin sul-
fate, polymyxin
B sulfate) for
4 days followed
by dexam-
ethasone alone
for 4 weeks fol-
lowed by fluo-
rometholone
for at least 6
months
Yes Vehicle
13 Li 2011 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Diclofenac 1% Dexamethasone
(combined with
tobramycin)
No -
14 Mathys 2010 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Nepafenac 0.
1%
Prednisolone
1%
No -
15 Miyake 2007 Phacoemulsifi-
cation
NSAIDs versus
steroids
Diclofenac 0.
1%
Fluo-
rometholone 0.
1%
No -
16 Miyake 2011 Phacoemulsifi-
cation
NSAIDs versus
steroids
Nepafenac 0.
1%
Fluo-
rometholone 0.
1%
No -
17 Miyanaga 2009 Phacoemulsifi-
cation
NSAIDs plus
steroids
versus steroids/
NSAIDs versus
steroids
Bromfenac 0.
1%
Betametha-
sone 0.1%, flu-
orometholone
No -
18 Moschos 2012 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Diclofenac 0.
1%
Dexamethasone
0.1% (com-
binedwith chlo-
ramphenicol 0.
5%)
No -
19 Quentin 1989 ICCE NSAIDs plus
steroids versus
Diclofenac 0.
1%
Dexamethasone Yes Not specified
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Table 5. Interventions (Continued)
steroids
20 Rossetti 1996 ECCE NSAIDs plus
steroids versus
steroids
Diclofenac Dexamethasone
(combined with
tobramycin)
Yes Not specified
21 Singh 2012 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Nepafenac 1% Prednisolone Yes Vehicle
22 Solomon 1995 ECCE NSAIDs plus
steroids versus
steroids
Flurbiprofen 0.
03%
Indomethacin
1%
Prednisolone Yes Vehicle
23 Tauber 2006 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.4% Prednisolone
1%
No -
24 Ticly 2014 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.4% Prednisolone
1%
Yes Dextran 70/
hypromellose
25 Tunc 1999 ECCE NSAIDs plus
steroids versus
steroids
Diclofenac 0.
1%
Dexamethasone
1%
No -
26 Tzelikis 2015 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.
4%, Nepafenac
0.1%
Prednisolone
1%
Yes Artificial tears
27 Umer-Bloch
1983
ECCE/ICCE NSAIDs plus
steroids versus
steroids
Indomethacin
1%
Dexamethasone
(combined with
either chloram-
phenicol or
neomycin)
Yes Vehicle
28 Wang 2013 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Bromfenac 0.
1%
fluo-
rometholone 0.
1% and dexam-
ethasone 0.1%
No -
29 Wittpenn 2008 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.4% Prednisolone
1%
Yes Artificial tears
30 Yannuzzi 1981 ICCE NSAIDs plus
steroids versus
steroids
Indomethacin
1%
Steroids given as
part of standard
care, not
specified exactly
Yes Vehicle
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Table 5. Interventions (Continued)
what
31 Yavas 2007 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Indomethacin
0.1%
Prednisolone
1%
No -
32 Yung 2007 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Ketorolac 0.5% Prednisolone
1%
Yes Artificial tears
33 Zaczek 2014 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Nepafenac 0.
1%
Dexamethasone
0.1%
Yes Artifical tears
34 Zhang 2008 Phacoemulsifi-
cation
NSAIDs plus
steroids versus
steroids
Pranoprofen Dexamethasone
(combined with
tobramycin)
No -
ECCE: extracapsular cataract extraction
ICCE: intracapsular cataract extraction
NSAIDs: non-steroidal anti-inflammatory drugs
Table 6. Outcomes
Poor vi-
sion out-
come due
to MO
Quality of
life/pa-
tient satis-
faction
Cen-
tral retinal
thickness
Adverse
effects re-
ported
CMO Inflam-
mation
BCVA Addi-
tional out-
comes
Study Follow-up Analysis
1.1
No analy-
sis; only
one study
reported
this
Analysis
1.2;
Analysis
2.1
Table 7 Analysis
1.4;
Analysis
2.2
Analysis
1.5;
Analysis
1.6;
Analysis
2.3
Analysis
1.7;
Analysis
2.4
Analysis
1.3
Almeida
2008
1 month Yes OCT used
but CMO
not
defined
Change in
to-
tal macular
volume
Almeida
2012
1 month COM-
TOL ques-
tionnaire
Mean
change re-
ported but
not possi-
ble to cal-
culate SD
LogMAR Change in
total mac-
u-
lar volume;
change
in average
macular
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Table 6. Outcomes (Continued)
cube thick-
ness
Asano
2008
8 weeks Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
(at 5 weeks
only)
Laser flare-
cell pho-
tometry,
mean value
of anterior
chamber
flare (pho-
tons/mil-
lisecond)
LogMAR,
final value
Brown
1996
1 month Laser flare-
cell pho-
tometry,
mean value
of ante-
rior cham-
ber flare re-
ported
(photons)
but was
not possi-
ble to cal-
culate SD
Cervantes-
Coste
2009
6 weeks Quote:
”None
of the pa-
tients de-
vel-
oped clin-
ically sig-
nifi-
cant macu-
lar oedema
associated
with vision
loss“
Final value Yes Only
reported
CMO as-
sociated
with vision
loss
”Inflam-
matory
cells
greater
than
1+ during
first week
of postop-
erative vis-
its“
To-
tal macular
volume
Chatziralli
2011
6 weeks Fun-
doscopy
and
Amsler
grid test
Quote:
”no
evidence of
Yes ”No
evidence of
clinically
significant
CME was
detected in
any patient
via fun-
Corneal
oedema or
Tyndall
reaction or
conjuncti-
val hyper-
aemia
LogMAR,
final value
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Table 6. Outcomes (Continued)
clinically
significant
CME“
doscopy
and
the Amsler
grid test“
Donnen-
feld
2006
3 months Yes ”Clinically
significant
CME“ but
otherwise
not de-
fined, at 2
weeks only
”Mean in-
flamma-
tion score“
but was
not possi-
ble to cal-
culate SD
LogMAR,
final value
but could
not extract
data on SD
Elsawy
2013
12 weeks Clin-
ical exami-
nation, un-
clear if
OCT-
verified
Endo 2010 6 weeks Final value Yes Anterior
chamber
flare val-
ues, pho-
ton count
per mil-
lisecond
LogMAR,
final value
Italian
Diclofenac
Study
Group
1997
140 days Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Jung 2015 1 month Change Yes ”Inflam-
ma-
tory score“
(sumof an-
terior
chamber
cells and
flare grade”
Change
in macular
volume
Kraff 1982 Between 2.
5 and 12
months
Yes Fluo-
rescein an-
giog-
raphy us-
Snellen
acuity
only, not
included
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Table 6. Outcomes (Continued)
ingMiyake
1977 clas-
sification
in analyses
Li 2011 1 month Final value OCT,
“clinically
apparent”
CME oth-
erwise not
defined
Snellen
acuity
only, not
included
in analyses
Mathys
2010
2 months Change
from base-
line
Yes LogMAR Change in
foveal
thickness,
change
in macular
volume
Miyake
2007
5 weeks Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Unit of
measure-
ment un-
clear
Snellen
acuity
only, not
included
in analyses
Miyake
2011
5 weeks Final value Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Flare (pho-
tons/mil-
lisec), final
value
Change in
logMAR
BCVA,
categor-
ical 3+, 2,
1 lines in-
crease and
no change
Miyanaga
2009
2 months Yes “Obvi-
ous CMO
confirmed
by OCT”
Aqueous
flare (pho-
tons/mil-
lisecond)
LogMAR,
final value
Moschos
2012
1 month Final value LogMAR,
final value
Quentin
1989
180 days Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Snellen
acuity
only, not
included
in analyses
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Table 6. Outcomes (Continued)
Rossetti
1996
6 months Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Snellen
acuity
only, not
included
in analyses
Singh
2012
90 days Change
from base-
line
Yes “>= 30%
increase in
central
sub-
field mac-
ular thick-
ness from
baseline”
Flare men-
tioned but
data not re-
ported
Corrected
BCVA loss
of more
than 5 let-
ters
from day 7
postop
Solomon
1995
6 months Days 21 to
60, MO =
positive
angiogra-
phy and vi-
sual acuity
<= 20/40
Yes Fluo-
rescein an-
giog-
raphy us-
ing classifi-
cation***
Snellen
acuity
but not re-
ported by
treatment
group
Tauber
2006
30 days (3
months
mentioned
but not re-
ported)
Re-
ported but
no mean/
SD
Propor-
tion with >
10%
increase in
retinal
thickness
Ticly 2014 5 weeks Final value Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
LogMAR
Tunc 1999 2 months Fluo-
rescein
angiogra-
phy 0 no
leakage
(CME
absent),
1 oedema
less than
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Table 6. Outcomes (Continued)
perifoveal,
2 mild
perifoveal
oedema, 3
moderate
perifoveal
oedema
(approx.
1 disc
diameter)
, 4 severe
perifoveal
oedema
plus drop
of 1 line
of Snellen
acuity
since
second
postopera-
tive week
defined as
“clinically
signifi-
cant”
Tzelikis
2015
12 weeks Final value Yes LogMAR,
final value
(at 30 days
only)
Umer-
Bloch
1983
12 weeks Yes Fluo-
rescein an-
giog-
raphy us-
ingMiyake
1977 clas-
sification
Snellen
acuity
only, not
included
in analyses
Wang
2013
2 months OCT-
confirmed
CMO
with
“visual im-
pair-
ment” (not
specified
cutpoint)
Final value Yes “CME was
defined as
central
retinal
thickness >
250 µm
and the
presence of
intrareti-
nal cystoid
Mean pho-
ton count
values
LogMAR,
final value
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Table 6. Outcomes (Continued)
space
beneath
the foveal,
with the
diag-
nosis con-
firmed by
the same
retinal
specialist”
Wittpenn
2008
4 weeks OCT-
confirmed
CMO
with visual
acuity < 6/
9
Yes Clinical
and OCT-
based
Yannuzzi
1981
1 year CMO on
fluo-
rescein an-
giography
with visual
acuity < 6/
60
Yes Fluo-
rescein an-
giography,
evidence
but not de-
fined
Yavas 2007 3 months “Slight flu-
orescein
leakage
into
the cystic
space with-
out enclos-
ing the en-
tire central
fovea or
com-
plete fluo-
rescein ac-
cumula-
tion in the
cystic
space was
diagnosed
as angio-
graphic
CME”
LogMAR,
final value
Yung 2007 12 weeks
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Table 6. Outcomes (Continued)
Zaczek
2014
6 weeks Yes OCT-
verified
but not de-
fined
Mean an-
te-
rior cham-
ber flare re-
ported in
figure but
no SD
LogMAR,
final value
Change in
to-
tal macular
volume
Zhang
2008
1 month OCT-
verified
but not de-
fined
Tyn gran-
ule +
BCVA: best corrected visual acuity
CME: cystoid macular oedema (edema)
CMO: cystoid macular oedema
COMTOL: Comparison of Ophthalmic Medications for Tolerability (questionnaire)
MO: macular oedema
OCT: ocular coherence tomography
SD: standard deviation
Table 7. Adverse effects
Study Follow-up Number of people followed
up
Adverse effects
Almeida 2008 1 month 74 Quote: “There were 3 dropouts
in the treatment group related
to ketorolac corneal toxicity,
most notably pain attributed to
the drops.”
Almeida 2012 1 month 162 Quote: “One patient in the ke-
torolac group was hospitalized
with a cardiovascular event and
could not complete the fol-
low-up. Finally, 1 patient on
nepafenac had side effects of oc-
ular redness and irritation and
could not continue with the
study.”
Asano 2008 8 weeks 142 2 “complications” not specified.
Brown 1996 1 month NR Adverse effects not reported.
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Table 7. Adverse effects (Continued)
Cervantes-Coste 2009 6 weeks 60 Quote: “There were no seri-
ous treatment-related adverse
events or toxicity related to the
use of nepafenac 0.1%.”
Chatziralli 2011 6 weeks 138 Quote: “All patients reported
pain and ocular discomfort
lower than 1/10 on the visual
analog scale at all time points.”
Donnenfeld 2006 2 weeks 100 Quote: “Use of ketorolac 0.4%
for 1 or 3 days provided de-
creased levels of patient discom-
fort intraoperatively and post-
operatively. Intraoperatively, 3
days of ketorolac 0.4% pro-
vided significantly lower dis-
comfort scores than with 1-
hour and placebo dosing (P < 0.
001). One day of ketorolac 0.
4% also provided significantly
reduced intraoperative discom-
fort scores than with 1-hour
dosing (P = 0.001) and placebo
dosing (P < 0.001). Postoper-
atively, 3 days of ketorolac 0.
4%provided significantly lower
discomfort scores than 1-hour
dosing or control dosing (P <
0.001) (Figure 5). In addition,
patients randomised to 1 or 3
days of ketorolac 0.4%were sig-
nificantly less likely to require
additional intravenous anesthe-
sia (8% in each group) than
patients in the control group
(40%) (P = 0.008). Twenty per-
cent of patients in the 1-hour
group required additional anes-
thesia for pain control.”
Elsawy 2013 12 weeks 86 Adverse effects not reported.
Endo 2010 6 weeks 62 Quote: “No adverse events were
noted in either group.”
Italian Diclofenac Study Group
1997
140 days 229 Quote: “No major adverse ef-
fects were noted in either group.
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Table 7. Adverse effects (Continued)
” “Subjective tolerance of the
two treatments was good and
remained similar throughout
the study, although a trend to-
wards increased burning was
seen in the diclofenac group.”
Jung 2015 1 month 91 Quote: “There were no adverse
events except for amild burning
sensation in one patient in the
ketorolac group; the symptom
was tolerable and did not lead
to discontinuation of the med-
ication.”
Kraff 1982 between 2.5 and 12 months 492 Quote: “There were no compli-
cations that could be ascribed to
the use of topical indomethacin
other than minor stinging and
burning noted by the patients.”
Li 2011 1 month 217 Adverse effects not reported.
Mathys 2010 2 months 79 Quote: “There were no adverse
events reported by patients us-
ing nepafenac.”
Miyake 2007 5 weeks 50 Adverse effects not reported.
Miyake 2011 5 weeks 55 NSAIDs: 6 adverse effects: de-
creased lacrimation, conjunc-
tivitis allergic, abnormal sensa-
tion in eye, vomiting (2), con-
stipation
Steroid group: 9 adverse ef-
fects: decreased lacrimation,
conjunctivitis allergic, retinal
haemorrhage, keratoconjunc-
tivitis sicca, chorioretinopathy,
influenza, insomnia, diarrhoea,
humeral fracture
Miyanaga 2009 2 months 72 Adverse effects not reported.
Moschos 2012 1 month 79 Adverse effects not reported.
Quentin 1989 180 days 112 Quote: “Diclofenac group: two
patients were feeling burning
after application of eye drops
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Table 7. Adverse effects (Continued)
during the stationary care, for
placebo: none. In both groups
burningwas reported later on in
the examinations.”
Rossetti 1996 6 months 88 Quote: “Treatment regimens
were well tolerated with no evi-
dence of relevant side effects.”
Singh 2012 90 days 251 Quote: “No patient deaths
were reported during the study.
Overall, 13 patients reported
other serious adverse events,
none of which were related to
treatment. Three of the seri-
ous adverse events reported in
the vehicle group (cardiac fail-
ure congestive, coronary artery
occlusion, and pancreatitis) led
to patient discontinuation; no
other serious adverse events
led to discontinuation in ei-
ther treatment group. Separate
from the three patients who dis-
continued due to serious ad-
verse events, four other pa-
tients discontinued study par-
ticipation due to nonserious ad-
verse events. Of these nonse-
rious events, two reported in-
stances of punctate keratitis
(one in each treatment group)
were assessed as being related to
the study drugs. No instances
of targeted adverse events (de-
fined as corneal erosions) were
reported during the study
Two reports of punctate kerati-
tis and a single report of corneal
epithelium defect were assessed
as being related to treatment
with nepafenac. A single re-
port of punctate keratitiswas as-
sessed as being related to treat-
ment with vehicle. No other oc-
ular or nonocular adverse events
reported in the study were as-
sessed as being related to the
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Table 7. Adverse effects (Continued)
study drugs
In both treatment groups,
corneal staining and intraocu-
lar pressure were each generally
similar at the presurgical base-
line and at the day 90 visit (or
early exit). Additionally, no sa-
fety issues or trends were iden-
tified based upon changes from
baseline in fundus parameters
(retina/macula/choroid and op-
tic nerve) and ocular signs
(inflammatory cells, aqueous
flare, corneal oedema, and bul-
bar conjunctival injection). The
study results indicate no new
clinically relevant risks associ-
ated with increasing the dosing
of nepafenac from 14 days to 90
days, even in the higher-risk di-
abetic patient population.”
Solomon 1995 6 months 364 Quote: “During the study, the
mean severity of foreign-body
sensation, pain, photophobia,
and tearing did not become
more than mild (1 +) in any
treatment group. This was also
true of burning and stinging
following treatment instillation
(Figure 4). The severity of burn-
ing and stinging was signifi-
cantly greater in the flurbipro-
fen group on days 4-20 and
21-60 and in the indomethacin
group on days 1-3, 4-20, 21-
60, and 61-120 than in the ve-
hicle group. At day 1-3, moder-
ate to severe burning and sting-
ing were reported by 7.0% (16/
230) of the patients treatedwith
flurbiprofen, 9.7% (23/237) of
the patients treated with in-
domethacin, and 3.1% (7/224)
of the patients treated with ve-
hicle.”
Tauber 2006 30 days (3 months mentioned
but not reported)
32 Adverse effects not reported.
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Table 7. Adverse effects (Continued)
Ticly 2014 5 weeks 81 One patient withdrew because
of burning.
Tunc 1999 2 months 75 Adverse effects not reported.
Tzelikis 2015 1 month 126 Quote: “There were no adverse
side effects in either group.”
Umer-Bloch 1983 12 weeks 73 Quote from translation: “40%
reported a short burning af-
ter using indomethacin eye
drops, only rare in patients of
the placebo group. One pa-
tient had 6 weeks after treat-
ment an allergic blepharitis
due to indomethacin. Long-
term: 52 patients were followed
for 6 months and 34 patients
one year. 4 patients with in-
domethacin had visual acuity
reduction because of a clinically
new cystoid edema; 2 of these
patients had spontaneous heal-
ing after 4-6 weeks, the other 2
edema cases did not resolve. 2
patients had a new senile mac-
ula pathology, and 2 patients
had a retinal detachment due to
aphakia. Placebo: 2 patients still
had an edema after 12 weeks,
while one patient developed a
new edema later.”
Wang 2013 2 months 167 Quote: “No drug-related ad-
verse events were identified.”
Wittpenn 2008 4 weeks 478 Quote: “The most commonly
reported adverse events (investi-
gator self-report) in the ketoro-
lac/steroid group were burning/
stinging/tearing (4/268). Tran-
sient elevations in intraocu-
lar pressure (IOP) were the
most commonly reported ad-
verse event in the steroid group
(3/278). There were two se-
rious adverse events, both in
the steroid group: one patient
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Table 7. Adverse effects (Continued)
developed endophthalmitis and
one patient died (cause deter-
mined to be unrelated to the
study medication).”
Yannuzzi 1981 1 year 231 Adverse effects not reported.
Yavas 2007 3 months 179 Adverse effects not reported.
Yung 2007 12 weeks 37 Adverse effects not reported.
Zaczek 2014 6 weeks 152 Quote: “Mild to moderate
punctuate epithelial defects of
the cornea were found in both
groups 3 weeks after treatment.
Statistically significantly more
patients in the nepafenac group
than in the control group had
corneal fluorescein staining (20
[26.7%] versus 8 [10.4%]) (PZ.
0119). Headache was reported
by 3 patients (4.0%) in the
nepafenac group and 2 patients
(2.6%) in the control group
(PZ.9750). No other systemic
or local untoward effects were
recorded during 3 weeks of
treatment in either study group.
”
Zhang 2008 1 month 220 Adverse effects not reported.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Edema, Cystoid
#2 macula* near/3 (edema* or odema*)
#3 (cme or cmo)
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal
#6 nsaid*
#7 nonsteroidal anti-inflammator*
#8 non-steroidal anti-inflammator*
#9 MeSH descriptor Diclofenac
#10 diclofenac* OR fenoprofen* OR flurbiprofen*
#11 MeSH descriptor Indomethacin
#12 indometacin*
#13 MeSH descriptor Ketoprofen
#14 ketoprofen*
#15 ketorolac
#16 piroxicam
#17 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#18 (#4 AND #17)
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular edema cystoid/
14. exp macula lutea/
15. (macula$ adj3 oedema).tw.
16. (macula$ adj3 edema).tw.
17. (CME or CMO).tw.
18. or/13-17
19. exp anti inflammatory agents non steroidal/
20. nsaid$.tw.
21. nonsteroidal anti-inflammator$.tw.
22. non-steroidal anti-inflammator$.tw.
23. exp diclofenac/
24. diclofenac$.tw.
25. fenoprofen$.tw.
26. flurbiprofen$.tw.
27. exp indometacin/
28. indometacin$.tw.
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29. exp ketoprofen/
30. ketoprofen$.tw.
31. ketorolac$.tw.
32. piroxicam$.tw.
33. or/19-32
34. 18 and 33
35. 12 and 34
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or propspectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula cystoid edema/
34. exp eye edema/
35. exp retina macula lutea/
36. (macula$ adj3 oedema).tw.
37. (macula$ adj3 edema).tw.
38. (CME or CMO).tw.
39. or/33-38
40. exp nonsteroidal antiinflammatory agent/
41. nsaid$.tw.
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42. nonsteroidal anti-inflammator$.tw.
43. non-steroidal anti-inflammator$.tw.
44. exp diclofenac/
45. diclofenac$.tw.
46. fenoprofen$.tw.
47. flurbiprofen$.tw.
48. exp indometacin/
49. indometacin$.tw.
50. exp ketoprofen/
51. ketoprofen$.tw.
52. ketorolac$.tw.
53. exp piroxicam/
54. piroxicam$.tw.
55. or/40-54
56. 39 and 55
57. 32 and 56
Appendix 4. LILACS search strategy
Anti-Inflammatory Agents, Non-Steroidal [Subject descriptor] or nonsteroidal antiinflammator$ or nonsteroidal anti inflammator$ or
non steroidal anti inflammator$ or NSAID$ and macula$ edema or macula$ oedema or CMO or CME
Appendix 5. ISRCTN search strategy
“( Condition: macular edemaORmacular oedema AND Interventions: NSAIDOR nonsteroidal anti-inflammatory OR non-steroidal
anti-inflammatory )”
Appendix 6. ClinicalTrials.gov search strategy
macular edema OR macular oedema OR CMO OR CME | NSAID OR nonsteroidal anti-inflammatory OR non-steroidal anti-
inflammatory
Appendix 7. WHO ICTRP search strategy
macular edema OR macular oedema OR CMO OR CME = Condition AND NSAID OR nonsteroidal anti-inflammatory OR non-
steroidal anti-inflammatory = Intervention
Appendix 8. Data for characteristics of included studies
Mandatory items Optional items
Methods
Study design ·Parallel groupRCT i.e. people randomised
to treatment
·Within-person RCT i.e. eyes randomised
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
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(Continued)
to treatment
·Cluster-RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within-person correlation/both
and not adjusted for within-person correla-
tion) and specify if mixture one eye and two
eyes
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up, please indicate.
Number (%) of men and women Number (%) of men and women
Average age and age range Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n= )
Comparator (n= )
See MECIR 65 and 70
· Number of people randomised to this
group
· Drug (or intervention) name
· Dose
· Frequency
· Route of administration
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
List outcomes
Adverse effects reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
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(Continued)
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 11, 2016
Date Event Description
10 July 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
• Conceiving the review: Cochrane Eyes and Vision (CEV)
• Designing the review: JE
• Co-ordinating the review: JE
• Data collection for the review
◦ designing search strategies: CEVG Information Specialist
◦ undertaking electronic searches: CEVG Information Specialist
◦ screening search results: BL, CL, DL
◦ organising retrieval of papers: CEVG Information Specialist
◦ screening retrieved papers against inclusion criteria: BL, CL, DL
◦ appraising quality of papers: BL, CL, DL, JE
◦ extracting data from papers: BL, CL, DL, JE
◦ writing to authors of papers for additional information: BL, JE
◦ providing additional data about papers: BL, JE
◦ obtaining and screening data on unpublished studies: JE, BL
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• Data management for the review
◦ entering data into RevMan 5: JE
◦ analysis of data: JE, CB
• Interpretation of data
◦ providing a methodological perspective: JE, CB, RW
◦ providing a clinical perspective: BL, CL, DL, RW
◦ providing a policy perspective: RW
• Writing the review: BL, CL, DL, JE, RW
• Providing general advice on the review: RW
D E C L A R A T I O N S O F I N T E R E S T
JE: None known
BL: Noneknown
CL: None known
DL: None known
CB: None known
RW: None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
• Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV
research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• The NIHR also funds the CEV Editorial Base in London which funds part of Jennifer Evan’s salary.
• Cochrane Incentive Scheme awarded in 2015.
The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of
Health.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we had planned to contact pharmaceutical companies for more information (Goh 2007). We did not do this because
since the protocol was written, the role of clinical trial registries have meant that it is much easier to identify potentially unpublished
trials.
We had planned to use confidence intervals for the I2 value, but as this is not routinely implemented in RevMan 5 as yet, we have not
done this. We felt the extra effort required to analyse the data in a software package that could provide these confidence intervals, such
as Stata, was not worth it.
We added some additional outcomes as a result of our collaboration with the National Institute for Health and Care Excellence
(NICE). These are clearly identified in the text. We have clarified our definition of macular oedema to include all 3 levels of the Miyake
classification and whether or not cystic spaces are detectable on imaging which we have termed simply macular oedema (MO). Cystoid
has been removed from the title.
N O T E S
The protocol for this review question was first published in 2007 (Goh 2007). The original review team were unable to complete the
review and therefore a new review team was found. The latest protocol for this review was published in 2011 (Abeysiri 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal [adverse effects; ∗therapeutic use]; Cataract Extraction [∗adverse
effects]; Macular Edema [etiology; ∗prevention & control]; Postoperative Complications [∗prevention & control]; Randomized Con-
trolled Trials as Topic; Steroids [therapeutic use]
MeSH check words
Aged; Humans
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